
<html lang="en"     class="pb-page"  data-request-id="b3eadb23-3c1c-48ef-8b6d-546bc032c3ae"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-8;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm5018237;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination" /></meta><meta name="dc.Creator" content="Philip  Jones" /></meta><meta name="dc.Creator" content="Keith  Wilcoxen" /></meta><meta name="dc.Creator" content="Michael  Rowley" /></meta><meta name="dc.Creator" content="Carlo  Toniatti" /></meta><meta name="dc.Description" content="Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has become clear over the past decade that inhibition of PARP in the contex..." /></meta><meta name="Description" content="Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has become clear over the past decade that inhibition of PARP in the contex..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 11, 2015" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5018237" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2015 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5018237" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5018237" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5018237" /></link>
        
    
    

<title>Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5018237" /></meta><meta property="og:title" content="Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0020.jpeg" /></meta><meta property="og:description" content="Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability. Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. It is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5018237"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5018237">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5018237&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5018237&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5018237&amp;href=/doi/10.1021/jm5018237" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3302-3314</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5012319" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/jm500829b" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Jones">Philip Jones</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Wilcoxen">Keith Wilcoxen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Rowley">Michael Rowley</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carlo++Toniatti">Carlo Toniatti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Istituto di Ricerche di Biologia Molecolare, Via Pontina km 30600, 00040 Pomezia, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">TESARO, Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +41 413182426. E-mail: <a href="/cdn-cgi/l/email-protection#610c08020900040d4f130e160d0418210c0413020a4f020e0c"><span class="__cf_email__" data-cfemail="365b5f555e57535a184459415a534f765b5344555d1855595b">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5018237&amp;href=/doi/10.1021%2Fjm5018237" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3302â3314</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 11, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 November 2014</li><li><span class="item_label"><b>Published</b> online</span>11 March 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 April 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5018237" title="DOI URL">https://doi.org/10.1021/jm5018237</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3302%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPhilip%2BJones%252C%2BKeith%2BWilcoxen%252C%2BMichael%2BRowley%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D8%26contentID%3Djm5018237%26title%3DNiraparib%253A%2BA%2BPoly%2528ADP-ribose%2529%2BPolymerase%2B%2528PARP%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BTumors%2Bwith%2BDefective%2BHomologous%2BRecombination%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3314%26publicationDate%3DApril%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5018237"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">10656</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">68</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5018237" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Wilcoxen&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Rowley&quot;},{&quot;first_name&quot;:&quot;Carlo&quot;,&quot;last_name&quot;:&quot;Toniatti&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;3302-3314&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5018237&quot;},&quot;abstract&quot;:&quot;Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability. Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. It is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5018237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018237" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5018237&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018237" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5018237&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018237" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5018237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5018237&amp;href=/doi/10.1021/jm5018237" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5018237" /></input><a href="/doi/pdf/10.1021/jm5018237" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26pmid%3D25761096%26genre%3Darticle%26aulast%3DJones%26date%3D2015%26atitle%3DNiraparib%253A%2BA%2BPoly%2528ADP-ribose%2529%2BPolymerase%2B%2528PARP%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BTumors%2Bwith%2BDefective%2BHomologous%2BRecombination%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D8%26spage%3D3302%26epage%3D3314%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jmcmar.2015.58.issue-8/20150423/jmcmar.2015.58.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability. Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. It is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Rationale</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86586" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86586" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> DNA Repair Response</h3><div class="NLM_p">DNA repair processes are critical for accurate cell replication and maintenance of genomic stability, as cells are continually faced by an onslaught of DNA damage. This occurs both through normal cellular functions, such as metabolic processes resulting in the generation of reactive oxygen radicals or through replication errors, but also as a result of exogenous damage such as UV light, ambient and therapeutic radiation, and through exposure to chemicals, including those in diets. To cope with these injuries, cells have evolved sophisticated defense mechanisms, with multiple overlapping DNA damage repair responses, focused on resolution of both DNA single-strand breaks (SSB) as well as DNA double-strand breaks (DSB) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). There are at least five major DNA damage repair mechanisms operational in mammalian cells,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> which include base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR), which are the primary mechanisms to resolve SSB. Homologous recombination (HR) and nonhomologous end joining (NHEJ) are the two pathways responsible for repairing DSB. HR is a high fidelity repair system which relies on a homologous sequence of chromosomes adjacent to the site of breakage as a template to ensure accurate restoration of the DNA sequence. NHEJ is an error prone pathway with lower fidelity: it dissects the DNA damage and joins unrelated DNA strands, thereby causing altered nucleotide sequences and gene rearrangements. DSB are deleterious lesions to cells and are difficult to repair. If these lesions remain uncorrected they result in mutagenesis, or in the case of gross DNA damage, in cell death. All five pathways are complex processes involving an orchestrated interplay of many distinct proteins, and loss-of-function in one or more enzyme in these detection and repair processes results in an accumulation of mutations and DNA defects and predisposition to cancer.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. DNA repair pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Given that DNA damage is the cornerstone of chemo- and radiotherapy widely used for the treatment of cancer and that DNA repair pathways have the ability to overcome the cytotoxic lesions induced by these treatments, there has been more than two decades of interest in targeting DNA repair pathways for clinical benefit.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, it is only within the past decade, with the development<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> of PARP inhibitors such as niraparib and related compounds described herein, that significant treatment advances have been made. These advances have been enabled by an improved understanding of how critical alternative DNA repair pathways become in the context of defects in DNA DSB repair, allowing them to be exploited for therapeutic gain.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> PARP Family</h3><div class="NLM_p">Poly(ADP-ribose) polymerase (PARP)-1 is the founding and most abundant member of poly(ADP-ribosyl)ating proteins, also known as the ADP-ribosyltransferase diphtheria toxin-like proteins (ARTD), a family of some 17 proteins.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The primary function of the PARPs is to post-translationally modify target proteins with ADP-ribose units using NAD<sup>+</sup> as substrate. The best characterized PARPs, PARP-1, -2, -5A, and -5B, all possess the ability to catalyze the transfer of multiple ADP-ribose units, resulting in the formation of long, branched poly(ADP-ribose) (PAR) chains. In contrast, the remaining PARPs transfer single ADP-ribose units onto target proteins.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a></div><div class="NLM_p">PARP-1 and the closely related PARP-2 are nuclear proteins and possess DNA binding domains with zinc fingers.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The basal catalytic activity of PARP-1 is low, but upon DNA damage to cells the DNA binding domains within PARP-1 serve to localize and rapidly bind at the sites of damage (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Upon binding at the lesion, conformational rearrangement occurs throughout the protein, relaying information from the DNA binding domain to the catalytic domain, thereby increasing the catalytic activity up to 500-fold. This activation results in the addition of PAR chains on several proteins associated with chromatin, including: histones, p53, topoisomerases, and PARP itself.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The addition of these negatively charged PAR chains relaxes chromatin and results in the fast recruitment of DNA repair factors such as XRCC1, which access the DNA breaks and repair them through BER. Additionally, PARP is involved in several other nuclear processes including acting as a facilitator of HR. It has also been implicated in NHEJ, and PARP-1 also regulates transcription by modulating chromatin structure, acting as a coregulator of transcription factors and interacting with chromatin insulators.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic describing role of PARP-1/2 in base excision repair pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The knockout of PARP-1 significantly impairs repair of DNA damage following exposure to radiation or cytotoxic insult,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> with the residual PARP dependent repair activity being due to PARP-2, which contributes about 10% to nuclear PARP activity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Similarly, PARP-1 and -2 inhibition with small molecules has been demonstrated to sensitize tumor cells to cytotoxic agents and ionizing radiation. On the basis of these findings, beginning in the 1990s multiple companies and academic groups developed PARP inhibitors as chemo- and radiopotentiators and progressed molecules into early stage clinical trials.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, despite these agents being efficacious in initial clinical trials, they proved to be highly toxic in combination with chemo- and radiotherapy, and they were not advanced into late stage clinical testing. It should be noted, although it is outside the scope of this manuscript, that PARP plays a role in multiple pathological conditions,<a onclick="showRef(event, 'ref2 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref7">(2, 7)</a> and PARP inhibitors have also shown applicability in models of reperfusion injury, inflammation, cardiovascular disease, and neurodegenerative disorders.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> BRCA1/2 Connection and Synthetic Lethality</h3><div class="NLM_p">As noted above, tumor cells frequently possess defects in DNA repair mechanisms and these promote growth and survival advantages; however, unlike normal cells, these defects provide an opportunity for therapeutic exploitation. In 2005, a major breakthrough occurred when two seminal papers appeared in <i>Nature</i> from independent groups demonstrating that targeting more than one DNA repair pathway in tumor cells could induce âsynthetic lethalityâ,<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> achieving profound cytotoxicity within the tumor cells while sparing the normal cells. Two genes are described as being synthetic lethal if mutation/loss/inhibition of either alone is compatible with cell viability, but loss of function of both concurrently results in cell death.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Specifically, the publications described the selective killing of BRCA1 or BRCA2 deficient tumor cells by PARP inhibitors. In contrast, normal cells with an intact BRCA pathway are viable when treated with a PARP inhibitor, and minimal cytotoxicity is seen. BRCA1 and BRCA2 are known tumor suppressors and are key components involved in the repair of DNA double-strand breaks by HR, and mutations in these genes predispose individuals to hereditary breast and ovarian cancer. It has also been shown that BRCA1/2 mutations have been found in prostate, pancreatic, and other types of cancer.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Germline BRCA1/2 mutations are inherited in the heterozygous state, with one wild-type allele, and this second allele is lost to confer complete loss of BRCA function. This accelerates genomic instability, acquisition of mutations, and tumor development. In contrast, normal cells retain the wild-type copy, thus maintaining HR repair function. It is the differential HR capacity between the tumor and the surrounding tissue that allows a unique opportunity for targeting PARP activity to achieve cell killing.</div><div class="NLM_p">Farmer and Ashworth,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> in collaboration with scientists at KuDOS Pharmaceuticals, described the hypersensitivity of BRCA1 and BRCA2 deficient cells to both silencing of PARP-1 by RNA interference and also inhibition with small molecule PARP-1/2 inhibitors. Both genetic knockdown and pharmacological inhibition of PARP activity profoundly sensitized these HR deficient cells, resulting in a reduction of clonogenic survival, chromosomal instability, cell cycle arrest, and subsequent apoptosis. In clonogenic assays, BRCA1 and BRCA2 deficient cells were extremely sensitive to PARP inhibitors, with some compounds showing IC<sub>50</sub>s in the nanomolar range. In contrast, wild-type cells were 2 orders of magnitude less sensitive to PARP inhibition, with IC<sub>50</sub>s around the 2 micromolar range. The effects of one compound, KU0058684 (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), were also studied in vivo, and this PARP inhibitor was demonstrated to prevent formation of HR-deficient tumors. When BRCA2 deficient embryonic stem (ES) cells were injected into athymic mice and allowed to form teratocarcinomas, well tolerated doses of <b>1</b> severely inhibited tumor formation from these BRCA2 deficient cells. These effects were selective for HR deficient tumors, as injection of the corresponding wild type ES cells with concomitant administration of <b>1</b> failed to prevent tumor formation. In follow up studies in a genetically engineered mouse model for BRCA1 associated breast cancer, treatment of tumor bearing mice with the PARP inhibitor olaparib<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> resulted in inhibition of tumor growth without signs of toxicity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Tool compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In related work, Bryant and Helleday described the acute sensitivity of BRCA2 deficient cell lines to PARP inhibitors AG14361 (<b>2</b>) and NU1025 (<b>3</b>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> They demonstrated the HR defective cell lines irs1 and irs1SF are sensitive to PARP inhibition, and correction of the HR defects in these cell lines by reintroduction of XRCC2 or XRCC3 reversed that sensitivity. They also showed that the BRCA2 deficient cell line V-C8 was profoundly sensitive to PARP inhibitors <b>2</b> and <b>3</b> compared to the isogenic cell line V-C8+B2 with functional BRCA2. To demonstrate the therapeutic potential of PARP inhibition for the treatment of BRCA2 deficient tumors the V-C8 cells, and the isogenic V-C8+B2 cells, were implanted into mice, and the growth rates following treatment with <b>2</b> monitored. The PARP inhibitor had no effect on the outgrowth of the BRCA2 proficient cells compared to vehicle treatment. In contrast, three out of five mice bearing the BRCA deficient V-C8 xenograft responded with complete remission.</div><div class="NLM_p">Cell death arises from combining both conditions: PARP inhibition resulting in blockage of BER and defects in DSB repair through loss of BRCA1/2. Neither alone is itself sufficient to affect cell viability. This is illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, whereby DNA damage in the presence of a PARP inhibitor results in persistent SSB. During replication, these SSBs cause stalled replication forks and subsequently develop into DSB. In normal patients, and in normal tissue of BRCA1/2 mutant patients, these DSB can be repaired uneventfully through HR repair. But in BRCA1 and BRCA2 deficient tumor cells, where both alleles have been lost, these lesions are not repaired by the homologous recombination repair pathway. Instead these HR deficient cells rely on the error prone NHEJ repair pathway, resulting in gross genomic instability, chromosomal mutations, cell cycle arrest, and eventually apoptosis. Of note, more recent evidence<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> suggests that additional mechanisms, including PARP-1 trapping on the SSB during BER, as well as a direct role of PARP-1 in reactivating stalled replication forks, might be responsible for the synthetic lethality of PARP inhibitors in HR-deficient cells.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Homologous recombination defective cells are hypersensitive to PARP inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These reports triggered great excitement and led to drug discovery efforts across the industry, including the initiation of our program at the IRBM (Merck Research Laboratories, Rome), which resulted in the identification of niraparib.</div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Defects in Homologous Recombination</h3><div class="NLM_p last">Although the initial data focused on tumors with inactivation mutations in BRCA1/2, there is a growing body of evidence supporting the expansion of this strategy beyond hereditary cancers into sporadic (i.e., nonfamiliar) tumors bearing defects in other HR related genes.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> It is widely accepted that HR deficiency is the main determinant for PARP inhibitor sensitivity in BRCA1/2 mutant tumors and, given that the HR repair machinery involves multiple interacting genes,<a onclick="showRef(event, 'ref7 ref13'); return false;" href="javascript:void(0);" class="ref ref7 ref13">(7, 13)</a> disruption of any of the HR genes should have a deleterious effect on HR and confer hypersensitivity to PARP inhibition. For instance, it is estimated that in high grade serous ovarian cancer, 15% of women have germline mutations in BRCA1/2, yet large scale genomic evidence suggest up to half of patients may have acquired defects in HR and thereby be sensitive to PARP inhibition. HR deficiency may arise through genetic or epigenetic mechanisms, sometimes called âBRCAnessâ, which is used to describe the phenotype of HR deficient sporadic cancers that share phenotypes with BRCA1/2 associated hereditary cancers.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> For example, genes involved in HR that have been identified to contribute to hereditary epithelial ovarian cancer include PALB2, Rad51C, Rad51D, BRIP1, BARD1, Chk2, Mre11A, MSH6, NBN, and Rad50,<a onclick="showRef(event, 'ref3 ref4 ref5 ref21'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref21">(3-5, 21)</a> and it has been shown that approximately half of high-grade serous ovarian cancers have defects in HR.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Epigenetic silencing of BRCA1 (11â35% of epithelial cancers) and FANCF (5â20%) genes through promoter methylation has been shown to confer sensitivity to PARP inhibition, as has overexpression of the EMSY gene, which is known to suppress BRCA2 transcription. Similarly, several other genes including ATM, CHK2, and Fancomi anemia genes, which are essential for the repair of stalled replication forks, have been reported to be disrupted in sporadic tumors and can sensitize to PARP inhibition. Studies have also demonstrated that loss of the tumor suppressor PTEN in endometrial cancers causes sensitivity to PARP inhibition. Given the complexity of the HR DNA damage response, rather than genotyping at the single gene level, it may be more instructive to use functional assays that can identify tumors with defects in the HR repair pathway. BRCA1/2 loss through epigenetic silencing can be identified through immunohistochemistry and the formation of RAD51 nuclear foci could possibly be used to identify sporadic tumors with HR defects. These foci form at the site of DNA DSB in HR repair competent cells, but not in HR defective tumors, hence detection of RAD51 by immunofluorescence may serve as a measurement of HR integrity.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Compound Design and Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There has been an interest in the discovery and development of PARP inhibitors for a number of years.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Efforts from many groups have resulted in a good understanding of key pharmacophore elements for the binding of small molecules to PARP-1/-2 enzymes. This allowed us to take a design approach to hit finding, incorporating prior knowledge with novel approaches, in order to find starting points for lead optimization. Early inhibitors<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> were based on the knowledge that nicotinamide (<b>4</b>) is a weak PARP inhibitor, with one of the key elements in improving potency to constrain the amide bond (which can rotate in nicotinamide). This is supported by X-ray structures,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in which three key hydrogen bonding interactions are seen between the inhibitors with backbone CO and NH of glycine, and the hydroxyl group of serine (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Nicotinamide and a schematic of the H-bond pattern of PARP-1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The restraint in amide rotation is made (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) either by constraining the amide into a ring such as rucaparib<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (<b>5</b>, AG-14699, PF-01367338) and olaparib<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<b>6</b>, KU 0059436, AZD2281), or by placing a hydrogen bond accepting group such that the amide NH <i>anti</i> to the carbonyl forms a ring via an intramolecular H-bond as in veliparib<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<b>7</b>, ABT-888). We utilized both approaches; however, it was the latter that led to the discovery of niraparib (<b>8</b>, MK-4827) and is discussed below.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of PARP inhibitors in mid to late stage clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the outset,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> we designed a number of [6,5] fused aromatic azabicycles, in which a nitrogen atom in the five-membered ring was placed to make the key intramolecular H-bond to the <i>anti</i> NH of the amide (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). This proved a fruitful exercise, with several examples showing moderate to good inhibition of PARP-1 activity in an in vitro enzyme assay.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Heterobicylic carboxamides as PARP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The most promising of these early analogues was the 2<i>H</i>-indazole <b>10</b>, showing IC<sub>50</sub> = 24 nM in the PARP-1 assay and some, albeit weak, activity (EC<sub>50</sub> = 3 700 nM) in a cell based PARylation assay. Compound <b>10</b> also had promising rat pharmacokinetics (<i>F</i> 41%, CLp 30 mL/min/kg, terminal half-life 5.1 h). We explored structureâactivity relationships on compound <b>10</b> as a scaffold, with the most interesting finding being that incorporating a basic group off the <i>para</i> position of the phenyl group (dimethylaminomethyl derivative <b>14</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) gave an improvement in enzyme inhibition (PARP-1 IC<sub>50</sub> = 3.7 nM). More importantly, <b>14</b> showed a significant improvement in the cell based PARP inhibition assay (PARylation EC<sub>50</sub> = 110 nM), presumably in large part due to improved physicochemical properties allowing better cell penetration. Compound <b>14</b> was also active against a HeLa cell line in which BRCA1 had been silenced by shRNA (CC<sub>50</sub> [concentration required to reduce cell viability by 50%] = 520 nM), with more than 10-fold selectivity over the nonsilenced control. The monomethyl derivative (<b>15</b>, PARP-1 IC<sub>50</sub> = 3.8 nM, PARylation EC<sub>50</sub> = 68 nM) had a similar profile to <b>14</b>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Functionalizing the core PARP inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Where these two molecules differed was in their in vitro clearance profiles: in rat liver microsomes, <b>14</b> had rather high turnover (Cl<sub>int</sub> 177 Î¼L/min/mg protein), <b>15</b> considerably lower (Cl<sub>int</sub> 28 Î¼L/min/mg protein), but both showed very high in vivo clearance in rats (<b>14</b> CLp = 450; <b>15</b> CLp = 220 mL/min/kg), in excess of liver blood flow. Compounds <b>14</b> and <b>15</b> showed a similar rat plasma free fraction, were stable in rat plasma, and did not partition into blood cells, leading us to hypothesize extrahepatic metabolism as a route of clearance. Compound <b>14</b> was radiolabeled, dosed intravenously (iv) to rats, and urine and bile examined; the majority of the dosed radioactivity was excreted as the carboxylic acid <b>16</b> and its acylglucuronide. These results pointed to oxidation as a major clearance route, and we believed this to be nonhepatic. To test this hypothesis, microsomes from lung, kidney, intestine, and heart were screened: compound <b>14</b> showed turnover in lung and kidney, in addition to liver and microsomes. Cytochrome P450 phenotyping showed that metabolism was very largely via CYPs 1A1 and 1A2 (which are expressed in the lung), so we placed turnover via recombinant CYP1A1 into our in vitro screening cascade in order to drive down clearance. Because compounds <b>14</b> and <b>15</b> showed appropriate levels of PARP inhibition in vitro and in cells, our strategy focused on maintaining the major features of these molecules (the 2-phenyl-2<i>H</i>-indazole-7-carboxamide with a basic nitrogen appended to the <i>para</i> position of the phenyl group) and to attempt to reduce benzylic oxidation. Among the approaches we took (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), blocking the benzylic methylene (<b>17</b>) and constraining the amine into a ring (<b>18</b>) proved promising, yielding compounds with similar potency, reduced in vitro clearance in both rat liver microsomes and CYP1A1, and correspondingly reduced plasma clearance in rat.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Blocking Benzylic Oxidation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0016.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0017.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Inhibition of PARP-1 enzymatic activity.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Inhibition of hydrogen peroxide induced PARylation in HeLa cells.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Rat liver microsome intrinsic clearance: units are Î¼L per min per mg of protein.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Recombinant CYP1A1 intrinsic clearance.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Rat in vivo total clearance following iv dosing.</p></div></div><div></div></div><div class="NLM_p">As an alternative to fusing a ring as in <b>18</b>, we also appended saturated nitrogen heterocycles to the <i>para</i> position of the phenyl group (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). With the basic nitrogen in the benzylic position (<b>19</b>), we still observed high turnover by CYP1A1, and the 4-substituted piperidine <b>20</b> showed reduced PARP-1 inhibition and activity in BRCA1 silenced HeLa cells (CC<sub>50</sub> 410 nM). However, the 3-substituted piperidine (<b>21</b>) proved very promising, with good enzyme and cell potency, reduced liver microsome and CYP1A1 in vitro clearance, and moderate in vivo plasma clearance in rat. Resolution of <b>21</b> gave compounds <b>22</b> and <b>8</b>, both showing excellent inhibition of PARP-1. The <i>R</i>-enantiomer <b>22</b> had somewhat lower in vitro metabolic clearance than the <i>S</i>-enantiomer <b>8</b> in rat liver microsomes, but compound <b>8</b> was more potent in cell based assays (PARylation EC<sub>50</sub>, <b>22</b> = 30 nM, <b>8</b> = 4.0 nM; BRCA1-HeLa CC<sub>50</sub>, <b>22</b> = 470, <b>8</b> = 34 nM). Given this improved potency and similar in vitro turnover in human liver microsomes (HLM Cl<sub>int</sub>, <b>22</b> = 4, <b>8</b> = 3 Î¼L/min/mgP) we focused on compound <b>8</b> (niraparib). As well as its moderate clearance in rat, <b>8</b> showed good bioavailability (65%) and a high volume of distribution (<i>V</i><sub>dss</sub> = 6.9 L/kg), leading to a reasonably long terminal half-life (<i>t</i><sub>1/2</sub> = 3.4 h).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Appending a Basic Heterocycle</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0018.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0019.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Inhibition of PARP-1 enzymatic activity.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Inhibition of hydrogen peroxide induced PARylation in HeLa cells.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Rat liver microsome intrinsic clearance: units are Î¼L per min per mg of protein.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Recombinant CYP1A1 intrinsic clearance.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Rat in vivo total clearance following iv dosing.</p></div></div><div></div></div><div class="NLM_p">During the course of its preclinical development, we needed to address the issue of species specific pharmacokinetics. Although rat pharmacokinetics was acceptable, <b>8</b> showed high clearance in dog (CLp = 31 mL/min/kg). Despite this, it had good oral bioavailability (<i>F</i> = 57%), a high volume of distribution (<i>V</i><sub>dss</sub> = 12.3 L/kg), and a good terminal half-life (<i>t</i><sub>1/2</sub> = 5.7 h). <b>8</b> was stable in blood from rat, dog, and human, but experiments in hepatocytes showed high turnover in dogs to the product of amide hydrolysis, acid <b>23</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). This was confirmed with in vivo experiments in dogs, in which 52% of the radioactivity of [<sup>14</sup>C]-<b>8</b> dosed iv to bile duct cannulated dogs was recovered as <b>23</b>, with less than 5% recovered as parent. As expected, given the lack of the key H-bond donor, <b>23</b> is not a potent PARP-1 inhibitor (PARP-1 IC<sub>50</sub> > 500 nM). Unlike dogs, [<sup>14</sup>C]-<b>8</b> dosed iv to bile duct cannulated rats gave 45% of recovered radioactivity as parent drug along with numerous metabolites, none of which accounted for more than 5% of the dose. Because this metabolism appeared to be a dog-specific phenomenon, we were not concerned that this hydrolysis would have a major impact on human pharmacokinetics. With the different routes of clearance in preclinical species, the quantitative prediction of human pharmacokinetics was difficult. Nonetheless, given good physical properties, preclinical bioavailability, and low metabolic turnover in human in vitro systems, we had reasonable confidence that human PK would be good. This, indeed, turned out to be the case as discussed below. An important lesson that this illustrates is the value of mechanistic PK studies. The understanding of extrahepatic oxidative metabolism in rats helped find stable compounds, and an understanding of the dog specific clearance mechanism allowed us to go forward despite high dog in vivo clearance.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Representative HPLC radiochromatograms of <b>8</b> incubated in the presence of rat, dog, and human hepatocytes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Preclinical Characterization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Niraparib is a potent and selective PARP-1 and PARP-2 inhibitor with in vitro IC<sub>50</sub> = 3.8 and 2.1 nM, respectively, and displays at least a 100-fold window over the other PARP-family members PARP-3, v-PARP, and Tankyrase-1 (TANK-1).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Monotherapy Activity in Cell Based Assays</h3><div class="NLM_p">The ability of niraparib to inhibit intracellular PARP-1/-2 activity was evaluated in an assay that measures the amount of poly(ADP-ribose) (PAR) chains formed in cells as a result of DNA damage induced by exposure to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). In these conditions, niraparib inhibited intracellular PARylation in three different cell lines, with IC<sub>50</sub> and IC<sub>90</sub> of about 4 and 50 nM, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibition of Intracellular PARylation</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">BRCA status</th><th class="colsep0 rowsep0" align="center">PARylation IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="Â±">PARylation IC<sub>90</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HeLa</td><td class="colsep0 rowsep0" align="left">wild type</td><td class="colsep0 rowsep0" align="center">4Â Â±Â 2</td><td class="colsep0 rowsep0" align="char" char="Â±">46Â Â±Â 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="left">wild type</td><td class="colsep0 rowsep0" align="center">4Â +Â 1</td><td class="colsep0 rowsep0" align="char" char="Â±">52Â Â±Â 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAPAN-1</td><td class="colsep0 rowsep0" align="left">BRCA2Â deficient</td><td class="colsep0 rowsep0" align="center">3.5Â Â±Â 1</td><td class="colsep0 rowsep0" align="char" char="Â±">50Â Â±Â 9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><p class="first last">Values represent the mean Â± SD derived from a minimum of three experiments.</p></div></div></div><div class="NLM_p">The selectivity of niraparib for BRCA1 or BRCA2 deficient cells was demonstrated in several cell lines. Niraparib selectively inhibited proliferation of cancer cell lines which had been stably silenced for BRCA1 or BRCA2 compared to their wild-type counterparts. The CC<sub>50</sub> for HeLa BRCA1-deficient cells was 34 nM, with a 25-fold selectivity window over the BRCA1wt matched pair HeLa cells. Niraparib inhibited the proliferation of BRCA2 silenced A549 human lung cancer cells lines, with CC<sub>50</sub> = 11 nM and more than 100-fold selectivity window over the BRCA2wt matched pair A549 cells (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). It also strongly inhibited the growth of cancer cell lines carrying inactivating mutations of BRCA1 (SUM149PT and SUM1315MO2) or BRCA2 (DoTc2-4510) genes with CC<sub>50</sub>s of approximately 20 nM. The selectivity of niraparib for BRCA mutant cells was confirmed using UWB1.289 cell lines, which are derived from a tumor of a patient with papillary serous adenocarcinoma histology and that carry an inactivating mutation in the BRCA1 gene.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The CC<sub>50</sub> for the UWB1.289 line was 56 nM, with 18-fold selectivity over the UWB1.289+BRCA1 cell line, a stable cell line derived from UWB1.289 cells in which expression of wild-type BRCA1 has been restored.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibition of Proliferation of BRCA1 and BRCA2 Deficient Cancer Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">BRCA defect</th><th class="colsep0 rowsep0" align="center" char="Â±">CC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wild-type HeLa</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="char" char="Â±">852Â Â±Â 262</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HeLaÂ BRCA1Â minus</td><td class="colsep0 rowsep0" align="left">yes (shRNA)</td><td class="colsep0 rowsep0" align="char" char="Â±">34Â Â±Â 17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wild-type A549</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="char" char="Â±">1760Â Â±Â 670</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549Â BRCA-2Â minus</td><td class="colsep0 rowsep0" align="left">yes (shRNA)</td><td class="colsep0 rowsep0" align="char" char="Â±">11Â Â±Â 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">UWB1.289</td><td class="colsep0 rowsep0" align="left">BRCA1 mutant</td><td class="colsep0 rowsep0" align="char" char="Â±">56Â Â±Â 20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">UWB1.289+BRCA1</td><td class="colsep0 rowsep0" align="left">noÂ (BRCA1Â restored)</td><td class="colsep0 rowsep0" align="char" char="Â±">975Â Â±Â 40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SUM149PT</td><td class="colsep0 rowsep0" align="left">BRCA1 mutant</td><td class="colsep0 rowsep0" align="char" char="Â±">24Â Â±Â 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SUM1315MO2</td><td class="colsep0 rowsep0" align="left">BRCA1 mutant</td><td class="colsep0 rowsep0" align="char" char="Â±">20Â Â±Â 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT-20</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="char" char="Â±">2,200Â Â±Â 180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DoTc2-4510</td><td class="colsep0 rowsep0" align="left">BRCA2 mutant</td><td class="colsep0 rowsep0" align="char" char="Â±">23Â Â±Â 6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><p class="first last">Proliferation was measured after 12 days (for SUM1315MO2) or 5â7 days (for all other cell lines) after addition of niraparib to the medium, using the CellTiter-Blue assay (Promega) according to manufacturerâs instruction. Values represent the mean CC<sub>50</sub> Â± SD derived from a minimum of four experiments</p></div></div></div><div class="NLM_p last">In agreement with data published for other PARP inhibitors,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> mechanism of action studies in cell culture demonstrated that niraparib exerted its cytotoxic activity on BRCA-defective cells by inducing cell cycle arrest at the G2/M phase followed by apoptosis and then mitotic catastrophe. This last event is presumably due to inhibition of PARP, leading to the persistence of DNA double-strand break lesions that cannot be repaired by HR and the consequent use of alternative error-prone pathways such as single-strand annealing and/or nonhomologous end joining.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Monotherapy Activity in Preclinical in Vivo Models</h3><div class="NLM_p">Xenograft studies were performed on the hydrochloride salt of niraparib. In a single-dose pharmacokinetic study in CD-1 mice, the plasma concentration was approximately 100 nM 24 h after oral administration of 50 mg/kg. Free fraction in mouse and human plasma are 26% and 16%, respectively. Niraparib inhibits the proliferation of BRCA1 mutant MDA-MB-436 cells with CC<sub>50</sub> = 18 nM. These human mammary adenocarcinoma cells form tumors when implanted subcutaneously in the flank of immunocompromised mice and were used as a model system to test niraparib in vivo activity on BRCA1 mutant cells. Preliminary dose-dependent experiments demonstrated that efficacy was achieved at a daily oral dose of 50 mg/kg. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>, at 80 mg/kg, a significant inhibition of tumor growth was observed after only 1 or 2 weeks of treatment. Continuous daily dosing for 3 or 4 weeks was more efficacious and induced tumor shrinkage, with complete and sustained regression observed after 4-week treatment. Niraparib was well-tolerated. as indicated by the less than 10% reduction in body weight in all treatment groups.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Efficacy in BRCA1 mutant mouse xenograft assay following 1, 2, 3, or 4 weeks once daily oral dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Niraparib was also shown to be active in a CAPAN-1 pancreatic cancer cell xenograft model. CAPAN-1 cells are BRCA2 deficient cells that are sensitive to niraparib (CC<sub>50</sub> = 90 nM). Niraparib was dosed using a similar schedule as for the BRCA1 mutant xenograft model (80 mg/kg for 2, 3, or 4 weeks) and showed around 60% tumor growth inhibition (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). Again, it was well-tolerated, with less than 10% reduction in body weight in all treatment groups.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Efficacy in BRCA2 mutant mouse xenograft assay following 2, 3, or 4 weeks once daily oral dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A PARP pharmacodynamic (PD) assay was developed to monitor PARP activity in tumor extracts and in peripheral blood mononuclear cells (PBMCs). This assay measures PARP activity by detecting the incorporation of <sup>3</sup>H-NAD in PAR chains synthesized in response to nicked DNA. Tumor or PBMC homogenates are normalized for PARP-1 levels, and the PARylation reaction is initiated by addition of a nicked DNA strand. Using this assay, we showed that maximum efficacious doses of niraparib strongly (>90%) and continuously inhibited PARP activity in MDA-MB-436 and CAPAN-1 BRCA mutant tumors over 24 h. Data are shown for the MDA-MB-436 model in Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a> (data in the CAPAN-1 model are similar). This level of intratumoral inhibition correlated with 50% or greater inhibition observed peripherally in PBMCs at 24 h postdose. These results suggested that PARP inhibition in a peripheral tissue like PBMCs can be explored as a pharmacodynamic biomarker in the clinic to determine whether niraparib has sufficient activity (i.e., inhibits PARP activity in PBMC by >50%) at the maximum tolerated dose (MTD) to warrant further development.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pharmacodynamic activity of niraparib in MDA-MB-436 xenografts. % PARP activity is shown at 4, 8, and 24 h post po dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Combination Therapy</h3><div class="NLM_p">PARP-1/2 inhibitors have been demonstrated to be effective in preclinical models in combination with platinum, alkylating and methylation agents, radiation therapy, and topoisomerase I inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In contrast to the rationale for monotherapy, in which PARP inhibitors causes DNA damage in HR deficient cancers, PARP is required for repair of DNA damage induced by standard cytotoxic chemotherapy. In some cases, the specific role of PARP has yet not been fully elucidated,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> but PARP-1 is known to be required to release trapped topoisomerase I/irinotecan complexes from DNA and Temozolomide induced DNA damage is repaired by the BER pathway which requires PARP to recruit repair proteins.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> It is noteworthy that, because of the myelosuppression induced by PARP inhibitors, it is of paramount importance to their clinical development as chemosensitizers to establish proper dose and schedule in combination, in addition to monotherapy.</div><div class="NLM_p last">Niraparib strongly enhanced the therapeutic effect of radiation administered using a clinically relevant dose fractionation protocol in breast and lung cancer models.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The mechanism of radiosensitization is p53-independent and seems to depend on the conversion of radiation induced sublethal SSBs into lethal DSBs as a consequence of BER inhibition.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Niraparib has also been shown to sensitize colorectal cancer cell lines in vitro and in vivo to irinotecan. Interestingly, we demonstrated that in subcutaneous xenograft models oral doses of niraparib 50% lower than those efficacious in monotherapy administered for not more than 5 days can still strongly potentiates irinotecan activity in vivo.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Short-term treatment (5 days) has also been shown to potentiate Temozolomide activity in preclinical models, but in this case no significant efficacy was observed at niraparib doses lower than those used in monotherapy. The reasons underlying this difference between irinotecan and Temozolomide remain to be investigated and might be related to the different mechanism of action of the two drugs.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Other PARP Inhibitors in Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There has been, and continues to be,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> considerable interest in the discovery and development of PARP inhibitors. For the sake of brevity, we limit ourselves to the discussion of PARP inhibitors in mid- or late-stage clinical development. Structures are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. Rucaparib (<b>5</b>) was characterized<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> as a potent PARP inhibitor in cell based assays of radio- and chemosensitization and is a very potent (PARP-1 IC<sub>50</sub> = 2 nM) enzyme inhibitor. It was in development by Pfizer but was out-licensed to Clovis in June, 2011. Rucaparib is currently being evaluated in a phase 3 ovarian cancer trial and is in earlier phase clinical trials for other cancer indications. Olaparib (<b>6</b>) was discovered<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> by KuDOS. In 2005, AstraZeneca bought KuDOS while olaparib was in phase I and continues its development. It is a potent PARP-1/2 inhibitor (PARP-1 IC<sub>50</sub> = 5 nM) with good activity in cell based assays and bioavailable in rats and dogs. Olaparib is dosed at 300 mg twice daily (bid) and is currently in a number of phase 2 or 3 clinical trials alone or in combination for the treatment of breast, ovarian, pancreatic, and prostate cancer. Veliparib<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<b>7</b>) is a potent PARP-1/2 inhibitor (PARP-1 <i>K</i><sub>i</sub> = 5 nM) with nanomolar cell based activity and good bioavailability that was discovered and is in development by AbbVie (previously Abbott). It is dosed bid orally and is in multiple combination studies in a variety or tumor types, including breast, ovarian, lung, and pancreatic. BMN 673 (<b>9</b>)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> is a subnanomolar PARP-1/2 inhibitor (PARP-1 IC<sub>50</sub> = 0.6 nM) with good activity (EC<sub>50</sub> = 2.5 nM) in the cell based PARylation assay and good oral bioavailability that is in development by BioMarin. Similarly to niraparib, <b>9</b> is dosed once daily, unlike rucaparib, olaparib, and veliparib, which require bid dosing. <b>9</b> has started a phase 3 study, dosed at 1 mg qd in breast cancer with germline BRCA mutations, along with other earlier stage cancer trials.</div><div class="NLM_p">While there was growing excitement about PARP inhibitors in the early years of this century, the field received two setbacks at the beginning of its second decade. The first<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> came from clinical trials with iniparib (<b>25</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>), a molecule licensed by Sanofi from BiPar and reported to be a prodrug of a covalent PARP inhibitor (via reduction of the nitro group to the corresponding nitroso analogue). Despite a promising phase 2 trial<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> in triple-negative breast cancer in combination with gemcitabine and carboplatin, it was disclosed in 2011 that there was no positive effect in a phase 3 trial.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> It was later shown that iniparib is not, in fact, a PARP inhibitor.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Second, despite promising early trials, AstraZeneca announced<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> in 2011 that olaparib would not be progressed to phase 3 trials. Reasons given were that it was believed unlikely that it would improve overall survival and issues in developing a formulation. However, a later analysis of the data<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> by BRCA status was performed, and it was observed that ovarian cancer patients harboring a BRCA mutation achieved significant clinical benefit from the treatment of olaparib in the maintenance setting. AstraZeneca restarted<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> its clinical development program after a nearly two-year hiatus. Meanwhile, in 2011, Pfizer out-licensed rucaparib to Clovis and in 2012 Merck out-licensed niraparib to Tesaro.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Iniparib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Clinical Experience</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Phase 1</h3><div class="NLM_p">Niraparib entered clinical studies in the fall of 2008. The form being developed is the <i>para</i>-toluenesulfonate salt.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The first human study was a nonrandomized, open-label, dose-comparison, single-group assignment, safety and efficacy phase 1 trial at centers in the US and UK (NCT00749502).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The trial consisted of a phase 1a portion in patients (<i>n</i> = 60) with advanced solid tumors and a phase 1b portion in patients (<i>n</i> = 40) with high-grade serous ovarian cancer or castration-resistant prostate cancer. Patients enrolled into the dose-escalation and dose-confirmation phases of the study (phase 1a) had cancers of any histological subtype. However, enrichment for germline BRCA1 mutation (gBRCA1<sup>mut</sup>) and gBRCA2<sup>mut</sup> carriers was conducted prospectively in phase 1a to establish evidence that niraparib could have anticancer activity in tumors defective in HR function. Patients were considered to have a gBRCA1<sup>mut</sup> or gBRCA2<sup>mut</sup> if they had previous confirmation of a pathological <i>BRCA</i> mutation as determined by Myriad Genetics BRCA mutation testing (BRAC Analysis). Dose expansion (phase 1b) was conducted in patients with sporadic platinum-resistant high-grade serous ovarian cancer and castration-resistant prostate cancer, as it was believed at the time these patients may harbor defects in DNA repair.</div><div class="NLM_p">The starting dose of 30 mg/day once daily orally in phase 1a was selected based on preclinical safety studies. A modified 3 + 3 design<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> was pursued for dose escalation at approximately 40% dose increments. Tumor response was assessed by response evaluation criteria in solid tumors (RECIST). Bone scans and prostate-specific antigen (PSA) levels were obtained for patients with castration-resistant prostate cancer. Serial serum CA125 levels were obtained for high-grade serous ovarian cancer patients. Pharmacokinetic parameters were determined at all dose levels. Pharmacodynamic measurements consisted of PARP activity in PBMCs, changes in circulating tumor cells, and molecular characterization of tumor tissue if available.</div><div class="NLM_p">Ten dose levels were investigated between 30 and 400 mg/day in both BRCA1/2 mutant and BRCA1/2 wild-type patients, with the latter dose considered dose limiting due the occurrence of reversible grade 4 thrombocytopenia. A dose reduction to 300 mg/day was evaluated in an additional 10 patients and determined to be the recommended phase 1b dose due to the absence of previously defined dose-limiting toxicities. In addition to these 10 patients, a further 40 were treated in phase 1b at this dose of 300 mg/day. Consistent with known toxicities of other PARP inhibitors, dose proportional hematological toxicities were observed. All hematological toxicities were reversible and manageable with dose interruptions or reductions. The most common nonhematological treatment related adverse events were nausea, fatigue, constipation, anorexia, vomiting, and insomnia. However, these were considered mild to moderate in severity.</div><div class="NLM_p">Pharmacokinetic analysis indicated exposure to niraparib was dose proportional between the 30 and 400 mg/day doses, with moderate variability between patients at the same dose. It was rapidly absorbed, with peak plasma concentrations occurring 3â4 h after dosing and had a mean terminal half-life of 36.4 h. It is currently believed that it is important to maintain continuous inhibition of PARP-1 enzyme for monotherapy regimens. Importantly, the plasma trough concentrations were >2 Î¼M at the 300 mg/day dose, with all doses of 40 mg/day or above achieving plasma trough concentrations of 288 nM or greater which, based on xenograft studies, may be expected to be efficacious. Peripheral blood mononuclear cells (PBMCs) were collected at predose on days 1, 5, and 21, and at 4 h postdose on days 5 and 21. Pharmacodynamic evaluation showed PARP inhibition in PBMCs exceeded 50% at doses of 80 mg/day or greater.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Induction of gH2AX foci was observed in post-treatment tumor tissue and in circulating tumor cells in patients, confirming the presence of DNA double-strand breaks consistent with PARP inhibition.</div><div class="NLM_p">Antitumor activity was documented in patients with and without germline BRCA mutations, with particularly compelling efficacy observed in ovarian cancer patients (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>). In 20 radiologically assessable gBRCA<sup>mut</sup>ovarian cancer patients, eight (40%) achieved a confirmed RECIST and CA125 GCIG partial response at doses ranging from 80 to 400 mg/day with a median duration of response of 387 days. (CA125 is a serum marker adopted by the Gynecological Cancer Intergroup (GCIG) that is often used a biomarker of response in ovarian cancer.) Three of these responding patients were platinum resistant and five were platinum sensitive. Stable disease of 120 days or greater was reported in two additional gBRCA<sup>mut</sup> ovarian cancer patients. Four gBRCA<sup>mut</sup> breast cancer patients were evaluable in this study, and two (50%) achieved partial responses lasting approximately 3 months at starting doses of 210 and 150 mg/day. One nonsmall cell lung cancer (NSCLC) patient with a documented gBRCA2<sup>mut</sup> had stable disease for 175 days at 110 mg/day. In 22 germline BRCA wild type high-grade serous ovarian cancer patients, five (23%) achieved a durable partial response by RECIST or CA125 GCIG at starting doses of 60 mg/day or greater. Two of these responding patients were platinum resistant, and three were platinum sensitive. Stable disease of 120 days or greater was reported in three additional gBRCA<sup>wt</sup> high-grade serous ovarian cancer patients. An additional NSCLC patient experienced sustained RECIST stable disease for 316 days on 40 mg/day. Nine of 21 (43%) castration-resistant prostate cancer patients had stable disease for a median duration of 254 days. Collectively, niraparib demonstrated clinical validation of its mechanism of action and pharmacological properties amenable to once daily administration and resulted in significant antitumor activity in gBRCA<sup>mut</sup> and sporadic cancers within a large therapeutically effective dosing window (60â300 mg/day).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Antitumor activity in ovarian cancer *BRCA1/2 mutation carriers. â Reduction in overall sum of measurable disease but new lesion seen (overall: PD). Refractory patient (<i>BRCA</i> mutated) not included.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In February 2011, an open-label, nonrandomized, phase I trial (NCT01294735) was initiated in the US to evaluate niraparib given with Temozolomide in patients with advanced cancer. The trial was completed in May 2012 following recruitment of 19 patients. Patients received niraparib (30, 40, and 70 mg/day orally, days 1â8 of a 28 day cycle) plus Temozolomide (150 mg/m<sup>2</sup> orally, days 4â8 of the 28 day cycle). The maximum tolerated dose was found to be niraparib (40 mg/day) plus Temozolomide (150 mg/m<sup>2</sup>/day). Overall, the highest incidence of adverse events observed was myelosuppression, including thrombocytopenia (63%) and leukopenia (42%, 8/19), as well as nausea (42%) and fatigue (37%). One glioblastoma patient exhibited a partial response after six treatment cycles of niraparib (40 mg), and stable disease was reported in a malignant melanoma and a serous ovarian cancer patient after 4 cycles of niraparib, 40 and 30 mg/day, respectively. No pharmacodynamic markers of target engagement were evaluated. This study highlights one of the challenges in developing PARP inhibitors in combination with traditional chemotherapies, particularly when the chemotherapeutic agents are administered at full doses. Doses and schedules of a single agent PARP inhibitor determined as safe in phase I monotherapy clinical trials are likely to be toxic when given in combination with anticancer cytotoxic chemotherapy, while the dosing regimen determined as safe in combination with a cytotoxic is unlikely to be sufficient as a single agent.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Higher doses are probably required for single-agent activity because PARP activity needs to be nearly completely suppressed to ensure that the relatively modest levels of endogenous damage persist and are rendered cytotoxic. Conversely, for chemo-and radiopotentiation, where high levels of damage are induced in a short period, PARP does not need to be totally suppressed for such levels of damage to be cytotoxic.</div><div class="NLM_p">Starting in the summer of 2010, three additional phase 1 studies were opened. In July 2010, an open-label, nonrandomized, dose-escalation, phase 1b trial (NCT01110603) was initiated in the US to evaluate niraparib in combination with approved doses of common standard of care agents carboplatin, or carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin used for the treatment of breast and ovarian cancers and establish the recommended phase 2 dose in adults with advanced solid cancers. In November 2010, an open-label, nonrandomized, dose-escalation, phase 1b trial (NCT01227941) was initiated in the US to evaluate niraparib in combination with pegylated liposomal doxorubicin in patients with advanced solid tumors. In November 2010, an open-label, nonrandomized, phase 1 trial (NCT01226901) was initiated in Japan in patients with advanced solid tumors. None of these three phase 1 studies were completed; niraparib was out-licensed by Merck to Tesaro, and the clinical development program became focused on bringing forward the benefits of a PARP inhibitor to patients with breast and ovarian cancer as quickly as possible.</div><div class="NLM_p last">Currently, there is one ongoing phase 1 niraparib combination study. In the fall of 2013, a phase 1 trial was initiated to assess whether Temozolomide could sensitize tumor cells to niraparib in patients with pretreated, incurable Ewingâs sarcoma based on efficacy in preclinical models. A key element in this clinical investigation will be to identify the optimal efficacious dosing regimen of both agents and pharmacodynamic markers validating target engagement and mechanism(s) of efficacy.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Phase 3</h3><div class="NLM_p last">On the basis of phase 1 results with niraparib and evidence of clinical efficacy with other PARP inhibitors,<a onclick="showRef(event, 'ref44 ref50'); return false;" href="javascript:void(0);" class="ref ref44 ref50">(44, 50)</a> two phase 3 studies of niraparib were initiated in 2013. The first study initiated was NOVA, a phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum sensitive ovarian cancer who have either gBRCA<sup>mut</sup> or a tumor with high-grade serous histology (NCT01847274). The patients must have received at least two platinum based regimens, had a response to their last regimen, have no measurable disease >2 cm, and normal CA125 (or >90% decrease) following their last treatment. The study is designed to assess the primary end point of whether maintenance with niraparib will extend progression free survival (PFS) in this population. There are two independent patient cohorts, one with deleterious gBRCA<sup>mut</sup> and the other with high-grade serous histology but without such germline BRCA mutations. Each cohort will contain 180 patients, with 120 being treated with niraparib at 300 mg/day continuously daily and 60 receiving placebo. It is anticipated that gBRCA<sup>mut</sup> patients will experience an increased PFS versus placebo and some patients in the non-gBRCA<sup>mut</sup> population will experience an increased PFS due to other deficiencies in DNA damage repair. Analysis of biomarkers from blood and archival tumor tissue predicting increased PFS in this cohort will be valuable in understanding sensitivity to niraparib beyond germline BRCA mutations such as deficiencies in homologous recombination. The second phase 3 study was initiated in late 2013 and referred to as BRAVO. This study is a randomized, open-label, multicenter, controlled trial to compare niraparib versus physicianâs choice, in patients with germline BRCA mutations who have advanced HER2 negative breast cancer. Eligible patients are randomized 2:1 for receiving niraparib orally at a dose of 300 mg once daily on a continuous dosing regimen or physicianâs choice among one of the following four single agents: eribulin, vinorelbine, gemcitabine, or capecitabine. The primary end point is PFS. The hypothesized median PFS improvement is 6 versus 3 months (hazard ratio = 0.5) for niraparib versus physicianâs choice. The study has 99.6% power for the primary PFS analysis at a 1-sided Î± of 0.025. Assuming an increase in overall survival from 9 to 13 months (hazard ratio = 0.69), the study has 80% power for the overall survival comparison at a 1-sided Î± of 0.025. The evaluation of predictive biomarkers related to efficacy of niraparib will include tumor biomarkers, assessment of circulating plasma DNA, humoral immune response monitoring, and PBMCs. Additional phase 3 studies in ovarian cancer and small cell lung cancer have been announced, but details are not available publically yet.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although there has been interest in PARP inhibitors for a variety of therapeutic applications for some time, it was the discovery that PARP inhibition in the context of defects in other DNA repair mechanisms was toxic to tumor cells (synthetic lethal) that spurred enormous interest in the field. The chemical series that led to niraparib was designed based on knowledge of the pharmacophore necessary for PARP inhibition. A number of challenges were addressed during its discovery, including at the outset obtaining good cell based activity. The preclinical pharmacokinetic profiles at first were suboptimal, but good mechanistic studies of clearance provided solutions, in rats showing that extrahepatic oxidation played a major role and that a hydrolysis seen in dogs was species specific. Niraparib was shown to have cytotoxic activity in a number of BRCA1 and BRCA2 negative or mutant cells lines with good selectivity over normal cells. Preclinical xenograft experiments showed proof of principle that niraparib would inhibit relevant tumor cell growth in vivo, and characterization of the extent of PARP inhibition in tumor and in PBMCs allowed development of a peripheral biomarker that could be used in the clinic. Niraparib has excellent human pharmacokinetics with a long half-life allowing once daily oral dosing, and doses of 80 mg/day or more show PARP inhibition expected to provide clinical benefit. In a phase 1 trial niraparib has shown very promising activity in BRCA mutant patients and in sporadic cancers, and these activities are being further investigated in two phase 3 trials in breast and in ovarian cancer. In addition to patients with germline BRCA mutations, there is increasing evidence that other deficiencies in homologous recombination may impart sensitivity to PARP inhibitors such as niraparib. A significant activity in its future development will include methods of identifying patients other than those that carry a germline BRCA mutation that would most probably gain clinical benefit from niraparib treatment.</div><div class="NLM_p last">After great enthusiasm 10 years ago, a hiccup along the way around the beginning of the current decade but recent studies showing great promise, it appears that PARP inhibitors are back on track.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The outcomes of ongoing late stage trials of niraparib and other PARP inhibitors are awaited with excitement, and it is hoped that this will provide significant benefit to patients suffering from cancer.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm5018237" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Rowley</span> - <span class="hlFld-Affiliation affiliation">Istituto
di Ricerche di Biologia Molecolare, Via Pontina km 30600, 00040 Pomezia, Italy</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#472a2e242f26222b693528302b223e072a2235242c6924282a"><span class="__cf_email__" data-cfemail="86ebefe5eee7e3eaa8f4e9f1eae3ffc6ebe3f4e5eda8e5e9eb">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Jones</span> - <span class="hlFld-Affiliation affiliation">Istituto
di Ricerche di Biologia Molecolare, Via Pontina km 30600, 00040 Pomezia, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Wilcoxen</span> - <span class="hlFld-Affiliation affiliation">TESARO,
Inc., 1000 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlo Toniatti</span> - <span class="hlFld-Affiliation affiliation">Istituto
di Ricerche di Biologia Molecolare, Via Pontina km 30600, 00040 Pomezia, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): PJ owns shares in Tesaro, KW is an employee of Tesaro, Inc., MR is an employee of MSD and holds restricted stock in Merck.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1670e1286-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank our many colleagues at the IRBM, Merck Research Laboratories and at Tesaro who contributed to discovering and advancing niraparib through discovery and clinical development.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i23" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i23"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i24" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i24"> Abbreviations Used</h2><tr><td class="NLM_term">BER</td><td class="NLM_def"><p class="first last">base excision repair</p></td></tr><tr><td class="NLM_term">CLp</td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">DSB</td><td class="NLM_def"><p class="first last">(DNA) double-strand break</p></td></tr><tr><td class="NLM_term">GCIG</td><td class="NLM_def"><p class="first last">gynecological cancer intergroup</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">homologous recombination</p></td></tr><tr><td class="NLM_term">IRBM</td><td class="NLM_def"><p class="first last">Istituto di Ricerche di Biologia Molecolare</p></td></tr><tr><td class="NLM_term">MMR</td><td class="NLM_def"><p class="first last">mismatch repair</p></td></tr><tr><td class="NLM_term">NER</td><td class="NLM_def"><p class="first last">nucleotide excision repair</p></td></tr><tr><td class="NLM_term">NHEJ</td><td class="NLM_def"><p class="first last">nonhomologous end joining</p></td></tr><tr><td class="NLM_term">PAR</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression free survival</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">prostate specific antigen</p></td></tr><tr><td class="NLM_term">RECIST</td><td class="NLM_def"><p class="first last">response evaluation criteria in solid tumors</p></td></tr><tr><td class="NLM_term">shRNA</td><td class="NLM_def"><p class="first last">small hairpin RNA</p></td></tr><tr><td class="NLM_term">SSB</td><td class="NLM_def"><p class="first last">(DNA) single-strand break</p></td></tr><tr><td class="NLM_term">UK</td><td class="NLM_def"><p class="first last">United Kingdom (of Great Britain and Northern Ireland)</p></td></tr><tr><td class="NLM_term">US</td><td class="NLM_def"><p class="first last">United States (of America)</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Plummer, R.</span><span> </span><span class="NLM_article-title">Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4527</span><span class="NLM_x">â</span> <span class="NLM_lpage">4531</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1078-0432.CCR-10-0984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=20823148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4527-4531&author=R.+Plummer&title=Perspective+on+the+pipeline+of+drugs+being+developed+with+modulation+of+DNA+damage+as+a+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target</span></div><div class="casAuthors">Plummer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4527-4531</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Inhibitors of various elements of the DNA repair pathways have entered clin. development or are in late preclin. stages of drug development.  It was initially considered that agents targeting DNA repair would act to overcome tumor resistance to chemotherapy and radiotherapy.  More recent data have shown that targeting DNA repair pathways can be effective in selected tumors via a synthetically lethal route, with single agent activity having been shown with poly-ADP ribose polymerase (PARP) inhibitors.  An increased understanding of the biol. and interaction of the DNA repair pathways also means that rational combination of DNA repair inhibitors may also give great benefit in the clinic.  Clin Cancer Res; 16(18); 4527-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ZUVcQq98zbVg90H21EOLACvtfcHk0liJ2uAxbs2dXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bP&md5=76990efc619368c2e364fc4e7b80be50</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0984%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26atitle%3DPerspective%2520on%2520the%2520pipeline%2520of%2520drugs%2520being%2520developed%2520with%2520modulation%2520of%2520DNA%2520damage%2520as%2520a%2520target%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4527%26epage%3D4531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">â</span> <span class="NLM_lpage">4584</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors.+From+concept+to+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></div><div class="casAuthors">Ferraris, Dana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4561-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) has been an actively pursued drug discovery target for almost 3 decades.  Often referred to as the "guardian angel of DNA", this abundant nuclear enzyme has been the focus of over 20 medicinal chem. programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes.  Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clin. trials.  Recent results from several PARP-1 inhibitors in phase II clin. trials for cancer therapy have attracted the attention of national media.  Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer.  This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs.  This Perspective will offer a historical account of the crit. PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s.  Furthermore, I will discuss why PARP- 1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chem. efforts today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhFTTs4raarVg90H21EOLACvtfcHk0lhd9apzjR2ZUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D&md5=6c093238562c908d45dfcd2f3055457d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2034</span><span class="NLM_x">â</span> <span class="NLM_lpage">2044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2174%2F138945011798829438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=21777194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFyisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=2034-2044&author=S.+K.+Sandhuauthor=T.+A.+Yapauthor=J.+S.+de+Bono&title=The+emerging+role+of+poly%28ADP-ribose%29+polymerase+inhibitors+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment</span></div><div class="casAuthors">Sandhu, Shahneen K.; Yap, Timothy A.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2034-2044</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase (PARP) is a crit. DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway.  PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and to also selectively kill homologous recombination repair-defective cancers, such as those arising in BRCA1 and BRCA2 mutation carriers.  Recent proof-of-concept clin. studies have demonstrated the safety and substantial antitumor activity of the PARP inhibitor, olaparib in BRCA1/2 mutation carriers, highlighting the wide therapeutic window that can be achieved with this synthetic lethal strategy.  Likewise, the PARP inhibitor, BSI-201, in combination with carboplatin and gemcitabine have produced promising results in "triple-neg." breast cancers.  There are also currently numerous other PARP inhibitors in clin. development.  The potential broader therapeutic application of these approaches to a wide range of sporadic tumors harboring specific defects in the homologous recombination repair pathway has generated a great deal of excitement within the oncol. community.  This review discusses the rationale for targeting PARP and details the strategies and challenges involved in the clin. development of such inhibitors and their future potential applications in cancer medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2fm_RjFRzq7Vg90H21EOLACvtfcHk0lhd9apzjR2ZUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFyisA%253D%253D&md5=55d1f258f6ecea5140a8de7bbc83927b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F138945011798829438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011798829438%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520emerging%2520role%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520in%2520cancer%2520treatment%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D2034%26epage%3D2044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Basu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">â</span> <span class="NLM_lpage">1590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1579-1590&author=B.+Basuauthor=S.+K.+Sandhuauthor=J.+S.+de+Bono&title=PARP+inhibitors%3A+mechanism+of+action+and+their+potential+role+in+the+prevention+and+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DPARP%2520inhibitors%253A%2520mechanism%2520of%2520action%2520and%2520their%2520potential%2520role%2520in%2520the%2520prevention%2520and%2520treatment%2520of%2520cancer%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26spage%3D1579%26epage%3D1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E. C.</span><span> </span><span class="NLM_article-title">PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">â</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1093%2Fannonc%2Fmdt384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=24225019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A280%3ADC%252BC2c7mtl2lsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=32-40&author=J.+M.+Leeauthor=J.+A.+Ledermannauthor=E.+C.+Kohn&title=PARP+inhibitors+for+BRCA1%2F2+mutation-associated+and+BRCA-like+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies</span></div><div class="casAuthors">Lee J-M; Ledermann J A; Kohn E C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poly(ADP-ribose)polymerase inhibitors (PARPis) have shown promising activity in patients with BRCA1/2 mutation-associated (BRCA1/2(MUT+)) ovarian and breast cancers.  Accumulating evidence suggests that PARPi may have a wider application in the treatment of sporadic high-grade serous ovarian cancer, and cancers defective in DNA repair pathways, such as prostate, endometrial, and pancreatic cancers.  Several PARPis are currently in phase 1/2 clinical investigation, with registration trials now being designed.  Olaparib, one of the most studied PARPis, has demonstrated activity in BRCA1/2(MUT+) and BRCA-like sporadic ovarian and breast cancers, and looks promising in prostate and pancreatic cancers.  Understanding more about the molecular abnormalities involved in BRCA-like tumors, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers, is critical to rapidly advancing the field of PARPi therapy and improve clinical outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtDJRDtld96tK0qsdY6Nc1fW6udTcc2eag6l3Ud5esZ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7mtl2lsg%253D%253D&md5=7198a00ebba514a62de969ab28e42d3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt384%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26atitle%3DPARP%2520inhibitors%2520for%2520BRCA1%252F2%2520mutation-associated%2520and%2520BRCA-like%2520malignancies%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D32%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span> <span class="citation_source-journal">Front. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3046</span><span class="NLM_x">â</span> <span class="NLM_lpage">3082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2741%2F2909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17981777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=3046-3082&author=P.+O.+Hassaauthor=M.+O.+Hottiger&title=The+diverse+biological+roles+of+mammalian+PARPs%2C+a+small+but+powerful+family+of+poly-ADP-ribose+polymerases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span></div><div class="casAuthors">Hassa, Paul O.; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3046-3082</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Poly-ADP-ribose metab. plays a mayor role in a wide range of biol. processes, such as maintenance of genomic stability, transcriptional regulation, energy metab., and cell death.  Poly-ADP-ribose polymerases (PARPs) are an ancient family of enzymes, as evidenced by the poly-ADP-ribosylating activities reported in dinoflagellates and archaebacteria and by the identification of Parp-like genes in eubacterial and archaeabacterial genomes.  Six genes encoding "bona fide" PARP enzymes have been identified in mammalians: PARP1, PARP2, PARP3, PARP4/vPARP, PARP5/Tankyrases-1, and PARP6/Tankyrases-2.  The best studied of these enzymes, PARP1, plays a primary role in the process of poly-ADP-ribosylation.  PARP1-mediated poly-ADP-ribosylation has been implicated in the pathogenesis of cancer, inflammatory, and neurodegenerative disorders.  Here, the authors summarize novel findings and concepts for PARP enzymes and their poly-ADP-ribosylation activity in the regulation of physiol. and pathophysiol. processes.  A special focus is placed on the proposed mol. mechanisms involved in these processes, such as signaling, regulation of telomere dynamics, remodeling of chromatin structure, and transcriptional regulation.  A potential functional cross-talk between PARP family members and other NAD-consuming enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoNyzgIk1gtrVg90H21EOLACvtfcHk0liy26bRGQ7_Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D&md5=1e62c4597ec219b0797a29c1458b98b4</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.2741%2F2909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F2909%26sid%3Dliteratum%253Aachs%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DThe%2520diverse%2520biological%2520roles%2520of%2520mammalian%2520PARPs%252C%2520a%2520small%2520but%2520powerful%2520family%2520of%2520poly-ADP-ribose%2520polymerases%26jtitle%3DFront.%2520Biosci.%26date%3D2008%26volume%3D13%26spage%3D3046%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">AmÃ©, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlehauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">The PARP superfamily</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">â</span> <span class="NLM_lpage">893</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=882-893&author=J.-C.+Am%C3%A9author=C.+Spenlehauerauthor=G.+de+Murcia&title=The+PARP+superfamily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAm%25C3%25A9%26aufirst%3DJ.-C.%26aulast%3DSpenlehauer%26aufirst%3DC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DThe%2520PARP%2520superfamily%26jtitle%3DBioEssays%26date%3D2004%26volume%3D26%26spage%3D882%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SzabÃ³, C.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">440</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=421-440&author=P.+Jagtapauthor=C.+Szab%C3%B3&title=Poly%28ADP-ribose%29+polymerase+and+the+therapeutic+effects+of+its+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSzab%25C3%25B3%26aufirst%3DC.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520and%2520the%2520therapeutic%2520effects%2520of%2520its%2520inhibitors%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D421%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Sejas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span> </span><span class="NLM_article-title">New PARP targets for cancer therapy</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">â</span> <span class="NLM_lpage">509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=502-509&author=V.+Sejasauthor=P.+Chang&title=New+PARP+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSejas%26aufirst%3DV.%26aulast%3DChang%26aufirst%3DP.%26atitle%3DNew%2520PARP%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2014%26volume%3D7%26spage%3D502%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Huber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">â</span> <span class="NLM_lpage">1108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1103-1108&author=A.+Huberauthor=P.+Baiauthor=J.+M.+de+Murciaauthor=G.+de+Murcia&title=PARP-1%2C+PARP-2+and+ATM+in+the+DNA+damage+response%3A+functional+synergy+in+mouse+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DA.%26aulast%3DBai%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPARP-1%252C%2520PARP-2%2520and%2520ATM%2520in%2520the%2520DNA%2520damage%2520response%253A%2520functional%2520synergy%2520in%2520mouse%2520development%26jtitle%3DDNA%2520Repair%26date%3D2004%26volume%3D3%26spage%3D1103%26epage%3D1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omidiji, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shall, S.</span><span> </span><span class="NLM_article-title">(ADP-ribose)<sub>n</sub> participates in DNA excision repair</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">â</span> <span class="NLM_lpage">596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1980&pages=593-596&author=B.+W.+Durkaczauthor=O.+Omidijiauthor=D.+A.+Grayauthor=S.+Shall&title=%28ADP-ribose%29n+participates+in+DNA+excision+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DOmidiji%26aufirst%3DO.%26aulast%3DGray%26aufirst%3DD.%2BA.%26aulast%3DShall%26aufirst%3DS.%26atitle%3D%2528ADP-ribose%2529n%2520participates%2520in%2520DNA%2520excision%2520repair%26jtitle%3DNature%26date%3D1980%26volume%3D283%26spage%3D593%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedergang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trucco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricoul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutrillaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dierich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMeur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walztinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">7303</span><span class="NLM_x">â</span> <span class="NLM_lpage">7307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1073%2Fpnas.94.14.7303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=9207086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=7303-7307&author=J.+M.+de+Murciaauthor=C.+Niedergangauthor=C.+Truccoauthor=M.+Ricoulauthor=B.+Dutrillauxauthor=M.+Markauthor=F.+J.+Oliverauthor=M.+Massonauthor=A.+Dierichauthor=M.+LeMeurauthor=C.+Walztingerauthor=P.+Chambonauthor=G.+de+Murcia&title=Requirement+of+poly%28ADP-ribose%29+polymerase+in+recovery+from+DNA+damage+in+mice+and+in+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span></div><div class="casAuthors">Menissier de Murcia, Josiane; Niedergang, Claude; Trucco, Carlotta; Ricoul, Michele; Dutrillaux, Bernard; Mark, Manuel; Oliver, F. Javier; Masson, Murielle; Dierich, Andree; LeMeur, Marianne; Walztinger, Caroline; Chambon, Pierre; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7303-7307</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase [PARP; NAD+ ADP-ribosyltransferase; NAD+:poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyltransferase, EC 2.4.2.30] is a zinc-finger DNA-binding protein that detects specifically DNA strand breaks generated by genotoxic agents.  To det. its biol. function, the authors have inactivated both alleles by gene targeting in mice.  Treatment of PARP-/- mice either by the alkylating agent N-methyl-N-nitrosourea (MNU) or by Î³-irradn. revealed an extreme sensitivity and a high genomic instability to both agents.  Following whole body Î³-irradn. (8 Gy) mutant mice died rapidly from acute radiation toxicity to the small intestine.  Mice-derived PARP-/- cells displayed a high sensitivity to MNU exposure: a G2/M arrest in mouse embryonic fibroblasts and a rapid apoptotic response and a p53 accumulation were obsd. in splenocytes.  Altogether these results demonstrate that PARP is a survival factor playing an essential and pos. role during DNA damage recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlwmTBk-nHc7Vg90H21EOLACvtfcHk0ljk24H3YtEM4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D&md5=a652d7d877fa0c29ff1aeb9769fbd86f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.14.7303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.14.7303%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3DNiedergang%26aufirst%3DC.%26aulast%3DTrucco%26aufirst%3DC.%26aulast%3DRicoul%26aufirst%3DM.%26aulast%3DDutrillaux%26aufirst%3DB.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26aulast%3DMasson%26aufirst%3DM.%26aulast%3DDierich%26aufirst%3DA.%26aulast%3DLeMeur%26aufirst%3DM.%26aulast%3DWalztinger%26aufirst%3DC.%26aulast%3DChambon%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DRequirement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520recovery%2520from%2520DNA%2520damage%2520in%2520mice%2520and%2520in%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D7303%26epage%3D7307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">â</span> <span class="NLM_lpage">917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger Î³-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0ljk24H3YtEM4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">â</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.N.+J.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+B.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+M.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0ljk24H3YtEM4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.N.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluzek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bialkowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zdzienicka, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8109</span><span class="NLM_x">â</span> <span class="NLM_lpage">8115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8109-8115&author=N.+McCabeauthor=N.+C.+Turnerauthor=C.+J.+Lordauthor=K.+Kluzekauthor=A.+Bialkowskaauthor=S.+Swiftauthor=S.+Giavaraauthor=M.+J.+O%E2%80%99Connorauthor=A.+N.+Tuttauthor=M.+Z.+Zdzienickaauthor=G.+C.+M.+Smithauthor=A.+Ashworth&title=Deficiency+in+the+repair+of+DNA+damage+by+homologous+recombination+and+sensitivity+to+poly%28ADP-ribose%29+polymerase+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DKluzek%26aufirst%3DK.%26aulast%3DBialkowska%26aufirst%3DA.%26aulast%3DSwift%26aufirst%3DS.%26aulast%3DGiavara%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DZdzienicka%26aufirst%3DM.%2BZ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DDeficiency%2520in%2520the%2520repair%2520of%2520DNA%2520damage%2520by%2520homologous%2520recombination%2520and%2520sensitivity%2520to%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8109%26epage%3D8115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Nijman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, S. H.</span><span> </span><span class="NLM_article-title">Cancer. Potential of the synthetic lethality principle</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">811</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=809-811&author=S.+M.+Nijmanauthor=S.+H.+Friend&title=Cancer.+Potential+of+the+synthetic+lethality+principle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNijman%26aufirst%3DS.%2BM.%26aulast%3DFriend%26aufirst%3DS.%2BH.%26atitle%3DCancer.%2520Potential%2520of%2520the%2520synthetic%2520lethality%2520principle%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D809%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Venkitaraman, A. R.</span><span> </span><span class="NLM_article-title">Cancer susceptibility and the functions of BRCA1 and BRCA2</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2002&pages=171-182&author=A.+R.+Venkitaraman&title=Cancer+susceptibility+and+the+functions+of+BRCA1+and+BRCA2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DCancer%2520susceptibility%2520and%2520the%2520functions%2520of%2520BRCA1%2520and%2520BRCA2%26jtitle%3DCell%26date%3D2002%26volume%3D108%26spage%3D171%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Narod, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foulkes, W. D.</span><span> </span><span class="NLM_article-title">BRCA1 and BRCA2: 1994 and beyond</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">â</span> <span class="NLM_lpage">676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnrc1431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15343273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCmsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=665-676&author=S.+A.+Narodauthor=W.+D.+Foulkes&title=BRCA1+and+BRCA2%3A+1994+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">BRCA1 and BRCA2: 1994 and beyond</span></div><div class="casAuthors">Narod, Steven A.; Foulkes, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-676</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of the first gene assocd. with hereditary breast cancer, BRCA1, was anticipated to greatly increase our understanding of both hereditary and sporadic forms of breast cancer, and to lead to therapeutic and preventive breakthroughs.  Much has been learned during the past decade about the genetic epidemiol. of breast cancer, the ethnic distribution and clin. consequences of BRCA1 and BRCA2 mutations, and the central role of DNA repair in breast cancer susceptibility.  The ability to translate this knowledge into novel treatments, however, remains elusive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1a5S77C977bVg90H21EOLACvtfcHk0ljUDVAbSw164A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCmsbk%253D&md5=200600041061619ba39dfbd8dfc91850</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1038%2Fnrc1431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1431%26sid%3Dliteratum%253Aachs%26aulast%3DNarod%26aufirst%3DS.%2BA.%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26atitle%3DBRCA1%2520and%2520BRCA2%253A%25201994%2520and%2520beyond%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D665%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">â</span> <span class="NLM_lpage">6591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.-l.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=I.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+W.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+B.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.-l.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DI.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%2BW.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Burg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, A. O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, S. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derksen, P. W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zevenhoven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">17079</span><span class="NLM_x">â</span> <span class="NLM_lpage">17084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1073%2Fpnas.0806092105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=18971340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=17079-17084&author=S.+Rottenbergauthor=J.+E.+Jaspersauthor=A.+Kersbergenauthor=E.+van+der+Burgauthor=A.+O.+H.+Nygrenauthor=S.+A.+L.+Zanderauthor=P.+W.+B.+Derksenauthor=M.+de+Bruinauthor=J.+Zevenhovenauthor=A.+Lauauthor=R.+Boulterauthor=A.+Cranstonauthor=M.+J.+O%E2%80%99Connorauthor=N.+M.+B.+Martinauthor=P.+Borstauthor=J.+Jonkers&title=High+sensitivity+of+BRCA1-deficient+mammary+tumors+to+the+PARP+inhibitor+AZD2281+alone+and+in+combination+with+platinum+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span></div><div class="casAuthors">Rottenberg, Sven; Jaspers, Janneke E.; Kersbergen, Ariena; van der Burg, Eline; Nygren, Anders O. H.; Zander, Serge A. L.; Derksen, Patrick W. B.; de Bruin, Michiel; Zevenhoven, John; Lau, Alan; Boulter, Robert; Cranston, Aaron; O'Connor, Mark J.; Martin, Niall M. B.; Borst, Piet; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17079-17084</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-pos. breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-neg. ("triple-neg.") mammary carcinomas.  Triple-neg. tumors account for 15% of all breast cancers and frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction.  The DNA-repair defects characteristic of BRCA1-deficient cells confer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which could be relevant to treatment of triple-neg. tumors.  To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-assocd. breast cancer.  Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival.  Long-term treatment with AZD2281 in this model did result in the development of drug resistance, caused by up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps.  This resistance to AZD2281 could be reversed by coadministration of the P-glycoprotein inhibitor tariquidar.  Combination of AZD2281 with cisplatin or carboplatin increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.  Our results demonstrate in vivo efficacy of AZD2281 against BRCA1-deficient breast cancer and illustrate how GEMMs of cancer can be used for preclin. evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95zB9OKZ4ObVg90H21EOLACvtfcHk0lj0gEzbu945WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F&md5=788a7d8b5341b731d007753d5a234dec</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0806092105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0806092105%26sid%3Dliteratum%253Aachs%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DNygren%26aufirst%3DA.%2BO.%2BH.%26aulast%3DZander%26aufirst%3DS.%2BA.%2BL.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%2BB.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3DZevenhoven%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHigh%2520sensitivity%2520of%2520BRCA1-deficient%2520mammary%2520tumors%2520to%2520the%2520PARP%2520inhibitor%2520AZD2281%2520alone%2520and%2520in%2520combination%2520with%2520platinum%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D17079%26epage%3D17084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">12</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2013&pages=1-12&author=S.+B.+De+Lorenzoauthor=A.+G.+Patelauthor=R.+M.+Hurleyauthor=S.+H.+Kaufmann&title=The+elephant+and+the+blind+men%3A+making+sense+of+PARP+inhibitors+in+homologous+recombination+deficient+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DHurley%26aufirst%3DR.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DThe%2520elephant%2520and%2520the%2520blind%2520men%253A%2520making%2520sense%2520of%2520PARP%2520inhibitors%2520in%2520homologous%2520recombination%2520deficient%2520tumor%2520cells%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D228%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP2 by clinical PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5588</span><span class="NLM_x">â</span> <span class="NLM_lpage">5599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23118055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.+Y.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP2+by+clinical+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-yin N.; Das, Benu Brata; Renaud, Amelie; Zhang, Yiping; Doroshow, James H.; Ji, Jiuping; Takeda, Shunichi; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5588-5599</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings indicate that PARP inhibitors in clin. trials not only block catalytic function but also trap PARP enzymes on DNA, illuminating the mechanistic basis for their cytotoxic activity in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3m55HXn9ObVg90H21EOLACvtfcHk0lj0gEzbu945WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE&md5=81c590b6a4fbb9efc9c64f7de5e89524</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP2%2520by%2520clinical%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Hallmarks of âBRCAnessâ in sporadic cancers</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">814</span><span class="NLM_x">â</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnrc1457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15510162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=814-819&author=N.+Turnerauthor=A.+Tuttauthor=A.+Ashworth&title=Hallmarks+of+%E2%80%99BRCAness%E2%80%99+in+sporadic+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of 'BRCAness' in sporadic cancers</span></div><div class="casAuthors">Turner, Nicholas; Tutt, Andrew; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">814-819</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Germline mutations in the BRCA1, BRCA2 and Fanconi anemia genes confer cancer susceptibility, and the proteins encoded by these genes have distinct functions in related DNA-repair processes.  Emerging evidence indicates that these processes are disrupted by numerous mechanisms in sporadic cancers.  Collectively, there are properties that define 'BRCAness' - i.e., traits that some sporadic cancers share with those occurring in either BRCA1- or BRCA2-mutation carriers.  These common properties might have important implications for the clin. management of these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSK5dEe3-aKLVg90H21EOLACvtfcHk0lj0gEzbu945WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D&md5=b2ec7c226f4ca388e2dc3a6c1d030e7d</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1457%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DHallmarks%2520of%2520%25E2%2580%2599BRCAness%25E2%2580%2599%2520in%2520sporadic%2520cancers%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D814%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Summa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambiasi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petriella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradiso, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradiso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommasi, S.</span><span> </span><span class="NLM_article-title">BRCAness: a deeper insight into basal-like breast tumors</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 8</span><span class="NLM_x">) </span> <span class="NLM_fpage">viii13</span><span class="NLM_x">â</span> <span class="NLM_lpage">viii21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1093%2Fannonc%2Fmdt306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=24131964" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=viii13-viii21&issue=Suppl.+8&author=S.+De+Summaauthor=R.+Pintoauthor=D.+Sambiasiauthor=D.+Petriellaauthor=V.+Paradisoauthor=A.+Paradisoauthor=S.+Tommasi&title=BRCAness%3A+a+deeper+insight+into+basal-like+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt306%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSumma%26aufirst%3DS.%26aulast%3DPinto%26aufirst%3DR.%26aulast%3DSambiasi%26aufirst%3DD.%26aulast%3DPetriella%26aufirst%3DD.%26aulast%3DParadiso%26aufirst%3DV.%26aulast%3DParadiso%26aufirst%3DA.%26aulast%3DTommasi%26aufirst%3DS.%26atitle%3DBRCAness%253A%2520a%2520deeper%2520insight%2520into%2520basal-like%2520breast%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26issue%3DSuppl.%25208%26spage%3Dviii13%26epage%3Dviii21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">The Cancer Genome Atlas Research Network.</span><span> </span><span class="NLM_article-title">Integrated genomic analyses of ovarian carcinoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">474</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=609-615&author=The+Cancer+Genome+Atlas+Research+Network.&title=Integrated+genomic+analyses+of+ovarian+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DIntegrated%2520genomic%2520analyses%2520of%2520ovarian%2520carcinoma%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">â</span> <span class="NLM_lpage">1575</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=1530940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=1569-1575&author=M.+Banasikauthor=H.+Komuraauthor=M.+Shimoyamaauthor=K.+Ueda&title=Specific+inhibitors+of+poly%28ADP-ribose%29+synthetase+and+mono%28ADP-ribosyl%29transferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span></div><div class="casAuthors">Banasik, Marek; Komura, Hajime; Shimoyama, Makoto; Ueda, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1569-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Two classes of enzymes, poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferases, catalyze covalent attachment of multiple or single residues, resp., of the ADP-ribose moiety of NAD to various proteins.  In order to find good inhibitors of poly(ADP-ribose) synthetase free of side actions and applicable to in vivo studies, a large scale survey was made using an in vitro assay system, and many potent inhibitors were found.  The four strongest were 4-amino-1,8-naphthalimide, 6(5H)- and 2-nitro-6(5H)-phenanthridinones, and 1,5-dihydroxyisoquinoline.  Their 50% inhibitory concns., 0.18-0.39 Î¼M, were about two orders of magnitude lower than that of 3-aminobenzamide that is currently most popularly used.  A common structural feature among all potent inhibitors, including 1-hydroxyisoquinoline, chlorthenoxazin, 3-hydroxybenzamide, and 4-hydroxyquinazoline, in addn. to the four mentioned above, was the presence of a carbonyl group built in a polyarom. heterocyclic skeleton or a carbamoyl group attached to an arom. ring.  Most of the inhibitors exhibited mixed-type inhibition with respect to NAD.  Comparative studies of the effects on poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase from hen heterophils revealed high specificity of most of the potent inhibitors for poly(ADP-ribose) synthetase.  On the other hand, unsatd. long-chain fatty acids inhibited both enzymes, and satd. long-chain fatty acids and vitamin K1 acted selectively on mono(ADP-ribosyl)transferase.  The finding of many inhibitors of ADP-ribosyltransferases, esp. poly(ADP-ribose) synthetase, supports the view that ADP-ribosylation of proteins may be regulated by a variety of metabolites or structural constituents in the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Jh_eRCjHdbVg90H21EOLACvtfcHk0lhxe3hvw0o0sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D&md5=21bb51821a1caaeb30c42643a82116f4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DSpecific%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%2520and%2520mono%2528ADP-ribosyl%2529transferase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D1569%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Arundel-Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scavone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span> </span><span class="NLM_article-title">Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells</span> <span class="citation_source-journal">Radiat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">â</span> <span class="NLM_lpage">371</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2307%2F3577927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=1903547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK3MXksVGiu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1991&pages=367-371&author=C.+M.+Arundel-Sutoauthor=S.+V.+Scavoneauthor=W.+R.+Turnerauthor=M.+J.+Sutoauthor=J.+S.+Sebolt-Leopold&title=Effects+of+PD+128763%2C+a+new+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase%2C+on+X-ray-induced+cellular+recovery+processes+in+Chinese+hamster+V79+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on x-ray-induced cellular recovery processes in Chinese hamster V79 cells</span></div><div class="casAuthors">Arundel-Suto, Carla M.; Scavone, Sylvia V.; Turner, William R.; Suto, Mark J.; Sebolt-Leopold, Judith S.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-71</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">The modifying effects of PD 128763 (3,4-dihydro-5-methyl-1(2H)-isoquinolinone) (I), a potent inhibitor of poly(ADP-ribose)polymerase, on radiation-induced cell killing were examd. in Chinese hamster V79 cells.  I has an IC50 value against the purified enzyme 50-fold lower than 3-aminobenzamide (3-AB), a widely used specific inhibitor of the enzyme.  Exposure of exponentially growing cells to a noncytotoxic concn. (0.5 mM) of I for 2 h immediately following x-irradn. increased their radiation sensitivity, modifying both the shoulder and the slope of the survival curve.  When recovery from sublethal damage and potentially lethal damage was examd. in exponential and plateau-phase cells, resp., postirradn. incubation with 0.5 mM I not only to inhibited both these processes fully, but also enhanced further the level of radiation-induced cell killing.  This is in contrast to the slight effect seen with the less potent inhibitor, 3-AB.  The mechanism of radiosensitization by I is related to the potent inhibition of poly(ADP-ribose) polymerase by this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-K-Ex9TzkMbVg90H21EOLACvtfcHk0lhxe3hvw0o0sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVGiu7c%253D&md5=7834088129032193a156f8cc6a832b38</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2307%2F3577927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3577927%26sid%3Dliteratum%253Aachs%26aulast%3DArundel-Suto%26aufirst%3DC.%2BM.%26aulast%3DScavone%26aufirst%3DS.%2BV.%26aulast%3DTurner%26aufirst%3DW.%2BR.%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26atitle%3DEffects%2520of%2520PD%2520128763%252C%2520a%2520new%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%252C%2520on%2520X-ray-induced%2520cellular%2520recovery%2520processes%2520in%2520Chinese%2520hamster%2520V79%2520cells%26jtitle%3DRadiat.%2520Res.%26date%3D1991%26volume%3D126%26spage%3D367%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wahlberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouznetsova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frostell, Ã.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ÃncÃ¼, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SchÃ¼ler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, J.</span><span> </span><span class="NLM_article-title">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnbt.2121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22343925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=283-288&author=E.+Wahlbergauthor=T.+Karlbergauthor=E.+Kouznetsovaauthor=N.+Markovaauthor=A.+Macchiaruloauthor=A.-G.+Thorsellauthor=E.+Polauthor=%C3%85.+Frostellauthor=T.+Ekbladauthor=D.+%C3%96nc%C3%BCauthor=B.+Kullauthor=G.+M.+Robertsonauthor=R.+Pellicciariauthor=H.+Sch%C3%BClerauthor=J.+Weigelt&title=Family-wide+chemical+profiling+and+structural+analysis+of+PARP+and+tankyrase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span></div><div class="casAuthors">Wahlberg, Elisabet; Karlberg, Tobias; Kouznetsova, Ekaterina; Markova, Natalia; Macchiarulo, Antonio; Thorsell, Ann-Gerd; Pol, Ewa; Frostell, Aasa; Ekblad, Torun; Oencue, Delal; Kull, Bjoern; Robertson, Graeme Michael; Pellicciari, Roberto; Schueler, Herwig; Weigelt, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clin. trials as cancer therapeutics, yet the specificity of many of these compds. is unknown.  Here we evaluated a series of 185 small-mol. inhibitors, including research reagents and compds. being tested clin., for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2.  Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these mols. lack specificity and have promiscuous inhibitory activity.  We also detd. X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes.  In addn. to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYSebsCVufibVg90H21EOLACvtfcHk0lhxe3hvw0o0sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D&md5=71f17fd5b6bb602dd70c8fcc17df95f9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2121%26sid%3Dliteratum%253Aachs%26aulast%3DWahlberg%26aufirst%3DE.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DKouznetsova%26aufirst%3DE.%26aulast%3DMarkova%26aufirst%3DN.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DThorsell%26aufirst%3DA.-G.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DFrostell%26aufirst%3D%25C3%2585.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3D%25C3%2596nc%25C3%25BC%26aufirst%3DD.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DG.%2BM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DWeigelt%26aufirst%3DJ.%26atitle%3DFamily-wide%2520chemical%2520profiling%2520and%2520structural%2520analysis%2520of%2520PARP%2520and%2520tankyrase%2520inhibitors%26jtitle%3DNature%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D283%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">â</span> <span class="NLM_lpage">956</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.-Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0lhaPPL-fCLd1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.-D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)Â·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. IÂ·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., IÂ·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0lhaPPL-fCLd1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.-D.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3<i>S</i>)-piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA1 and 2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">â</span> <span class="NLM_lpage">7185</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+a+novel+oral+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA1+and+2+mutant+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520a%2520novel%2520oral%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA1%2520and%25202%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">DelloRusso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welcsh, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, E. M.</span><span> </span><span class="NLM_article-title">Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">â</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1541-7786.MCR-06-0234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17259345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptFequg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=35-45&author=C.+DelloRussoauthor=P.+L.+Welcshauthor=W.+Wangauthor=R.+L.+Garciaauthor=M.+C.+Kingauthor=E.+M.+Swisher&title=Functional+characterization+of+a+novel+BRCA1-null+ovarian+cancer+cell+line+in+response+to+ionizing+radiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation</span></div><div class="casAuthors">DelloRusso, Christiana; Welcsh, Piri L.; Wang, Weixin; Garcia, Rochelle L.; King, Mary-Claire; Swisher, Elizabeth M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The breast and ovarian cancer susceptibility gene BRCA1 plays a major role in the DNA damage response pathway.  The lack of well-characterized human BRCA1-null cell lines has limited the investigation of BRCA1 function, particularly with regard to its role in ovarian cancer.  We propagated a novel BRCA1-null human ovarian cancer cell line UWB1.289 from a tumor of papillary serous histol., the most common form of ovarian carcinoma.  UWB1.289 carries a germline BRCA1 mutation within exon 11 and has a deletion of the wild-type allele.  UWB1.289 is estrogen and progesterone receptor neg. and has an acquired somatic mutation in p53, similar to the commonly used BRCA1-null breast cancer cell line HCC1937.  We used ionizing radiation to induce DNA damage in both UWB1.289 and in a stable UWB1.289 line in which wild-type BRCA1 was restored.  We examd. several responses to DNA damage in these cell lines, including sensitivity to radiation, cell cycle checkpoint function, and changes in gene expression using microarray anal.  We obsd. that UWB1.289 is sensitive to ionizing radiation and lacks cell cycle checkpoint functions that are a normal part of the DNA damage response.  Restoration of wild-type BRCA1 function in these cells partially restores DNA damage responses.  Expression array anal. not only supports this partial functional correction but also reveals interesting new information regarding BRCA1-pos. regulation of the expression of claudin 6 and other metastasis-assocd. genes and neg. regulation of multiple IFN-inducible genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sXbCj4NcjrVg90H21EOLACvtfcHk0lh1M0oimgCCAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptFequg%253D%253D&md5=d550d27a49dba53d150d86b24f25bcd5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-06-0234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-06-0234%26sid%3Dliteratum%253Aachs%26aulast%3DDelloRusso%26aufirst%3DC.%26aulast%3DWelcsh%26aufirst%3DP.%2BL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGarcia%26aufirst%3DR.%2BL.%26aulast%3DKing%26aufirst%3DM.%2BC.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26atitle%3DFunctional%2520characterization%2520of%2520a%2520novel%2520BRCA1-null%2520ovarian%2520cancer%2520cell%2520line%2520in%2520response%2520to%2520ionizing%2520radiation%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2007%26volume%3D5%26spage%3D35%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">PARP inhibitor development for systemic cancer targeting</span> <span class="citation_source-journal">Anticancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2174%2F187152007781668715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17896912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtV2gtr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=515-523&author=T.+Zarembaauthor=N.+J.+Curtin&title=PARP+inhibitor+development+for+systemic+cancer+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitor development for systemic cancer targeting</span></div><div class="casAuthors">Zaremba, Tomasz; Curtin, Nicola Jane</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">515-523</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase 1 (PARP-1) is a DNA-binding enzyme that is activated by DNA breaks, converting them into an intracellular signal via poly(ADP-ribosyl)ation of nuclear proteins.  Neg. charged polymers of ADP-ribose (PAR) attached to PARP-1 itself and histones lead to chromatin relaxation, facilitating the access of base excision/single strand break repair proteins and activating these repair enzymes.  PARP inhibitors have been developed to investigate the role of PARP-1 in cell biol. and to overcome DNA repair-mediated resistance of cancer cells to cytotoxic therapy.  Since the early benzamide inhibitors of the 1980s PARP inhibitors, developed through structure-activity relationships and crystal structure-based drug design, that are 1,000x more potent have been identified.  These novel PARP inhibitors have been shown to enhance the antitumor activity of temozolomide (a DNA-methylating agent), topoisomerase poisons and ionising radiation in advanced pre-clin. studies and are now under clin. evaluation.  PARP inhibitors can also selectively kill cells and tumors with homozygous defects in the hereditary breast cancer genes, BRCA1 and BRCA2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGS5VD2eu5HLVg90H21EOLACvtfcHk0lh1M0oimgCCAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtV2gtr3I&md5=72d70ab6c45db578407192319ca6c5db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F187152007781668715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152007781668715%26sid%3Dliteratum%253Aachs%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPARP%2520inhibitor%2520development%2520for%2520systemic%2520cancer%2520targeting%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D515%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barrows, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâArpa, P.</span><span> </span><span class="NLM_article-title">The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication</span> <span class="citation_source-journal">Mutat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2FS0921-8777%2898%2900022-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=9739812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK1cXks1Ontr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=1998&pages=103-110&author=L.+R.+Barrowsauthor=J.+A.+Holdenauthor=M.+Andersonauthor=P.+D%E2%80%99Arpa&title=The+CHO+XRCC1+mutant%2C+EM9%2C+deficient+in+DNA+ligase+III+activity%2C+exhibits+hypersensitivity+to+camptothecin+independent+of+DNA+replication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication</span></div><div class="casAuthors">Barrows, Louis R.; Holden, Joseph A.; Anderson, Melvin; D'Arpa, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, DNA Repair</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-110</span>CODEN:
                <span class="NLM_cas:coden">MRDRBE</span>;
        ISSN:<span class="NLM_cas:issn">0921-8777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have analyzed the x-ray-sensitive CHO mutant cell line EM9 for sensitivity to the topoisomerase I inhibitor camptothecin.  These cells exhibit defective repair of single strand DNA breaks.  Recently, EM9 were complemented the DNA ligase III interactive protein, XRCC1.  Defective XRCC1 apparently accounts for the low DNA ligase III activity that may explain the single-strand break repair deficiency of EM9 cells.  Here, we demonstrate cytotoxic hypersensitivity of EM9 cells following a brief camptothecin treatment.  Both the S-phase and non-S-phase populations of EM9 exhibited camptothecin sensitivity relative to the parent cell line AA8.  In AA8 cells, only the 55% of the population corresponding to the S-phase subpopulation were sensitive to camptothecin, while the remainder of the population were totally resistant to doses as high as 10 Î¼M.  The role of DNA replication in the camptothecin sensitivity was studied using the DNA polymerase inhibitor aphidicolin in co-treatment with camptothecin.  Aphidicolin treatment fully protected AA8 cells from camptothecin cytotoxicity.  In EM9 cells, aphidicolin protected the S-phase fraction to some degree but all the cells remained sensitive to camptothecin cytotoxicity.  These results suggest that EM9 cells are sensitized to camptothecin by a mechanism that is independent of DNA replication and may be a consequence of the XRCC1 mutation or the assocd. deficiency in DNA ligase III activity.  Mechanistic models for the replication-independent cytotoxicity of camptothecin in EM9 cells are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB-XcFm3kSEbVg90H21EOLACvtfcHk0lh1M0oimgCCAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXks1Ontr4%253D&md5=da2a05f19c82888da655c65c00316258</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0921-8777%2898%2900022-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0921-8777%252898%252900022-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarrows%26aufirst%3DL.%2BR.%26aulast%3DHolden%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Arpa%26aufirst%3DP.%26atitle%3DThe%2520CHO%2520XRCC1%2520mutant%252C%2520EM9%252C%2520deficient%2520in%2520DNA%2520ligase%2520III%2520activity%252C%2520exhibits%2520hypersensitivity%2520to%2520camptothecin%2520independent%2520of%2520DNA%2520replication%26jtitle%3DMutat.%2520Res.%26date%3D1998%26volume%3D408%26spage%3D103%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Chaudhuri, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrador, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelsen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fachinetti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermejo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopes, M.</span><span> </span><span class="NLM_article-title">Topoisomerase I poisoning results in PARP-mediated replication fork reversal</span> <span class="citation_source-journal">Nature Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">â</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnsmb.2258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22388737" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=417-423&author=A.+R.+Chaudhuriauthor=Y.+Hashimotoauthor=R.+Herradorauthor=K.+J.+Neelsenauthor=D.+Fachinettiauthor=R.+Bermejoauthor=A.+Cocitoauthor=V.+Costanzoauthor=M.+Lopes&title=Topoisomerase+I+poisoning+results+in+PARP-mediated+replication+fork+reversal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2258%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhuri%26aufirst%3DA.%2BR.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DHerrador%26aufirst%3DR.%26aulast%3DNeelsen%26aufirst%3DK.%2BJ.%26aulast%3DFachinetti%26aufirst%3DD.%26aulast%3DBermejo%26aufirst%3DR.%26aulast%3DCocito%26aufirst%3DA.%26aulast%3DCostanzo%26aufirst%3DV.%26aulast%3DLopes%26aufirst%3DM.%26atitle%3DTopoisomerase%2520I%2520poisoning%2520results%2520in%2520PARP-mediated%2520replication%2520fork%2520reversal%26jtitle%3DNature%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D417%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tentori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span> </span><span class="NLM_article-title">Chemopotentiation by PARP inhibitors in cancer therapy</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2Fj.phrs.2005.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15911331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Wltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=25-33&author=L.+Tentoriauthor=G.+Graziani&title=Chemopotentiation+by+PARP+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Chemopotentiation by PARP inhibitors in cancer therapy</span></div><div class="casAuthors">Tentori, Lucio; Graziani, Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-33</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARP) constitute a family of enzymes involved in the regulation of many cellular processes such as DNA repair, gene transcription, cell cycle progression, cell death, chromatin functions and genomic stability.  Among the 18 members identified so far, PARP-1 and PARP-2 are the only proteins stimulated by DNA strand breaks and implicated in the repair of DNA injury.  Therefore, these mols. have been exploited as potential targets for the development of pharmacol. strategies to increase the antitumor efficacy of chemotherapeutic agents, which induce DNA damage.  PARP inhibitors have been shown to restore sensitivity of resistant tumors to methylating agents or topoisomerase I inhibitors, drugs presently used for the treatment of primary and secondary brain tumors or malignancies refractory to std. chemotherapy.  Interestingly, PARP inhibitors may also provide protection from the untoward effects exerted by certain anticancer drugs, which cause oxidative stress and consequent PARP overactivation.  The aim of this article is to provide a brief overview of the recent literature on preclin. studies with the specific and potent inhibitors newly synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoImZCOb5elR7Vg90H21EOLACvtfcHk0lgU1soS05dNJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Wltr8%253D&md5=2a2f1893efeefc3f1d140979beae6f4d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2005.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2005.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DGraziani%26aufirst%3DG.%26atitle%3DChemopotentiation%2520by%2520PARP%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Res.%26date%3D2005%26volume%3D52%26spage%3D25%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdecanas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser-Doepner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milas, L.</span><span> </span><span class="NLM_article-title">MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2113</span><span class="NLM_x">â</span> <span class="NLM_lpage">2120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2113-2120&author=L.+Wangauthor=K.+A.+Masonauthor=K.+K.+Angauthor=T.+Buchholzauthor=D.+Valdecanasauthor=A.+Mathurauthor=C.+Buser-Doepnerauthor=C.+Toniattiauthor=L.+Milas&title=MK-4827%2C+a+PARP-1%2F-2+inhibitor%2C+strongly+enhances+response+of+human+lung+and+breast+cancer+xenografts+to+radiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMason%26aufirst%3DK.%2BA.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DBuchholz%26aufirst%3DT.%26aulast%3DValdecanas%26aufirst%3DD.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DBuser-Doepner%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DMilas%26aufirst%3DL.%26atitle%3DMK-4827%252C%2520a%2520PARP-1%252F-2%2520inhibitor%252C%2520strongly%2520enhances%2520response%2520of%2520human%2520lung%2520and%2520breast%2520cancer%2520xenografts%2520to%2520radiation%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2113%26epage%3D2120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Bridges, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyn, R. E.</span><span> </span><span class="NLM_article-title">Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">5076</span><span class="NLM_x">â</span> <span class="NLM_lpage">5086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5076-5086&author=K.+A.+Bridgesauthor=C.+Toniattiauthor=C.+A.+Buserauthor=H.+Liuauthor=T.+A.+Buchholzauthor=R.+E.+Meyn&title=Niraparib+%28MK-4827%29%2C+a+novel+poly%28ADP-Ribose%29+polymerase+inhibitor%2C+radiosensitizes+human+lung+and+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DK.%2BA.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBuchholz%26aufirst%3DT.%2BA.%26aulast%3DMeyn%26aufirst%3DR.%2BE.%26atitle%3DNiraparib%2520%2528MK-4827%2529%252C%2520a%2520novel%2520poly%2528ADP-Ribose%2529%2520polymerase%2520inhibitor%252C%2520radiosensitizes%2520human%2520lung%2520and%2520breast%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5076%26epage%3D5086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Genther Williams, S. M.; Kuznicki, A. M.; Andrade, P.; Dolinski, B. M.; Elbi, C.; OâHagan, R. C.; Toniatti, C.</span><span> </span><span class="NLM_article-title">Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status</span>.  <span class="citation_source-journal">Cancer Cell Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span>, DOI: <span class="refDoi">Â DOI: 10.1186/s12935-015-0162-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1186%2Fs12935-015-0162-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=25685067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A280%3ADC%252BC2MrlvVyrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=14&author=S.+M.+Genther+Williams&author=A.+M.+Kuznicki&author=P.+Andrade&author=B.+M.+Dolinski&author=C.+Elbi&author=R.+C.+O%E2%80%99Hagan&author=C.+Toniatti&title=Treatment+with+the+PARP+inhibitor%2C+niraparib%2C+sensitizes+colorectal+cancer+cell+lines+to+irinotecan+regardless+of+MSI%2FMSS+status&doi=10.1186%2Fs12935-015-0162-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status</span></div><div class="casAuthors">Genther Williams Sybil M; Dolinski Brian M; O'Hagan Ronan C; Kuznicki Apryle M; Andrade Paula; Elbi Cem; Toniatti Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer cell international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cells with homologous recombination (HR) deficiency, most notably caused by mutations in the BRCA1 or BRCA2 genes, are sensitive to PARP inhibition.  Microsatellite instability (MSI) accounts for 10-15% of colorectal cancer (CRC) and is hypothesized to lead to HR defects due to altered expression of Mre11, a protein required for double strand break (DSB) repair.  Indeed, others have reported that PARP inhibition is efficacious in MSI CRC.  METHODS:  Here we examine the response to niraparib, a potent PARP-1/PARP-2 inhibitor currently under clinical evaluation, in MSI versus microsatellite stable (MSS) CRC cell lines in vitro and in vivo.  We compiled a large panel of MSI and MSS CRC cell lines and evaluated the anti-proliferative activity of niraparib.  In addition to testing single agent cytotoxic activity of niraparib, we also tested irinotecan (or SN-38, the active metabolite of irinotecan) activity alone and in combination with niraparib in vitro and in vivo.  RESULTS:  In contrast to earlier reports, MSI CRC cell lines were not more sensitive to niraparib than MSS CRC cell lines suggesting that the MSI phenotype does not sensitize CRC cell lines to PARP inhibition.  Moreover, even the most sensitive MSI cell lines had niraparib EC50s greater than 10 fold higher than BRCA-deficient cell lines.  However, MSI lines were more sensitive to SN-38 than MSS lines, consistent with previous findings.  We have also demonstrated that combination of niraparib and irinotecan was more efficacious than either agent alone in both MSI and MSS cell lines both in vitro and in vivo, and that niraparib potentiates the effect of irinotecan regardless of MSI status.  CONCLUSIONS:  Our results support the clinical evaluation of this combination in all CRC patients, regardless of MSI status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKbTxgn1b3ESnGiHuhFGv8fW6udTcc2eYCqfe-dDOHabntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrlvVyrsA%253D%253D&md5=6338ddf35e24a28c4d00d336a726a520</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2Fs12935-015-0162-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-015-0162-8%26sid%3Dliteratum%253Aachs%26aulast%3DGenther%2BWilliams%26aufirst%3DS.%2BM.%26atitle%3DTreatment%2520with%2520the%2520PARP%2520inhibitor%252C%2520niraparib%252C%2520sensitizes%2520colorectal%2520cancer%2520cell%2520lines%2520to%2520irinotecan%2520regardless%2520of%2520MSI%252FMSS%2520status%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2015%26volume%3D15%26spage%3D14%26doi%3D10.1186%2Fs12935-015-0162-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Papco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors in cancer therapy: an update</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">â</span> <span class="NLM_lpage">514</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1517%2F13543776.2013.768615" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=503-514&author=G.+Papcoauthor=E.+Casaleauthor=A.+Montagnoliauthor=A.+Cirla&title=PARP+inhibitors+in+cancer+therapy%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.768615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.768615%26sid%3Dliteratum%253Aachs%26aulast%3DPapco%26aufirst%3DG.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DCirla%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520an%2520update%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D503%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boshuizen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">â</span> <span class="NLM_lpage">5015</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1078-0432.CCR-13-1391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23881923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5003-5015&author=Y.+Shenauthor=F.+L.+Rehmanauthor=Y.+Fengauthor=J.+Boshuizenauthor=I.+Bajramiauthor=R.+Elliottauthor=B.+Wangauthor=C.+J.+Lordauthor=L.+E.+Postauthor=A.+Ashworth&title=BMN673%2C+a+novel+and+highly+potent+PARP1%2F2+inhibitor+for+the+treatment+of+human+cancers+with+DNA+repair+deficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency</span></div><div class="casAuthors">Shen, Yuqiao; Rehman, Farah L.; Feng, Ying; Boshuizen, Julia; Bajrami, Ilirjana; Elliott, Richard; Wang, Bing; Lord, Christopher J.; Post, Leonard E.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5003-5015</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.  Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  Exptl. Design: Potency and selectivity of BMN 673 was detd. by biochem. assays.  Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models.  Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested.  BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concns. than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib).  In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors.  BMN 673 is readily orally bioavailable, with more than 40% abs. oral bioavailability in rats when dosed in carboxylmethyl cellulose.  Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice.  Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs.  Conclusion: BMN 673 is currently in early-phase clin. development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.  Clin Cancer Res; 19(18); 5003-15. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdmHIVEuoz7Vg90H21EOLACvtfcHk0liBJiQTznIRag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J&md5=f58b67f14784c0a0fa1197caffd8d96d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1391%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBoshuizen%26aufirst%3DJ.%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBMN673%252C%2520a%2520novel%2520and%2520highly%2520potent%2520PARP1%252F2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%2520with%2520DNA%2520repair%2520deficiency%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5003%26epage%3D5015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Mateo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, D. S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Appraising iniparib, the PARP inhibitor that never wasâwhat must we learn?</span> <span class="citation_source-journal">Nature Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">688</span><span class="NLM_x">â</span> <span class="NLM_lpage">696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnrclinonc.2013.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Clt7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=688-696&author=J.+Mateoauthor=M.+Ongauthor=D.+S.+P.+Tanauthor=M.+A.+Gonzalezauthor=J.+S.+de+Bono&title=Appraising+iniparib%2C+the+PARP+inhibitor+that+never+was%E2%80%94what+must+we+learn%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Appraising iniparib, the PARP inhibitor that never was-what must we learn?</span></div><div class="casAuthors">Mateo, Joaquin; Ong, Michael; Tan, David S. P.; Gonzalez, Michael A.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">688-696</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several drugs targeting poly(ADP-ribose) polymerase (PARP) enzymes are under development.  Responses have been obsd. in patients with germline mutations in BRCA1 and BRCA2, with further data supporting antitumor activity of PARP inhibitors in sporadic ovarian cancer.  Strategies to identify other predictive biomarkers remain under investigation.  Iniparib was purported to be a PARP inhibitor that showed promising results in randomized phase II trials in patients with triple-neg. breast cancer.  Neg. results from a phase III study in this disease setting, however, tempered enthusiasm for this agent.  Recently, data from in vitro expts. suggest that iniparib is not only structurally distinct from other described PARP inhibitors, but is also a poor inhibitor of PARP activity.  In this context, the neg. iniparib phase III data might have erroneously promulgated the notion that PARP inhibition is not an effective therapeutic strategy.  Here, we scrutinize the development of iniparib from preclin. studies to registration trials, and identify and discuss the pitfalls in the development of anticancer drugs to prevent future late-stage trial failures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWfclKdXsYk7Vg90H21EOLACvtfcHk0liBJiQTznIRag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Clt7fP&md5=d61aa0cc7ab5f4375e33c6059bc9928c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.177%26sid%3Dliteratum%253Aachs%26aulast%3DMateo%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BP.%26aulast%3DGonzalez%26aufirst%3DM.%2BA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DAppraising%2520iniparib%252C%2520the%2520PARP%2520inhibitor%2520that%2520never%2520was%25E2%2580%2594what%2520must%2520we%2520learn%253F%26jtitle%3DNature%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D688%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">OâShaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippen, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span> </span><span class="NLM_article-title">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">â</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1056%2FNEJMoa1011418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=21208101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=205-214&author=J.+O%E2%80%99Shaughnessyauthor=C.+Osborneauthor=J.+E.+Pippenauthor=M.+Yoffeauthor=D.+Pattauthor=C.+Rochaauthor=I.+C.+Kooauthor=B.+M.+Shermanauthor=C.+Bradley&title=Iniparib+plus+chemotherapy+in+metastatic+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span></div><div class="casAuthors">O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.; Yoffe, Mark; Patt, Debra; Rocha, Christine; Koo, Ingrid Chou; Sherman, Barry M.; Bradley, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(ADP-ribose) polymerase (PARP) inhibition.  We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small mol. with PARP-inhibitory activity, in patients with metastatic triple-neg. breast cancer.  A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equiv. to an area under the concn.-time curve of 2) on days 1 and 8 - with or without iniparib (at a dose of 5.6 mg per kg of body wt.) on days 1, 4, 8, and 11 - every 21 days.  Primary end points were the rate of clin. benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for â¥6 mo) and safety.  Addnl. end points included the rate of objective response, progression-free survival, and overall survival.  The addn. of iniparib to gemcitabine and carboplatin improved the rate of clin. benefit from 34 to 56% and the rate of overall response from 32 to 52%.  The addn. of iniparib also prolonged the median progression-free survival from 3.6 mo to 5.9 mo (hazard ratio for progression, 0.59) and the median overall survival from 7.7 mo to 12.3 mo (hazard ratio for death, 0.57).  The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level.  No significant difference was seen between the 2 groups in the rate of adverse events.  The addn. of iniparib to chemotherapy improved the clin. benefit and survival of patients with metastatic triple-neg. breast cancer without, significantly increased toxic effects.  On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7tn6oRjsja7Vg90H21EOLACvtfcHk0lggeB2_MS1FLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D&md5=d50866c03ab6a61f780f14e13fdbae28</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1011418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1011418%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DPippen%26aufirst%3DJ.%2BE.%26aulast%3DYoffe%26aufirst%3DM.%26aulast%3DPatt%26aufirst%3DD.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DKoo%26aufirst%3DI.%2BC.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%26atitle%3DIniparib%2520plus%2520chemotherapy%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">OâShaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danso, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charpentier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood-Chirchir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span> </span><span class="NLM_article-title">A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstract 1007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=Abstract+1007&issue=Suppl&author=J.+O%E2%80%99Shaughnessyauthor=L.+S.+Schwartzbergauthor=M.+A.+Dansoauthor=H.+S.+Rugoauthor=K.+Millerauthor=D.+A.+Yardleyauthor=R.+W.+Carlsonauthor=R.+S.+Finnauthor=E.+Charpentierauthor=M.+Freeseauthor=S.+Guptaauthor=A.+Blackwood-Chirchirauthor=E.+P.+Winer&title=A+randomized+phase+III+study+of+iniparib+%28BSI-201%29+in+combination+with+gemcitabine%2Fcarboplatin+%28G%2FC%29+in+metastatic+triple-negative+breast+cancer+%28TNBC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DDanso%26aufirst%3DM.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DCarlson%26aufirst%3DR.%2BW.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCharpentier%26aufirst%3DE.%26aulast%3DFreese%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DBlackwood-Chirchir%26aufirst%3DA.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3DA%2520randomized%2520phase%2520III%2520study%2520of%2520iniparib%2520%2528BSI-201%2529%2520in%2520combination%2520with%2520gemcitabine%252Fcarboplatin%2520%2528G%252FC%2529%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3DSuppl%26spage%3DAbstract%25201007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">â</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1078-0432.CCR-11-2890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22291137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1655-1662&author=A.+G.+Patelauthor=S.+B.+De+Lorenzoauthor=K.+S.+Flattenauthor=G.+G.+Poirierauthor=S.+H.+Kaufmann&title=Failure+of+iniparib+to+inhibit+poly%28ADP-ribose%29+polymerase+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro</span></div><div class="casAuthors">Patel, Anand G.; De Lorenzo, Silvana B.; Flatten, Karen S.; Poirier, Guy G.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clin. testing for their single-agent activity in homologous recombination (HR)-deficient tumors and ability to enhance the action of certain DNA-damaging agents.  Compared with other PARP inhibitors in development, iniparib (4-iodo-3-nitrobenzamide) is notable for its simple structure and the reported ability of its intracellular metabolite 4-iodo-3-nitrosobenzamide to covalently inhibit PARP1 under cell-free conditions.  The present preclin. studies were conducted to compare the actions iniparib with the more extensively characterized PARP inhibitors olaparib and veliparib.  Exptl. Design: The abilities of iniparib, olaparib, and veliparib to (i) selectively induce apoptosis or inhibit colony formation in HR-deficient cell lines, (ii) selectively sensitize HR-proficient cells to topoisomerase I poisons, and (iii) inhibit formation of poly(ADP-ribose) polymer (pADPr) in intact cells were compared.  RESULTS: Consistent with earlier reports, olaparib and veliparib selectively induced apoptosis and inhibited colony formation in cells lacking BRCA2 or ATM.  Moreover, like earlier generation PARP inhibitors, olaparib and veliparib sensitized cells to the topoisomerase I poisons camptothecin and topotecan.  Finally, olaparib and veliparib inhibited formation of pADPr in intact cells.  In contrast, iniparib exhibited little or no ability to selectively kill HR-deficient cells, sensitize cells to topoisomerase I poisons, or inhibit pADPr formation in situ.  In further expts., iniparib also failed to sensitize cells to cisplatin, gemcitabine, or paclitaxel.  CONCLUSIONS: While iniparib kills normal and neoplastic cells at high (>40 Î¼mol/L) concns., its effects are unlikely to reflect PARP inhibition and should not be used to guide decisions about other PARP inhibitors.  Clin Cancer Res; 18(6); 1655-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6PlliVCr5ErVg90H21EOLACvtfcHk0lggeB2_MS1FLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D&md5=82cb650b8bb7114cfc6afdc68fc5c3d9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2890%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DFlatten%26aufirst%3DK.%2BS.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DFailure%2520of%2520iniparib%2520to%2520inhibit%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520vitro%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span>AstraZeneca updates on olaparib and TC-5214 development programmes; <span class="NLM_publisher-name">AstraZeneca</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_month">December</span><span class="NLM_day">20</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development" class="extLink">http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development</a> (accessed 19 February<span class="NLM_x"> </span><span class="NLM_year">2015)</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AstraZeneca+updates+on+olaparib+and+TC-5214+development+programmes%3B+AstraZeneca%3A+London%2C+December20%2C+2011%3B+http%3A%2F%2Fwww.astrazeneca.com%2FMedia%2FPress-releases%2FArticle%2F20111220-az-updates-olaparib-TC5214-development+%28accessed+19+February+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAstraZeneca%2520updates%2520on%2520olaparib%2520and%2520TC-5214%2520development%2520programmes%26pub%3DAstraZeneca%26date%3D2011%26date%3D2015%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in patients with platinum sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">â</span> <span class="NLM_lpage">861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2FS1470-2045%2814%2970228-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=24882434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=852-861&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+L.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=A.+Fieldingauthor=S.+Spencerauthor=B.+Doughertyauthor=M.+Orrauthor=D.+Hodgsonauthor=J.+C.+Barrettauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+patients+with+platinum+sensitive+relapsed+serous+ovarian+cancer%3A+a+preplanned+retrospective+analysis+of+outcomes+by+BRCA+status+in+a+randomised+phase+2+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare L.; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Dougherty, Brian; Orr, Maria; Hodgson, Darren; Barrett, J. Carl; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-861</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer.  We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.We present data from the second interim anal. of overall survival and a retrospective, preplanned anal. of data by BRCA mutation status from our randomised, double-blind, phase 2 study that assessed maintenance treatment with olaparib 400 mg twice daily (capsules) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen.  Randomisation was by an interactive voice response system, stratified by time to progression on penultimate platinum-based regimen, response to the most recent platinum-based regimen before randomisation, and ethnic descent.  The primary endpoint was PFS, analyzed for the overall population and by BRCA status.  This study is registered with ClinicalTrials.gov, no. NCT00753545.Between Aug 28, 2008, and Feb 9, 2010, 136 patients were assigned to olaparib and 129 to placebo.  BRCA status was known for 131 (96%) patients in the olaparib group vs. 123 (95%) in the placebo group, of whom 74 (56%) vs. 62 (50%) had a deleterious or suspected deleterious germline or tumor BRCA mutation.  Of patients with a BRCA mutation, median PFS was significantly longer in the olaparib group than in the placebo group (11Â·2 mo [95% CI 8Â·3-not calculable] vs 4Â·3 mo [3Â·0-5Â·4]; HR 0Â·18 [0Â·10-0Â·31]; p<0Â·0001); similar findings were noted for patients with wild-type BRCA, although the difference between groups was lower (7Â·4 mo [5Â·5-10Â·3] vs 5Â·5 mo [3Â·7-5Â·6]; HR 0Â·54 [0Â·34-0Â·85]; p=0Â·0075).  At the second interim anal. of overall survival (58% maturity), overall survival did not significantly differ between the groups (HR 0Â·88 [95% CI 0Â·64-1Â·21]; p=0Â·44); similar findings were noted for patients with mutated BRCA (HR 0Â·73 [0Â·45-1Â·17]; p=0Â·19) and wild-type BRCA (HR 0Â·99 [0Â·63-1Â·55]; p=0Â·96).  The most common grade 3 or worse adverse events in the olaparib group were fatigue (in ten [7%] patients in the olaparib group vs four [3%] in the placebo group) and anemia (seven [5%] vs one [<1%]).  Serious adverse events were reported in 25 (18%) patients who received olaparib and 11 (9%) who received placebo.  Tolerability was similar in patients with mutated BRCA and the overall population.These results support the hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment.AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozZjZdcu1e4rVg90H21EOLACvtfcHk0li6KNAnBc9ZEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK&md5=bfc15e933746672148dd7237e3f67f01</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970228-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970228-1%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DOrr%26aufirst%3DM.%26aulast%3DHodgson%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520patients%2520with%2520platinum%2520sensitive%2520relapsed%2520serous%2520ovarian%2520cancer%253A%2520a%2520preplanned%2520retrospective%2520analysis%2520of%2520outcomes%2520by%2520BRCA%2520status%2520in%2520a%2520randomised%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D852%26epage%3D861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span>AstraZeneca initiates phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer; <span class="NLM_publisher-name">AstraZeneca</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_month">September</span><span class="NLM_day">4</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-enrollment-patient-phaseIII-olaparib" class="extLink">http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-enrollment-patient-phaseIII-olaparib</a> (accessed 19 February<span class="NLM_x"> </span><span class="NLM_year">2015)</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AstraZeneca+initiates+phase+III+clinical+programme+for+olaparib%2C+a+treatment+in+development+for+patients+with+BRCA+mutated+ovarian+cancer%3B+AstraZeneca%3A+London%2C+September4%2C+2013%3B+http%3A%2F%2Fwww.astrazeneca.com%2FMedia%2FPress-releases%2FArticle%2Fastrazeneca-enrollment-patient-phaseIII-olaparib+%28accessed+19+February+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAstraZeneca%2520initiates%2520phase%2520III%2520clinical%2520programme%2520for%2520olaparib%252C%2520a%2520treatment%2520in%2520development%2520for%2520patients%2520with%2520BRCA%2520mutated%2520ovarian%2520cancer%26pub%3DAstraZeneca%26date%3D2013%26date%3D2015%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Chung, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulger, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosjek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belyk, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphrey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limanto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachert, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, K. M.</span><span> </span><span class="NLM_article-title">Process development of CâN cross-coupling and enantioselective biocatalytic reactions for the asymmetric synthesis of niraparib</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/doi/10.1021/op400233z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=215-227&author=C.+K.+Chungauthor=P.+G.+Bulgerauthor=B.+Kosjekauthor=K.+M.+Belykauthor=N.+Riveraauthor=M.+E.+Scottauthor=G.+Humphreyauthor=J.+Limantoauthor=D.+C.+Bachertauthor=K.+M.+Emerson&title=Process+development+of+C%E2%80%93N+cross-coupling+and+enantioselective+biocatalytic+reactions+for+the+asymmetric+synthesis+of+niraparib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fop400233z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400233z%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BK.%26aulast%3DBulger%26aufirst%3DP.%2BG.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BE.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DLimanto%26aufirst%3DJ.%26aulast%3DBachert%26aufirst%3DD.%2BC.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520development%2520of%2520C%25E2%2580%2593N%2520cross-coupling%2520and%2520enantioselective%2520biocatalytic%2520reactions%2520for%2520the%2520asymmetric%2520synthesis%2520of%2520niraparib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D215%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelman, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hylands, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreischer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thway, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevensleben, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iannone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenham, R. M.</span><span> </span><span class="NLM_article-title">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">â</span> <span class="NLM_lpage">892</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2FS1470-2045%2813%2970240-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23810788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=882-892&author=S.+K.+Sandhuauthor=W.+R.+Schelmanauthor=G.+Wildingauthor=V.+Morenoauthor=R.+D.+Bairdauthor=S.+Mirandaauthor=L.+Hylandsauthor=R.+Riisnaesauthor=M.+Forsterauthor=A.+Omlinauthor=N.+Kreischerauthor=K.+Thwayauthor=H.+Gevenslebenauthor=L.+Sunauthor=J.+Loughneyauthor=M.+Chatterjeeauthor=C.+Toniattiauthor=C.+L.+Carpenterauthor=R.+Iannoneauthor=S.+B.+Kayeauthor=J.+S.+de+Bonoauthor=R.+M.+Wenham&title=The+poly%28ADP-ribose%29+polymerase+inhibitor+niraparib+%28MK4827%29+in+BRCA+mutation+carriers+and+patients+with+sporadic+cancer%3A+a+phase+1+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Sandhu, Shahneen K.; Schelman, William R.; Wilding, George; Moreno, Victor; Baird, Richard D.; Miranda, Susana; Hylands, Lucy; Riisnaes, Ruth; Forster, Martin; Omlin, Aurelius; Kreischer, Nathan; Thway, Khin; Gevensleben, Heidrun; Sun, Linda; Loughney, John; Chatterjee, Manash; Toniatti, Carlo; Carpenter, Christopher L.; Iannone, Robert; Kaye, Stan B.; de Bono, Johann S.; Wenham, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">882-892</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation.  Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclin. tumor models with loss of BRCA and PTEN function.  We investigated the safety, tolerability, max. tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumor activity of niraparib.In a phase 1 dose-escalation study, we enrolled patients with advanced solid tumors at one site in the UK and two sites in the USA.  Eligible patients were aged at least 18 years; had a life expectancy of at least 12 wk; had an Eastern Cooperative Oncol. Group performance status of 2 or less; had assessable disease; were not suitable to receive any established treatments; had adequate organ function; and had discontinued any previous anticancer treatments at least 4 wk previously.  In part A, cohorts of three to six patients, enriched for BRCA1 and BRCA2 mutation carriers, received niraparib daily at ten escalating doses from 30 mg to 400 mg in a 21-day cycle to establish the max. tolerated dose.  Dose expansion at the max. tolerated dose was pursued in 15 patients to confirm tolerability.  In part B, we further investigated the max. tolerated dose in patients with sporadic platinum-resistant high-grade serous ovarian cancer and sporadic prostate cancer.  We obtained blood, circulating tumor cells, and optional paired tumor biopsies for pharmacokinetic and pharmacodynamic assessments.  Toxic effects were assessed by common toxicity criteria and tumor responses ascribed by Response Evaluation Criteria in Solid Tumors (RECIST).  Circulating tumor cells and archival tumor tissue in prostate patients were analyzed for exploratory putative predictive biomarkers, such as loss of PTEN expression and ETS rearrangements.  This trial is registered with ClinicalTrials.gov, NCT00749502.Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B. 300 mg/day was established as the max. tolerated dose.  Dose-limiting toxic effects reported in the first cycle were grade 3 fatigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocytopenia (two given 400 mg/day).  Common treatment-related toxic effects were anemia (48 patients [48%]), nausea (42 [42%]), fatigue (42 [42%]), thrombocytopenia (35 [35%]), anorexia (26 [26%]), neutropenia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2.  Pharmacokinetics were dose proportional and the mean terminal elimination half-life was 36Â·4 h (range 32Â·8-46Â·0).  Pharmacodynamic analyses confirmed PARP inhibition exceeded 50% at doses greater than 80 mg/day and antitumor activity was documented beyond doses of 60 mg/day.  Eight (40% [95% CI 19-64]) of 20 BRCA1 or BRCA2 mutation carriers with ovarian cancer had RECIST partial responses, as did two (50% [7-93]) of four mutation carriers with breast cancer.  Antitumor activity was also reported in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer.  We recorded no correlation between loss of PTEN expression or ETS rearrangements and measures of antitumor activity in patients with prostate cancer.A recommended phase 2 dose of 300 mg/day niraparib is well tolerated.  Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.Merck Sharp and Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGQBD4DZcJn7Vg90H21EOLACvtfcHk0li6KNAnBc9ZEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF&md5=b6f27019bb7887156d1abcf05db2bca3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970240-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970240-7%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DSchelman%26aufirst%3DW.%2BR.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DHylands%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DForster%26aufirst%3DM.%26aulast%3DOmlin%26aufirst%3DA.%26aulast%3DKreischer%26aufirst%3DN.%26aulast%3DThway%26aufirst%3DK.%26aulast%3DGevensleben%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLoughney%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DCarpenter%26aufirst%3DC.%2BL.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DWenham%26aufirst%3DR.%2BM.%26atitle%3DThe%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520niraparib%2520%2528MK4827%2529%2520in%2520BRCA%2520mutation%2520carriers%2520and%2520patients%2520with%2520sporadic%2520cancer%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D882%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Simon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidlin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuck, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christian, M. C.</span><span> </span><span class="NLM_article-title">Accelerated titration designs for phase I clinical trials in oncology</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">â</span> <span class="NLM_lpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1093%2Fjnci%2F89.15.1138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=9262252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK2sXls1WnurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1138-114&author=R.+Simonauthor=B.+Freidlinauthor=L.+Rubinsteinauthor=S.+G.+Arbuckauthor=J.+Collinsauthor=M.+C.+Christian&title=Accelerated+titration+designs+for+phase+I+clinical+trials+in+oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerated titration designs for phase i clinical trials in oncology</span></div><div class="casAuthors">Simon, Richard; Freidlin, Boris; Rubinstein, Larry; Arbuck, Susan G.; Collins, Jerry; Christian, Michaele C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1138-1147</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Many cancer patients in phase I clin. trials are treated at doses of chemotherapeutic agents that are below the biol. active level, thus reducing their chances for therapeutic benefit.  Current phase I trials often take a long time to complete and provide little information about interpatient variability or cumulative toxicity.  Our objective was to develop alternative designs for phase I trials so that fewer patients are treated at subtherapeutic dose levels, trials are of reduced duration, and important information (i.e., cumulative toxicity and max. tolerated dose) needed to plan phase II trials is obtained.  We fit a stochastic model to data from 20 phase I trials involving the study of nine different drugs.  We then simulated new data from the model with the parameters estd. from the actual trials and evaluated the performance of alternative phase I designs on this simulated data.  Four designs were evaluated.  Design 1 was a conventional design (similar to the commonly used modified Fibonacci method) using cohorts of three to six patients, with 40% dose-step increments and no intrapatient dose escalation.  Designs 2 through 4 included only one patient per cohort until one patient experienced dose-limiting toxic effects or two patients experienced grade 2 toxic effects (during their first course of treatment for designs 2 and 3 or during any course of treatment for design 4).  Designs 3 and 4 used 100% dose steps during this initial accelerated phase.  After the initial accelerated phase, designs 2 through 4 resorted to std. cohorts of three to six patients, with 40% dose-step increments.  Designs 2 through 4 used intrapatient dose escalation if the worst toxicity is grade 0-1 in the previous course for that patient.  Only three of the actual trials demonstrated cumulative toxic effects of the chemotherapeutic agents in patients.  The av. no. of patients required for a phase I trial was reduced from 39.9 for design 1 to 24.4, 20.7, and 21.2 for designs 2, 3, and 4, resp.  The av. no. of patients who would be expected to have grade 0-1 toxicity as their worst toxicity over three cycles of treatment is 23.3 for design 1, but only 7.9, 3.9, and 4.8 for designs 2, 3, and 4, resp.  The av. no. of patients with grade 3 toxicity as their worst toxicity increases from 5.5 for design 1 to 6.2, 6.8, and 6.2 for designs 2, 3, and 4, resp.  The av. no. of patients with grade 4 toxicity as their worst toxicity increases from 1.9 for design 1 to 3.0, 4.3, and 3.2 for designs 2, 3, and 4, resp.  Accelerated titrn. (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the no. of patients who are undertreated, speed the completion of phase I trials, and provide a substantial increase in the information obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJZU1U_6M84LVg90H21EOLACvtfcHk0lgH1FAYVp85Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1WnurY%253D&md5=9bd1e7a56e6070e2f2ce4b1c1e339f59</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F89.15.1138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F89.15.1138%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DR.%26aulast%3DFreidlin%26aufirst%3DB.%26aulast%3DRubinstein%26aufirst%3DL.%26aulast%3DArbuck%26aufirst%3DS.%2BG.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DChristian%26aufirst%3DM.%2BC.%26atitle%3DAccelerated%2520titration%2520designs%2520for%2520phase%2520I%2520clinical%2520trials%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1997%26volume%3D89%26spage%3D1138%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SzabÃ³, C.</span><span> </span><span class="NLM_article-title">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">â</span> <span class="NLM_lpage">1256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2Fj.mam.2013.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23370117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1217-1256&author=N.+J.+Curtinauthor=C.+Szab%C3%B3&title=Therapeutic+applications+of+PARP+inhibitors%3A+Anticancer+therapy+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span></div><div class="casAuthors">Curtin, Nicola J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1256</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this article is to describe the current and potential clin. translation of pharmacol. inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases.  The first section of the present review summarizes the available preclin. and clin. data with PARP inhibitors in various forms of cancer.  In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-assocd. lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer.  HRR defects are classically assocd. with BRCA1 and 2 mutations assocd. with familial breast and ovarian cancer, but there may be many other causes of HRR defects.  Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects.  Multiple lines of preclin. data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation.  Both single agent and combination clin. trials are underway.  The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clin. development.  The second section of the present review summarizes the role of PARP in selected non-oncol. indications.  In a no. of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clin. translatability of PARP inhibition is supported by multiple lines of preclin. data, as well as observational data demonstrating PARP activation in human tissue samples.  In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathol.  Accordingly, multiple lines of preclin. data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses.  As the clin. trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clin. investigations, aimed at testing of PARP inhibitors for various non-oncol. indications, will be initiated, as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4INVXcZ0zbVg90H21EOLACvtfcHk0lgH1FAYVp85Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D&md5=6a514e160666b5dde38e1365211cd41e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DSzab%25C3%25B3%26aufirst%3DC.%26atitle%3DTherapeutic%2520applications%2520of%2520PARP%2520inhibitors%253A%2520Anticancer%2520therapy%2520and%2520beyond%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1217%26epage%3D1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span> <span class="citation_source-journal">N. Eng. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">1382</span><span class="NLM_x">â</span> <span class="NLM_lpage">1392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1056%2FNEJMoa1105535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22452356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1382-1392&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=E.+Macphersonauthor=C.+Watkinsauthor=J.+Carmichaelauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+platinum-sensitive+relapsed+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; MacPherson, Euan; Watkins, Claire; Carmichael, James; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1382-1392</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Olaparib (AZD2281) is an oral poly(ADP [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.  METHODS We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen.  Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo.  The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines.  RESULTS Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group.  Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 mo vs. 4.8 mo from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001).  Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression.  Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2.  An interim anal. of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P = 0.75).  CONCLUSIONS Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.  Interim anal. showed no overall survival benefit.  The toxicity profile of olaparib in this population was consistent with that in previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGMJNLsHGObVg90H21EOLACvtfcHk0lgH1FAYVp85Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D&md5=1612aa24cd17a29f03599a7c2acf5f0f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105535%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520platinum-sensitive%2520relapsed%2520ovarian%2520cancer%26jtitle%3DN.%2520Eng.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1382%26epage%3D1392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Garber, K.</span><span> </span><span class="NLM_article-title">PARP inhibitors bounce back</span> <span class="citation_source-journal">Nature Rev. Drug. Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">â</span> <span class="NLM_lpage">727</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=725-727&author=K.+Garber&title=PARP+inhibitors+bounce+back"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarber%26aufirst%3DK.%26atitle%3DPARP%2520inhibitors%2520bounce%2520back%26jtitle%3DNature%2520Rev.%2520Drug.%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D725%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 68 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hexiang Wang, Bo Ren, Ye Liu, Beibei Jiang, Yin Guo, Min Wei, Lusong Luo, Xianzhao Kuang, Ming Qiu, Lei Lv, Hong Xu, Ruipeng Qi, Huibin Yan, Dexu Xu, Zhiwei Wang, Chang-Xin Huo, Yutong Zhu, Yuan Zhao, Yiyuan Wu, Zhen Qin, Dan Su, Tristin Tang, Fan Wang, Xuebing Sun, Yingcai Feng, Hao Peng, Xing Wang, Yajuan Gao, Yong Liu, Wenfeng Gong, Fenglong Yu, Xuesong Liu, Lai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Changyou Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15541-15563. <a href="https://doi.org/10.1021/acs.jmedchem.0c01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPamiparib%252B%252528BGB-290%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BPoly%252B%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252BInhibitor%252Bin%252BClinical%252BDevelopment%26aulast%3DWang%26aufirst%3DHexiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01082020%26date%3D02122020%26volume%3D63%26issue%3D24%26spage%3D15541%26epage%3D15563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaoguo Cao, Jie Yang, Yong Chen, Peiting Zhou, Yingwei Wang, Wu Du, Lifeng Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Yuanwei Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11012-11033. <a href="https://doi.org/10.1021/acs.jmedchem.0c00821" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSK-575%252Bas%252Ba%252BHighly%252BPotent%252Band%252BEfficacious%252BProteolysis-Targeting%252BChimera%252BDegrader%252Bof%252BPARP1%252Bfor%252BTreating%252BCancers%26aulast%3DCao%26aufirst%3DChaoguo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01062020%26date%3D24092020%26date%3D14092020%26volume%3D63%26issue%3D19%26spage%3D11012%26epage%3D11033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rana Alsalim, Peter Lindemann, MarÃ­a Pascual LÃ³pez-Alberca, Sandra Miksche, Werngard Czechtizky, Nis Halland, <span class="NLM_string-name hlFld-ContribAuthor">Marc NazarÃ©</span>. </span><span class="cited-content_cbyCitation_article-title">A Palladium-Catalyzed Domino Reaction To Access 3-Amino-2H-indazoles from Hydrazines and 2-Halobenzonitriles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (18)
                                     , 7393-7396. <a href="https://doi.org/10.1021/acs.orglett.0c02766" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02766%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BPalladium-Catalyzed%252BDomino%252BReaction%252BTo%252BAccess%252B3-Amino-2H-indazoles%252Bfrom%252BHydrazines%252Band%252B2-Halobenzonitriles%26aulast%3DAlsalim%26aufirst%3DRana%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18082020%26date%3D01092020%26volume%3D22%26issue%3D18%26spage%3D7393%26epage%3D7396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Yungen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 122-139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00622" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BPoly%252528ADP-ribose%252529polymerase%252Band%252BPhosphoinositide%252B3-Kinase%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D27122019%26date%3D17122019%26volume%3D63%26issue%3D1%26spage%3D122%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lik Hang Yuen, Srikanta Dana, Yu Liu, Samuel I. Bloom, Ann-Gerd Thorsell, Dario Neri, Anthony J. Donato, Dmitri Kireev, Herwig SchÃ¼ler, <span class="NLM_string-name hlFld-ContribAuthor">Raphael M. Franzini</span>. </span><span class="cited-content_cbyCitation_article-title">A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (13)
                                     , 5169-5181. <a href="https://doi.org/10.1021/jacs.8b08039" title="DOI URL">https://doi.org/10.1021/jacs.8b08039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b08039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b08039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DA%252BFocused%252BDNA-Encoded%252BChemical%252BLibrary%252Bfor%252Bthe%252BDiscovery%252Bof%252BInhibitors%252Bof%252BNAD%25252B-Dependent%252BEnzymes%26aulast%3DYuen%26aufirst%3DLik%2BHang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28072018%26date%3D19032019%26date%3D11032019%26volume%3D141%26issue%3D13%26spage%3D5169%26epage%3D5181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Allyson
J. Boyington, Ciaran P. Seath, Avery M. Zearfoss, Zihao Xu, <span class="NLM_string-name hlFld-ContribAuthor">Nathan T. Jui</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Strategy for Regioselective Arylethylamine Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (9)
                                     , 4147-4153. <a href="https://doi.org/10.1021/jacs.9b01077" title="DOI URL">https://doi.org/10.1021/jacs.9b01077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b01077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b01077%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCatalytic%252BStrategy%252Bfor%252BRegioselective%252BArylethylamine%252BSynthesis%26aulast%3DBoyington%26aufirst%3DAllyson%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29012019%26date%3D21022019%26date%3D13022019%26volume%3D141%26issue%3D9%26spage%3D4147%26epage%3D4153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olga A.  Ivanova</span>, <span class="hlFld-ContribAuthor ">Alexey O.  Chagarovskiy</span>, <span class="hlFld-ContribAuthor ">Alexey N.  Shumsky</span>, <span class="hlFld-ContribAuthor ">Vasiliy D.  Krasnobrov</span>, <span class="hlFld-ContribAuthor ">Irina I.  Levina</span>, and <span class="hlFld-ContribAuthor ">Igor V.  Trushkov</span>  . </span><span class="cited-content_cbyCitation_article-title">Lewis Acid Triggered VinylcyclopropaneâCyclopentene Rearrangement. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (2)
                                     , 543-560. <a href="https://doi.org/10.1021/acs.joc.7b02351" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02351%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DLewis%252BAcid%252BTriggered%252BVinylcyclopropane%2525E2%252580%252593Cyclopentene%252BRearrangement%26aulast%3DIvanova%26aufirst%3DOlga%2BA.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D17092017%26date%3D10112017%26date%3D19012018%26date%3D07112017%26volume%3D83%26issue%3D2%26spage%3D543%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiarong  Shi</span>, <span class="hlFld-ContribAuthor ">Hai  Xu</span>, <span class="hlFld-ContribAuthor ">Dachuan  Qiu</span>, <span class="hlFld-ContribAuthor ">Jia  He</span>, and <span class="hlFld-ContribAuthor ">Yang  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Selective Aryne Formation via Grob Fragmentation from the [2+2] Cycloadducts of 3-Triflyloxyarynes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (2)
                                     , 623-626. <a href="https://doi.org/10.1021/jacs.6b12161" title="DOI URL">https://doi.org/10.1021/jacs.6b12161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b12161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b12161%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DSelective%252BAryne%252BFormation%252Bvia%252BGrob%252BFragmentation%252Bfrom%252Bthe%252B%25255B2%25252B2%25255D%252BCycloadducts%252Bof%252B3-Triflyloxyarynes%26aulast%3DShi%26aufirst%3DJiarong%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D25112016%26date%3D10012017%26date%3D18012017%26date%3D30122016%26volume%3D139%26issue%3D2%26spage%3D623%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Nieddu</span>, <span class="hlFld-ContribAuthor ">Giansalvo  Pinna</span>, <span class="hlFld-ContribAuthor ">Irene  Marchesi</span>, <span class="hlFld-ContribAuthor ">Luca  Sanna</span>, <span class="hlFld-ContribAuthor ">Battistina  Asproni</span>, <span class="hlFld-ContribAuthor ">Gerard A.  Pinna</span>, <span class="hlFld-ContribAuthor ">Luigi  Bagella</span>, and <span class="hlFld-ContribAuthor ">Gabriele  Murineddu</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Antineoplastic Evaluation of Novel Unsymmetrical 1,3,4-Oxadiazoles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (23)
                                     , 10451-10469. <a href="https://doi.org/10.1021/acs.jmedchem.6b00468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00468%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BAntineoplastic%252BEvaluation%252Bof%252BNovel%252BUnsymmetrical%252B1%25252C3%25252C4-Oxadiazoles%26aulast%3DNieddu%26aufirst%3DValentina%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01042016%26date%3D29112016%26date%3D08122016%26date%3D01112016%26volume%3D59%26issue%3D23%26spage%3D10451%26epage%3D10469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Ping-Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, and <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>  . </span><span class="cited-content_cbyCitation_article-title">An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9575-9598. <a href="https://doi.org/10.1021/acs.jmedchem.6b00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BPoly%252528ADP-ribose%252529polymerase-1%252B%252528PARP-1%252529%252BInhibitors%25253A%252BOpportunities%252Band%252BChallenges%252Bin%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DYing-Qing%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D13012016%26date%3D27072016%26date%3D10112016%26date%3D14072016%26volume%3D59%26issue%3D21%26spage%3D9575%26epage%3D9598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Safnas F.  AbdulSalam</span>, <span class="hlFld-ContribAuthor ">Fathima Shazna  Thowfeik</span>, and <span class="hlFld-ContribAuthor ">Edward J.  Merino</span>  . </span><span class="cited-content_cbyCitation_article-title">Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2016,</strong> <em>55 </em>
                                    (38)
                                     , 5341-5352. <a href="https://doi.org/10.1021/acs.biochem.6b00703" title="DOI URL">https://doi.org/10.1021/acs.biochem.6b00703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.6b00703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.6b00703%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DExcessive%252BReactive%252BOxygen%252BSpecies%252Band%252BExotic%252BDNA%252BLesions%252Bas%252Ban%252BExploitable%252BLiability%26aulast%3DAbdulSalam%26aufirst%3DSafnas%2BF.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11072016%26date%3D18082016%26date%3D13092016%26date%3D27092016%26date%3D01092016%26volume%3D55%26issue%3D38%26spage%3D5341%26epage%3D5352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bing  Wang</span>, <span class="hlFld-ContribAuthor ">Daniel  Chu</span>, <span class="hlFld-ContribAuthor ">Ying  Feng</span>, <span class="hlFld-ContribAuthor ">Yuqiao  Shen</span>, <span class="hlFld-ContribAuthor ">Mika  Aoyagi-Scharber</span>, and <span class="hlFld-ContribAuthor ">Leonard E.  Post</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 335-357. <a href="https://doi.org/10.1021/acs.jmedchem.5b01498" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01498</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252B%2525288S%25252C9R%252529-5-Fluoro-8-%2525284-fluorophenyl%252529-9-%2525281-methyl-1H-1%25252C2%25252C4-triazol-5-yl%252529-2%25252C7%25252C8%25252C9-tetrahydro-3H-pyrido%25255B4%25252C3%25252C2-de%25255Dphthalazin-3-one%252B%252528BMN%252B673%25252C%252BTalazoparib%252529%25252C%252Ba%252BNovel%25252C%252BHighly%252BPotent%25252C%252Band%252BOrally%252BEfficacious%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%25252F2%252BInhibitor%25252C%252Bas%252Ban%252BAnticancer%252BAgent%26aulast%3DWang%26aufirst%3DBing%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D27092015%26date%3D23122015%26date%3D14012016%26date%3D10122015%26volume%3D59%26issue%3D1%26spage%3D335%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gianluca  Papeo</span>, <span class="hlFld-ContribAuthor ">Helena  Posteri</span>, <span class="hlFld-ContribAuthor ">Daniela  Borghi</span>, <span class="hlFld-ContribAuthor ">Alina A.  Busel</span>, <span class="hlFld-ContribAuthor ">Francesco  Caprera</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span>, <span class="hlFld-ContribAuthor ">Marina  Ciomei</span>, <span class="hlFld-ContribAuthor ">Alessandra  Cirla</span>, <span class="hlFld-ContribAuthor ">Emiliana  Corti</span>, <span class="hlFld-ContribAuthor ">Matteo  DâAnello</span>, <span class="hlFld-ContribAuthor ">Marina  Fasolini</span>, <span class="hlFld-ContribAuthor ">Barbara  Forte</span>, <span class="hlFld-ContribAuthor ">Arturo  Galvani</span>, <span class="hlFld-ContribAuthor ">Antonella  Isacchi</span>, <span class="hlFld-ContribAuthor ">Alexander  Khvat</span>, <span class="hlFld-ContribAuthor ">Mikhail Y.  Krasavin</span>, <span class="hlFld-ContribAuthor ">Rosita  Lupi</span>, <span class="hlFld-ContribAuthor ">Paolo  Orsini</span>, <span class="hlFld-ContribAuthor ">Rita  Perego</span>, <span class="hlFld-ContribAuthor ">Enrico  Pesenti</span>, <span class="hlFld-ContribAuthor ">Daniele  Pezzetta</span>, <span class="hlFld-ContribAuthor ">Sonia  Rainoldi</span>, <span class="hlFld-ContribAuthor ">Federico  Riccardi-Sirtori</span>, <span class="hlFld-ContribAuthor ">Alessandra  Scolaro</span>, <span class="hlFld-ContribAuthor ">Francesco  Sola</span>, <span class="hlFld-ContribAuthor ">Fabio  Zuccotto</span>, <span class="hlFld-ContribAuthor ">Eduard R.  Felder</span>, <span class="hlFld-ContribAuthor ">Daniele  Donati</span>, and <span class="hlFld-ContribAuthor ">Alessia  Montagnoli</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (17)
                                     , 6875-6898. <a href="https://doi.org/10.1021/acs.jmedchem.5b00680" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%25255B1-%2525284%25252C4-Difluorocyclohexyl%252529piperidin-4-yl%25255D-6-fluoro-3-oxo-2%25252C3-dihydro-1H-isoindole-4-carboxamide%252B%252528NMS-P118%252529%25253A%252BA%252BPotent%25252C%252BOrally%252BAvailable%25252C%252Band%252BHighly%252BSelective%252BPARP-1%252BInhibitor%252Bfor%252BCancer%252BTherapy%26aulast%3DPapeo%26aufirst%3DGianluca%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D04052015%26date%3D26082015%26date%3D10092015%26date%3D29072015%26volume%3D58%26issue%3D17%26spage%3D6875%26epage%3D6898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pietro Paolo  Vitiello</span>, <span class="hlFld-ContribAuthor ">Giulia  Martini</span>, <span class="hlFld-ContribAuthor ">Luigi  Mele</span>, <span class="hlFld-ContribAuthor ">Emilio Francesco  Giunta</span>, <span class="hlFld-ContribAuthor ">Vincenzo  De Falco</span>, <span class="hlFld-ContribAuthor ">Davide  Ciardiello</span>, <span class="hlFld-ContribAuthor ">Valentina  Belli</span>, <span class="hlFld-ContribAuthor ">Claudia  Cardone</span>, <span class="hlFld-ContribAuthor ">Nunzia  Matrone</span>, <span class="hlFld-ContribAuthor ">Luca  Poliero</span>, <span class="hlFld-ContribAuthor ">Virginia  Tirino</span>, <span class="hlFld-ContribAuthor ">Stefania  Napolitano</span>, <span class="hlFld-ContribAuthor ">Carminia  Della Corte</span>, <span class="hlFld-ContribAuthor ">Francesco  Selvaggi</span>, <span class="hlFld-ContribAuthor ">Gianpaolo  Papaccio</span>, <span class="hlFld-ContribAuthor ">Teresa  Troiani</span>, <span class="hlFld-ContribAuthor ">Floriana  Morgillo</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Desiderio</span>, <span class="hlFld-ContribAuthor ">Fortunato  Ciardiello</span>, <span class="hlFld-ContribAuthor ">Erika  Martinelli</span>. </span><span class="cited-content_cbyCitation_article-title">Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2021,</strong> <em>40 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-020-01811-8" title="DOI URL">https://doi.org/10.1186/s13046-020-01811-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-020-01811-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-020-01811-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DVulnerability%252Bto%252Blow-dose%252Bcombination%252Bof%252Birinotecan%252Band%252Bniraparib%252Bin%252BATM-mutated%252Bcolorectal%252Bcancer%26aulast%3DVitiello%26aufirst%3DPietro%2BPaolo%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Shen</span>, <span class="hlFld-ContribAuthor ">Yiran  Ge</span>, <span class="hlFld-ContribAuthor ">Junwei  Wang</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Qihua  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128169. <a href="https://doi.org/10.1016/j.bmcl.2021.128169" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128169%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bmolecules%252Bas%252Bpotent%252BPARP-1%252Binhibitors%26aulast%3DShen%26aufirst%3DHui%26date%3D2021%26volume%3D47%26spage%3D128169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph M.  Gozgit</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Vasbinder</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Abo</span>, <span class="hlFld-ContribAuthor ">Kaiko  Kunii</span>, <span class="hlFld-ContribAuthor ">Kristy G.  Kuplast-Barr</span>, <span class="hlFld-ContribAuthor ">Bin  Gui</span>, <span class="hlFld-ContribAuthor ">Alvin Z.  Lu</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Molina</span>, <span class="hlFld-ContribAuthor ">Elena  Minissale</span>, <span class="hlFld-ContribAuthor ">Kerren K.  Swinger</span>, <span class="hlFld-ContribAuthor ">Tim J.  Wigle</span>, <span class="hlFld-ContribAuthor ">Danielle J.  Blackwell</span>, <span class="hlFld-ContribAuthor ">Christina R.  Majer</span>, <span class="hlFld-ContribAuthor ">Yue  Ren</span>, <span class="hlFld-ContribAuthor ">Mario  Niepel</span>, <span class="hlFld-ContribAuthor ">Zacharenia A.  Varsamis</span>, <span class="hlFld-ContribAuthor ">Sunaina P.  Nayak</span>, <span class="hlFld-ContribAuthor ">Ellen  Bamberg</span>, <span class="hlFld-ContribAuthor ">Jan-Rung  Mo</span>, <span class="hlFld-ContribAuthor ">W. David  Church</span>, <span class="hlFld-ContribAuthor ">Ahmed S.A.  Mady</span>, <span class="hlFld-ContribAuthor ">Jeff  Song</span>, <span class="hlFld-ContribAuthor ">Luke  Utley</span>, <span class="hlFld-ContribAuthor ">Patricia E.  Rao</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Mitchison</span>, <span class="hlFld-ContribAuthor ">Kevin W.  Kuntz</span>, <span class="hlFld-ContribAuthor ">Victoria M.  Richon</span>, <span class="hlFld-ContribAuthor ">Heike  Keilhack</span>. </span><span class="cited-content_cbyCitation_article-title">PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.ccell.2021.06.018" title="DOI URL">https://doi.org/10.1016/j.ccell.2021.06.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2021.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2021.06.018%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DPARP7%252Bnegatively%252Bregulates%252Bthe%252Btype%252BI%252Binterferon%252Bresponse%252Bin%252Bcancer%252Bcells%252Band%252Bits%252Binhibition%252Btriggers%252Bantitumor%252Bimmunity%26aulast%3DGozgit%26aufirst%3DJoseph%2BM.%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maninder  Singh</span>, <span class="hlFld-ContribAuthor ">Jyotika  Rajawat</span>, <span class="hlFld-ContribAuthor ">Jitendra  Kuldeep</span>, <span class="hlFld-ContribAuthor ">Nidhi  Shukla</span>, <span class="hlFld-ContribAuthor ">Durga Prasad  Mishra</span>, <span class="hlFld-ContribAuthor ">Mohammad Imran  Siddiqi</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>45 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2021.1913229" title="DOI URL">https://doi.org/10.1080/07391102.2021.1913229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1913229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1913229%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIntegrated%252Bsupport%252Bvector%252Bmachine%252Band%252Bpharmacophore%252Bbased%252Bvirtual%252Bscreening%252Bdriven%252Bidentification%252Bof%252Bthiophene%252Bcarboxamide%252Bscaffold%252Bcontaining%252Bcompound%252Bas%252Bpotential%252BPARP1%252Binhibitor%26aulast%3DSingh%26aufirst%3DManinder%26date%3D2021%26date%3D2021%26volume%3D45%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luigi  Della Corte</span>, <span class="hlFld-ContribAuthor ">Virginia  Foreste</span>, <span class="hlFld-ContribAuthor ">Claudia,  Di Filippo</span>, <span class="hlFld-ContribAuthor ">Pierluigi  Giampaolino</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Bifulco</span>. </span><span class="cited-content_cbyCitation_article-title">Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2021,</strong> <em>30 </em>
                                    (5)
                                     , 543-554. <a href="https://doi.org/10.1080/13543784.2021.1901882" title="DOI URL">https://doi.org/10.1080/13543784.2021.1901882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2021.1901882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2021.1901882%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DPoly%252B%252528ADP-ribose%252529%252Bpolymerase%252B%252528PARP%252529%252Bas%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bepithelial%252Bovarian%252Bcancer%25253A%252Bwhat%252Bto%252Bknow%26aulast%3DDella%2BCorte%26aufirst%3DLuigi%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D5%26spage%3D543%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junwei  Wang</span>, <span class="hlFld-ContribAuthor ">Guangchao  He</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Yiran  Ge</span>, <span class="hlFld-ContribAuthor ">Shuping  Wang</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Qihua  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113054. <a href="https://doi.org/10.1016/j.ejmech.2020.113054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BPARP%25252FPI3K%252Bdual%252Binhibitors%252Bwith%252Bhigh%252Befficiency%252Bagainst%252BBRCA-proficient%252Btriple%252Bnegative%252Bbreast%252Bcancer%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2021%26volume%3D213%26spage%3D113054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nour E. A.  Abd El-sattar</span>, <span class="hlFld-ContribAuthor ">Eman H. K.  Badawy</span>, <span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Nasser S. M.  Ismail</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrano[2,3-
              d
              ]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (8)
                                     , 4454-4464. <a href="https://doi.org/10.1039/D0RA10321G" title="DOI URL">https://doi.org/10.1039/D0RA10321G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA10321G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA10321G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252Bpyrano%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine-2%25252C4-dione%252Bderivatives%252Bas%252Bnovel%252BPARP-1%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%26aulast%3DAbd%2BEl-sattar%26aufirst%3DNour%2BE.%2BA.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D8%26spage%3D4454%26epage%3D4464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claire  Fritz</span>, <span class="hlFld-ContribAuthor ">Scott M.  Portwood</span>, <span class="hlFld-ContribAuthor ">Amanda  Przespolewski</span>, <span class="hlFld-ContribAuthor ">Eunice S.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. </span><span class="cited-content_cbyCitation_journal-name">Blood Reviews</span><span> <strong>2021,</strong> <em>45 </em>, 100696. <a href="https://doi.org/10.1016/j.blre.2020.100696" title="DOI URL">https://doi.org/10.1016/j.blre.2020.100696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.blre.2020.100696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.blre.2020.100696%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Reviews%26atitle%3DPARP%252Bgoes%252Bthe%252Bweasel%252521%252BEmerging%252Brole%252Bof%252BPARP%252Binhibitors%252Bin%252Bacute%252Bleukemias%26aulast%3DFritz%26aufirst%3DClaire%26date%3D2021%26volume%3D45%26spage%3D100696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianpeng  Chen</span>, <span class="hlFld-ContribAuthor ">Gaoyang  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiangwei  Meng</span>, <span class="hlFld-ContribAuthor ">Xingxian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of small molecules with anti-inflammatory activities for the treatment of acute lung injury. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112660. <a href="https://doi.org/10.1016/j.ejmech.2020.112660" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112660</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112660%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bof%252Bsmall%252Bmolecules%252Bwith%252Banti-inflammatory%252Bactivities%252Bfor%252Bthe%252Btreatment%252Bof%252Bacute%252Blung%252Binjury%26aulast%3DChen%26aufirst%3DTianpeng%26date%3D2020%26volume%3D207%26spage%3D112660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  An</span>, <span class="hlFld-ContribAuthor ">Mengbi  Guo</span>, <span class="hlFld-ContribAuthor ">Yingbo  Zang</span>, <span class="hlFld-ContribAuthor ">Hang  Xu</span>, <span class="hlFld-ContribAuthor ">Zhuang  Hou</span>, <span class="hlFld-ContribAuthor ">Chun  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Synthesis of Benzazoles via Imines. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2020,</strong> <em>24 </em>
                                    (17)
                                     , 1897-1942. <a href="https://doi.org/10.2174/1385272824999200818180845" title="DOI URL">https://doi.org/10.2174/1385272824999200818180845</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272824999200818180845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272824999200818180845%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252BSynthesis%252Bof%252BBenzazoles%252Bvia%252BImines%26aulast%3DAn%26aufirst%3DRan%26date%3D2020%26volume%3D24%26issue%3D17%26spage%3D1897%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lloreta  Kerliu</span>, <span class="hlFld-ContribAuthor ">Samantha  Myruski</span>, <span class="hlFld-ContribAuthor ">Afeefa  Bhatti</span>, <span class="hlFld-ContribAuthor ">Priyal  Soni</span>, <span class="hlFld-ContribAuthor ">Paulius  Petrosius</span>, <span class="hlFld-ContribAuthor ">Helen C.  Pervanas</span>, <span class="hlFld-ContribAuthor ">Evan R.  Horton</span>. </span><span class="cited-content_cbyCitation_article-title">Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. </span><span class="cited-content_cbyCitation_journal-name">Annals of Pharmacotherapy</span><span> <strong>2020,</strong> <em>54 </em>
                                    (10)
                                     , 1010-1015. <a href="https://doi.org/10.1177/1060028020912749" title="DOI URL">https://doi.org/10.1177/1060028020912749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1060028020912749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1060028020912749%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Pharmacotherapy%26atitle%3DNiraparib%252Bfor%252Bthe%252BTreatment%252Bof%252BRecurrent%252BEpithelial%252BOvarian%25252C%252BFallopian%252BTube%25252C%252Bor%252BPrimary%252BPeritoneal%252BCancer%26aulast%3DKerliu%26aufirst%3DLloreta%26date%3D2020%26date%3D2020%26volume%3D54%26issue%3D10%26spage%3D1010%26epage%3D1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stergios  Boussios</span>, <span class="hlFld-ContribAuthor ">Peeter  Karihtala</span>, <span class="hlFld-ContribAuthor ">Michele  Moschetta</span>, <span class="hlFld-ContribAuthor ">Charlotte  Abson</span>, <span class="hlFld-ContribAuthor ">Afroditi  Karathanasi</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Zakynthinakis-Kyriakou</span>, <span class="hlFld-ContribAuthor ">Jake Edward  Ryan</span>, <span class="hlFld-ContribAuthor ">Matin  Sheriff</span>, <span class="hlFld-ContribAuthor ">Elie  Rassy</span>, <span class="hlFld-ContribAuthor ">Nicholas  Pavlidis</span>. </span><span class="cited-content_cbyCitation_article-title">Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2020,</strong> <em>38 </em>
                                    (1)
                                     , 181-193. <a href="https://doi.org/10.1007/s10637-019-00867-4" title="DOI URL">https://doi.org/10.1007/s10637-019-00867-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-019-00867-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-019-00867-4%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DVeliparib%252Bin%252Bovarian%252Bcancer%25253A%252Ba%252Bnew%252Bsynthetically%252Blethal%252Btherapeutic%252Bapproach%26aulast%3DBoussios%26aufirst%3DStergios%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D1%26spage%3D181%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  Tang</span>, <span class="hlFld-ContribAuthor ">Kuan  Lu</span>, <span class="hlFld-ContribAuthor ">Huan  Zhao</span>, <span class="hlFld-ContribAuthor ">Weibin  Wu</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of piperidyl benzimidazole carboxamide derivatives as potent PARP-1 inhibitors and antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (1)
                                     , 136-140. <a href="https://doi.org/10.1016/j.cclet.2019.04.045" title="DOI URL">https://doi.org/10.1016/j.cclet.2019.04.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2019.04.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2019.04.045%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpiperidyl%252Bbenzimidazole%252Bcarboxamide%252Bderivatives%252Bas%252Bpotent%252BPARP-1%252Binhibitors%252Band%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DXinwei%26date%3D2020%26volume%3D31%26issue%3D1%26spage%3D136%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinyue  Chang</span>, <span class="hlFld-ContribAuthor ">Chixiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Shenxin  Zeng</span>, <span class="hlFld-ContribAuthor ">Meihao  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen  Ma</span>, <span class="hlFld-ContribAuthor ">Zunyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1606-1615. <a href="https://doi.org/10.1080/14756366.2020.1804382" title="DOI URL">https://doi.org/10.1080/14756366.2020.1804382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1804382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1804382%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bprobe-quality%252Bdegraders%252Bfor%252BPoly%252528ADP-ribose%252529%252Bpolymerase-1%252B%252528PARP-1%252529%26aulast%3DZhang%26aufirst%3DZhimin%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1606%26epage%3D1615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irem Durmaz  Sahin</span>, <span class="hlFld-ContribAuthor ">Jenny-Maria  JÃ¶nsson</span>, <span class="hlFld-ContribAuthor ">Ingrid  Hedenfalk</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (65)
                                     , 6981-6996. <a href="https://doi.org/10.18632/oncotarget.27363" title="DOI URL">https://doi.org/10.18632/oncotarget.27363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27363%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DCrizotinib%252Band%252BPARP%252Binhibitors%252Bact%252Bsynergistically%252Bby%252Btriggering%252Bapoptosis%252Bin%252Bhigh-grade%252Bserous%252Bovarian%252Bcancer%26aulast%3DSahin%26aufirst%3DIrem%2BDurmaz%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D65%26spage%3D6981%26epage%3D6996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Esha  Sachdev</span>, <span class="hlFld-ContribAuthor ">Roya  Tabatabai</span>, <span class="hlFld-ContribAuthor ">Varun  Roy</span>, <span class="hlFld-ContribAuthor ">B. J.  Rimel</span>, <span class="hlFld-ContribAuthor ">Monica M.  Mita</span>. </span><span class="cited-content_cbyCitation_article-title">PARP Inhibition in Cancer: An Update on Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (6)
                                     , 657-679. <a href="https://doi.org/10.1007/s11523-019-00680-2" title="DOI URL">https://doi.org/10.1007/s11523-019-00680-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-019-00680-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-019-00680-2%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DPARP%252BInhibition%252Bin%252BCancer%25253A%252BAn%252BUpdate%252Bon%252BClinical%252BDevelopment%26aulast%3DSachdev%26aufirst%3DEsha%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D6%26spage%3D657%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard T.  Golding</span>. </span><span class="cited-content_cbyCitation_article-title">The Story of Rucaparib (Rubraca). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 201-223. <a href="https://doi.org/10.1002/9783527814695.ch8" title="DOI URL">https://doi.org/10.1002/9783527814695.ch8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527814695.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527814695.ch8%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BStory%252Bof%252BRucaparib%252B%252528Rubraca%252529%26aulast%3DGolding%26aufirst%3DBernard%2BT.%26date%3D2019%26date%3D2019%26spage%3D201%26epage%3D223%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2019%26date%3D2019%26volume%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Yang</span>, <span class="hlFld-ContribAuthor ">Bin  Yang</span>, <span class="hlFld-ContribAuthor ">Yanli  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Zhankun  He</span>, <span class="hlFld-ContribAuthor ">Hejun  Zhao</span>, <span class="hlFld-ContribAuthor ">Lili  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Mu</span>. </span><span class="cited-content_cbyCitation_article-title">The CTIPâmediated repair of TNFâÎ±âinduced DNA doubleâstrand break was impaired by miRâ130b in cervical cancer cell. </span><span class="cited-content_cbyCitation_journal-name">Cell Biochemistry and Function</span><span> <strong>2019,</strong> <em>37 </em>
                                    (7)
                                     , 534-544. <a href="https://doi.org/10.1002/cbf.3430" title="DOI URL">https://doi.org/10.1002/cbf.3430</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbf.3430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbf.3430%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Biochemistry%2520and%2520Function%26atitle%3DThe%252BCTIP%2525E2%252580%252590mediated%252Brepair%252Bof%252BTNF%2525E2%252580%252590%2525CE%2525B1%2525E2%252580%252590induced%252BDNA%252Bdouble%2525E2%252580%252590strand%252Bbreak%252Bwas%252Bimpaired%252Bby%252BmiR%2525E2%252580%252590130b%252Bin%252Bcervical%252Bcancer%252Bcell%26aulast%3DYang%26aufirst%3DLei%26date%3D2019%26date%3D2019%26volume%3D37%26issue%3D7%26spage%3D534%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Zhong</span>, <span class="hlFld-ContribAuthor ">Ying  Meng</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Lulu  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>91 </em>, 103181. <a href="https://doi.org/10.1016/j.bioorg.2019.103181" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103181%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bphthalazinone%252Bthiohydantoin-based%252Bderivative%252Bas%252Bpotent%252BPARP-1%252Binhibitors%26aulast%3DZhong%26aufirst%3DYi%26date%3D2019%26volume%3D91%26spage%3D103181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monika  Toma</span>, <span class="hlFld-ContribAuthor ">Tomasz  Skorski</span>, <span class="hlFld-ContribAuthor ">Tomasz  Sliwinski</span>. </span><span class="cited-content_cbyCitation_article-title">DNA Double Strand Break Repair - Related Synthetic Lethality. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (8)
                                     , 1446-1482. <a href="https://doi.org/10.2174/0929867325666180201114306" title="DOI URL">https://doi.org/10.2174/0929867325666180201114306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180201114306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180201114306%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DDNA%252BDouble%252BStrand%252BBreak%252BRepair%252B-%252BRelated%252BSynthetic%252BLethality%26aulast%3DToma%26aufirst%3DMonika%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D1446%26epage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria J  Sambade</span>, <span class="hlFld-ContribAuthor ">Amanda E D  Van Swearingen</span>, <span class="hlFld-ContribAuthor ">Marni B  McClure</span>, <span class="hlFld-ContribAuthor ">Allison M  Deal</span>, <span class="hlFld-ContribAuthor ">Charlene  Santos</span>, <span class="hlFld-ContribAuthor ">Kaiming  Sun</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Keith  Mikule</span>, <span class="hlFld-ContribAuthor ">Carey K  Anders</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. </span><span class="cited-content_cbyCitation_journal-name">Neuro-Oncology Advances</span><span> <strong>2019,</strong> <em>1 </em>
                                    (1)
                                     <a href="https://doi.org/10.1093/noajnl/vdz005" title="DOI URL">https://doi.org/10.1093/noajnl/vdz005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/noajnl/vdz005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnoajnl%2Fvdz005%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuro-Oncology%2520Advances%26atitle%3DEfficacy%252Band%252Bpharmacodynamics%252Bof%252Bniraparib%252Bin%252BBRCA-mutant%252Band%252Bwild-type%252Bintracranial%252Btriple-negative%252Bbreast%252Bcancer%252Bmurine%252Bmodels%26aulast%3DSambade%26aufirst%3DMaria%2BJ%26date%3D2019%26date%3D2019%26volume%3D1%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Li</span>, <span class="hlFld-ContribAuthor ">Weihua  Li</span>, <span class="hlFld-ContribAuthor ">Huimin  Bai</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular and Molecular Medicine</span><span> <strong>2019,</strong> <em>23 </em>
                                    (4)
                                     , 2303-2313. <a href="https://doi.org/10.1111/jcmm.14133" title="DOI URL">https://doi.org/10.1111/jcmm.14133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcmm.14133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcmm.14133%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520and%2520Molecular%2520Medicine%26atitle%3DPARP%252Binhibitors%252Bin%252Bovarian%252Bcancer%25253A%252BSensitivity%252Bprediction%252Band%252Bresistance%252Bmechanisms%26aulast%3DJiang%26aufirst%3DXuan%26date%3D2019%26date%3D2019%26volume%3D23%26issue%3D4%26spage%3D2303%26epage%3D2313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Man  Keung</span>, <span class="hlFld-ContribAuthor ">Yanyuan  Wu</span>, <span class="hlFld-ContribAuthor ">Jaydutt  Vadgama</span>. </span><span class="cited-content_cbyCitation_article-title">PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2019,</strong> <em>8 </em>
                                    (4)
                                     , 435. <a href="https://doi.org/10.3390/jcm8040435" title="DOI URL">https://doi.org/10.3390/jcm8040435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm8040435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm8040435%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DPARP%252BInhibitors%252Bas%252Ba%252BTherapeutic%252BAgent%252Bfor%252BHomologous%252BRecombination%252BDeficiency%252Bin%252BBreast%252BCancers%26aulast%3DKeung%26aufirst%3DMan%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D4%26spage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mandy  Ducy</span>, <span class="hlFld-ContribAuthor ">Laura  Sesma-Sanz</span>, <span class="hlFld-ContribAuthor ">Laure  Guitton-Sert</span>, <span class="hlFld-ContribAuthor ">Anahita  Lashgari</span>, <span class="hlFld-ContribAuthor ">Yuandi  Gao</span>, <span class="hlFld-ContribAuthor ">Nadine  Brahiti</span>, <span class="hlFld-ContribAuthor ">AmÃ©lie  Rodrigue</span>, <span class="hlFld-ContribAuthor ">Guillaume  Margaillan</span>, <span class="hlFld-ContribAuthor ">Marie-Christine  Caron</span>, <span class="hlFld-ContribAuthor ">Jacques  CÃ´tÃ©</span>, <span class="hlFld-ContribAuthor ">Jacques  Simard</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Masson</span>. </span><span class="cited-content_cbyCitation_article-title">The Tumor Suppressor PALB2: Inside Out. </span><span class="cited-content_cbyCitation_journal-name">Trends in Biochemical Sciences</span><span> <strong>2019,</strong> <em>44 </em>
                                    (3)
                                     , 226-240. <a href="https://doi.org/10.1016/j.tibs.2018.10.008" title="DOI URL">https://doi.org/10.1016/j.tibs.2018.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tibs.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tibs.2018.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Biochemical%2520Sciences%26atitle%3DThe%252BTumor%252BSuppressor%252BPALB2%25253A%252BInside%252BOut%26aulast%3DDucy%26aufirst%3DMandy%26date%3D2019%26volume%3D44%26issue%3D3%26spage%3D226%26epage%3D240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuye  Zhao</span>, <span class="hlFld-ContribAuthor ">Tianlong  Lan</span>, <span class="hlFld-ContribAuthor ">Shang  Su</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (3)
                                     , 369-372. <a href="https://doi.org/10.1039/C8CC07813K" title="DOI URL">https://doi.org/10.1039/C8CC07813K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CC07813K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CC07813K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DInduction%252Bof%252Bapoptosis%252Bin%252BMDA-MB-231%252Bbreast%252Bcancer%252Bcells%252Bby%252Ba%252BPARP1-targeting%252BPROTAC%252Bsmall%252Bmolecule%26aulast%3DZhao%26aufirst%3DQiuye%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D3%26spage%3D369%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Zhi  Gao</span>, <span class="hlFld-ContribAuthor ">Wei  Dong</span>, <span class="hlFld-ContribAuthor ">Zhi-Wen  Cui</span>, <span class="hlFld-ContribAuthor ">Qiong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xia-Min  Hu</span>, <span class="hlFld-ContribAuthor ">Qing-Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Xianlin  Han</span>, <span class="hlFld-ContribAuthor ">Yao  Xu</span>, <span class="hlFld-ContribAuthor ">Zhen-Li  Min</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 150-162. <a href="https://doi.org/10.1080/14756366.2018.1530224" title="DOI URL">https://doi.org/10.1080/14756366.2018.1530224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1530224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1530224%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bpreliminarily%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnew%252BOlaparib%252Banalogues%252Bas%252Bmultifunctional%252BPARP-1%252Band%252Bcholinesterase%252Binhibitors%26aulast%3DGao%26aufirst%3DCheng-Zhi%26date%3D2019%26date%3D2018%26volume%3D34%26issue%3D1%26spage%3D150%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abid R.  Mattoo</span>, <span class="hlFld-ContribAuthor ">Alex  Joun</span>, <span class="hlFld-ContribAuthor ">J. Milburn  Jessup</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2019,</strong> <em>17 </em>
                                    (1)
                                     , 42-53. <a href="https://doi.org/10.1158/1541-7786.MCR-18-0650" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-18-0650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-18-0650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-18-0650%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DRepurposing%252Bof%252BmTOR%252BComplex%252BInhibitors%252BAttenuates%252BMCL-1%252Band%252BSensitizes%252Bto%252BPARP%252BInhibition%26aulast%3DMattoo%26aufirst%3DAbid%2BR.%26date%3D2019%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D42%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Josee-Lyne  Ethier</span>, <span class="hlFld-ContribAuthor ">Stephanie  Lheureux</span>, <span class="hlFld-ContribAuthor ">Amit M  Oza</span>. </span><span class="cited-content_cbyCitation_article-title">The role of niraparib for the treatment of ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (25)
                                     , 2565-2577. <a href="https://doi.org/10.2217/fon-2018-0101" title="DOI URL">https://doi.org/10.2217/fon-2018-0101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2018-0101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2018-0101%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DThe%252Brole%252Bof%252Bniraparib%252Bfor%252Bthe%252Btreatment%252Bof%252Bovarian%252Bcancer%26aulast%3DEthier%26aufirst%3DJosee-Lyne%26date%3D2018%26volume%3D14%26issue%3D25%26spage%3D2565%26epage%3D2577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teresa C.  Longoria</span>, <span class="hlFld-ContribAuthor ">Krishnansu S.  Tewari</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (5)
                                     , 543-550. <a href="https://doi.org/10.1080/17425255.2018.1461838" title="DOI URL">https://doi.org/10.1080/17425255.2018.1461838</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2018.1461838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2018.1461838%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DPharmacokinetic%252Bdrug%252Bevaluation%252Bof%252Bniraparib%252Bfor%252Bthe%252Btreatment%252Bof%252Bovarian%252Bcancer%26aulast%3DLongoria%26aufirst%3DTeresa%2BC.%26date%3D2018%26date%3D2018%26volume%3D14%26issue%3D5%26spage%3D543%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kathleen  Moore</span>, <span class="hlFld-ContribAuthor ">Zhi-Yi  Zhang</span>, <span class="hlFld-ContribAuthor ">Shefali  Agarwal</span>, <span class="hlFld-ContribAuthor ">Howard  Burris</span>, <span class="hlFld-ContribAuthor ">Manish R.  Patel</span>, <span class="hlFld-ContribAuthor ">Vikram  Kansra</span>. </span><span class="cited-content_cbyCitation_article-title">The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2018,</strong> <em>81 </em>
                                    (3)
                                     , 497-503. <a href="https://doi.org/10.1007/s00280-017-3512-5" title="DOI URL">https://doi.org/10.1007/s00280-017-3512-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-017-3512-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-017-3512-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DThe%252Beffect%252Bof%252Bfood%252Bon%252Bthe%252Bpharmacokinetics%252Bof%252Bniraparib%25252C%252Ba%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252B%252528PARP%252529%252Binhibitor%25252C%252Bin%252Bpatients%252Bwith%252Brecurrent%252Bovarian%252Bcancer%26aulast%3DMoore%26aufirst%3DKathleen%26date%3D2018%26date%3D2018%26volume%3D81%26issue%3D3%26spage%3D497%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Du</span>. </span><span class="cited-content_cbyCitation_article-title">The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2018,</strong> <em>99 </em>, 552-560. <a href="https://doi.org/10.1016/j.biopha.2018.01.094" title="DOI URL">https://doi.org/10.1016/j.biopha.2018.01.094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2018.01.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2018.01.094%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DThe%252Bpromising%252BPARP%252Binhibitors%252Bin%252Bovarian%252Bcancer%252Btherapy%25253A%252BFrom%252BOlaparib%252Bto%252Bothers%26aulast%3DChen%26aufirst%3DYing%26date%3D2018%26volume%3D99%26spage%3D552%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuxing  Chen</span>, <span class="hlFld-ContribAuthor ">Xiajuan  Huan</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yuqin  Wang</span>, <span class="hlFld-ContribAuthor ">Qian  He</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Zehong  Miao</span>, <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 389-403. <a href="https://doi.org/10.1016/j.ejmech.2018.01.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B2-%2525284%25252C5%25252C6%25252C7-tetrahydrothienopyridin-2-yl%252529-benzoimidazole%252Bcarboxamides%252Bas%252Bnovel%252Borally%252Befficacious%252BPoly%252528ADP-ribose%252529polymerase%252B%252528PARP%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DXuxing%26date%3D2018%26volume%3D145%26spage%3D389%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">LUMA G.  MAGALHAES</span>, <span class="hlFld-ContribAuthor ">LEONARDO L.G.  FERREIRA</span>, <span class="hlFld-ContribAuthor ">ADRIANO D.  ANDRICOPULO</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances and Perspectives in Cancer Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Anais da Academia Brasileira de CiÃªncias</span><span> <strong>2018,</strong> <em>90 </em>
                                    (1 suppl 2)
                                     , 1233-1250. <a href="https://doi.org/10.1590/0001-3765201820170823" title="DOI URL">https://doi.org/10.1590/0001-3765201820170823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1590/0001-3765201820170823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1590%2F0001-3765201820170823%26sid%3Dliteratum%253Aachs%26jtitle%3DAnais%2520da%2520Academia%2520Brasileira%2520de%2520Ci%25C3%25AAncias%26atitle%3DRecent%252BAdvances%252Band%252BPerspectives%252Bin%252BCancer%252BDrug%252BDesign%26aulast%3DMAGALHAES%26aufirst%3DLUMA%2BG.%26date%3D2018%26date%3D2018%26volume%3D90%26issue%3D1%2520suppl%25202%26spage%3D1233%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jyotika  Rajawat</span>, <span class="hlFld-ContribAuthor ">Nidhi  Shukla</span>, <span class="hlFld-ContribAuthor ">Durga Prasad  Mishra</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (6)
                                     , 1461-1491. <a href="https://doi.org/10.1002/med.21442" title="DOI URL">https://doi.org/10.1002/med.21442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21442%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTherapeutic%252BTargeting%252Bof%252BPoly%252528ADP-Ribose%252529%252BPolymerase-1%252B%252528PARP1%252529%252Bin%252BCancer%25253A%252BCurrent%252BDevelopments%25252C%252BTherapeutic%252BStrategies%25252C%252Band%252BFuture%252BOpportunities%26aulast%3DRajawat%26aufirst%3DJyotika%26date%3D2017%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1461%26epage%3D1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-hua  Chen</span>, <span class="hlFld-ContribAuthor ">Shan-shan  Song</span>, <span class="hlFld-ContribAuthor ">Ming-hui  Qi</span>, <span class="hlFld-ContribAuthor ">Xia-juan  Huan</span>, <span class="hlFld-ContribAuthor ">Ying-qing  Wang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Guo-bin  Ren</span>, <span class="hlFld-ContribAuthor ">Ze-hong  Miao</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2017,</strong> <em>38 </em>
                                    (11)
                                     , 1521-1532. <a href="https://doi.org/10.1038/aps.2017.104" title="DOI URL">https://doi.org/10.1038/aps.2017.104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2017.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2017.104%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DDiscovery%252Bof%252Bpotent%252B2%25252C4-difluoro-linker%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252B1%252Binhibitors%252Bwith%252Benhanced%252Bwater%252Bsolubility%252Band%252Bin%252Bvivo%252Banticancer%252Befficacy%26aulast%3DChen%26aufirst%3DWen-hua%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D11%26spage%3D1521%26epage%3D1532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gayathri  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Gurjit Singh  Sidhu</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Williamson</span>, <span class="hlFld-ContribAuthor ">Aruna S.  Jaiswal</span>, <span class="hlFld-ContribAuthor ">Nasreen  Najmunnisa</span>, <span class="hlFld-ContribAuthor ">Keith  Wilcoxen</span>, <span class="hlFld-ContribAuthor ">Dennie  Jones</span>, <span class="hlFld-ContribAuthor ">Thomas J.  George</span>, <span class="hlFld-ContribAuthor ">Robert  Hromas</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2017,</strong> <em>80 </em>
                                    (4)
                                     , 861-867. <a href="https://doi.org/10.1007/s00280-017-3401-y" title="DOI URL">https://doi.org/10.1007/s00280-017-3401-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-017-3401-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-017-3401-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DSynthetic%252Blethality%252Bin%252Bmalignant%252Bpleural%252Bmesothelioma%252Bwith%252BPARP1%252Binhibition%26aulast%3DSrinivasan%26aufirst%3DGayathri%26date%3D2017%26date%3D2017%26volume%3D80%26issue%3D4%26spage%3D861%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chia-Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Yi  Chang</span>, <span class="hlFld-ContribAuthor ">Peng-Hui  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Taiwanese Journal of Obstetrics and Gynecology</span><span> <strong>2017,</strong> <em>56 </em>
                                    (5)
                                     , 713-714. <a href="https://doi.org/10.1016/j.tjog.2017.08.026" title="DOI URL">https://doi.org/10.1016/j.tjog.2017.08.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tjog.2017.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tjog.2017.08.026%26sid%3Dliteratum%253Aachs%26jtitle%3DTaiwanese%2520Journal%2520of%2520Obstetrics%2520and%2520Gynecology%26atitle%3DPoly%252528ADP-ribose%252529%252Bpolymerase%252B%252528PARP%252529%252Binhibitors%252Band%252Bovarian%252Bcancer%26aulast%3DLiu%26aufirst%3DChia-Hao%26date%3D2017%26volume%3D56%26issue%3D5%26spage%3D713%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhua  Chen</span>, <span class="hlFld-ContribAuthor ">Ne  Guo</span>, <span class="hlFld-ContribAuthor ">Minghui  Qi</span>, <span class="hlFld-ContribAuthor ">Haiying  Dai</span>, <span class="hlFld-ContribAuthor ">Minghuang  Hong</span>, <span class="hlFld-ContribAuthor ">Longfei  Guan</span>, <span class="hlFld-ContribAuthor ">Xiajuan  Huan</span>, <span class="hlFld-ContribAuthor ">Shanshan  Song</span>, <span class="hlFld-ContribAuthor ">Jinxue  He</span>, <span class="hlFld-ContribAuthor ">Yingqing  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Xi</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Yanyan  Shen</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yiming  Sun</span>, <span class="hlFld-ContribAuthor ">Yinglei  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yun  Tang</span>, <span class="hlFld-ContribAuthor ">Guobin  Ren</span>, <span class="hlFld-ContribAuthor ">Zehong  Miao</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced inÂ vivo efficacy for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 514-531. <a href="https://doi.org/10.1016/j.ejmech.2017.06.053" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.053%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Bmechanism%252Band%252Bmetabolism%252Bstudies%252Bof%252B2%25252C3-difluorophenyl-linker-containing%252BPARP1%252Binhibitors%252Bwith%252Benhanced%252Bin%2525C2%2525A0vivo%252Befficacy%252Bfor%252Bcancer%252Btherapy%26aulast%3DChen%26aufirst%3DWenhua%26date%3D2017%26volume%3D138%26spage%3D514%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katsutoshi  Oda</span>, <span class="hlFld-ContribAuthor ">Michihiro  Tanikawa</span>, <span class="hlFld-ContribAuthor ">Kenbun  Sone</span>, <span class="hlFld-ContribAuthor ">Mayuyo  Mori-Uchino</span>, <span class="hlFld-ContribAuthor ">Yutaka  Osuga</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Fujii</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Clinical Oncology</span><span> <strong>2017,</strong> <em>22 </em>
                                    (4)
                                     , 611-618. <a href="https://doi.org/10.1007/s10147-017-1137-7" title="DOI URL">https://doi.org/10.1007/s10147-017-1137-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10147-017-1137-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10147-017-1137-7%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Clinical%2520Oncology%26atitle%3DRecent%252Badvances%252Bin%252Btargeting%252BDNA%252Brepair%252Bpathways%252Bfor%252Bthe%252Btreatment%252Bof%252Bovarian%252Bcancer%252Band%252Btheir%252Bclinical%252Brelevance%26aulast%3DOda%26aufirst%3DKatsutoshi%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D4%26spage%3D611%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramin  Ekhteiari Salmas</span>, <span class="hlFld-ContribAuthor ">Ayhan  Unlu</span>, <span class="hlFld-ContribAuthor ">Muhammet  BektaÅ</span>, <span class="hlFld-ContribAuthor ">Mine  Yurtsever</span>, <span class="hlFld-ContribAuthor ">Mert  Mestanoglu</span>, <span class="hlFld-ContribAuthor ">Serdar  Durdagi</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of
              in silico
              and
              in vitro
              studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2017,</strong> <em>35 </em>
                                    (9)
                                     , 1899-1915. <a href="https://doi.org/10.1080/07391102.2016.1199328" title="DOI URL">https://doi.org/10.1080/07391102.2016.1199328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2016.1199328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2016.1199328%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DVirtual%252Bscreening%252Bof%252Bsmall%252Bmolecules%252Bdatabases%252Bfor%252Bdiscovery%252Bof%252Bnovel%252BPARP-1%252Binhibitors%25253A%252Bcombination%252Bof%252Bin%252Bsilico%252Band%252Bin%252Bvitro%252Bstudies%26aulast%3DEkhteiari%2BSalmas%26aufirst%3DRamin%26date%3D2017%26date%3D2016%26volume%3D35%26issue%3D9%26spage%3D1899%26epage%3D1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Praveen  Ramakrishnan Geethakumari</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Schiewer</span>, <span class="hlFld-ContribAuthor ">Karen E.  Knudsen</span>, <span class="hlFld-ContribAuthor ">Wm. Kevin  Kelly</span>. </span><span class="cited-content_cbyCitation_article-title">PARP Inhibitors in Prostate Cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Oncology</span><span> <strong>2017,</strong> <em>18 </em>
                                    (6)
                                     <a href="https://doi.org/10.1007/s11864-017-0480-2" title="DOI URL">https://doi.org/10.1007/s11864-017-0480-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11864-017-0480-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11864-017-0480-2%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Oncology%26atitle%3DPARP%252BInhibitors%252Bin%252BProstate%252BCancer%26aulast%3DRamakrishnan%2BGeethakumari%26aufirst%3DPraveen%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lesley J.  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Niraparib: First Global Approval. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2017,</strong> <em>77 </em>
                                    (9)
                                     , 1029-1034. <a href="https://doi.org/10.1007/s40265-017-0752-y" title="DOI URL">https://doi.org/10.1007/s40265-017-0752-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-017-0752-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-017-0752-y%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DNiraparib%25253A%252BFirst%252BGlobal%252BApproval%26aulast%3DScott%26aufirst%3DLesley%2BJ.%26date%3D2017%26date%3D2017%26volume%3D77%26issue%3D9%26spage%3D1029%26epage%3D1034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angiolo  Gadducci</span>, <span class="hlFld-ContribAuthor ">Maria Elena  Guerrieri</span>. </span><span class="cited-content_cbyCitation_article-title">PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2017,</strong> <em>114 </em>, 153-165. <a href="https://doi.org/10.1016/j.critrevonc.2017.04.006" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2017.04.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2017.04.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DPARP%252Binhibitors%252Balone%252Band%252Bin%252Bcombination%252Bwith%252Bother%252Bbiological%252Bagents%252Bin%252Bhomologous%252Brecombination%252Bdeficient%252Bepithelial%252Bovarian%252Bcancer%25253A%252BFrom%252Bthe%252Bbasic%252Bresearch%252Bto%252Bthe%252Bclinic%26aulast%3DGadducci%26aufirst%3DAngiolo%26date%3D2017%26volume%3D114%26spage%3D153%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Yuan</span>, <span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Chuan-Huizi  Chen</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yan-Yan  Shen</span>, <span class="hlFld-ContribAuthor ">Yi-Ming  Sun</span>, <span class="hlFld-ContribAuthor ">Xin-Ying  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Shi-Yan  Guo</span>, <span class="hlFld-ContribAuthor ">Yong  Gan</span>, <span class="hlFld-ContribAuthor ">Zhi-Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Xiao-Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2017,</strong> <em>386 </em>, 47-56. <a href="https://doi.org/10.1016/j.canlet.2016.11.010" title="DOI URL">https://doi.org/10.1016/j.canlet.2016.11.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2016.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2016.11.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPoly%252528ADP-ribose%252529polymerase%252B%252528PARP%252529%252Binhibition%252Band%252Banticancer%252Bactivity%252Bof%252Bsimmiparib%25252C%252Ba%252Bnew%252Binhibitor%252Bundergoing%252Bclinical%252Btrials%26aulast%3DYuan%26aufirst%3DBo%26date%3D2017%26volume%3D386%26spage%3D47%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heike  Keilhack</span>, <span class="hlFld-ContribAuthor ">Paul  Chang</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 321-336. <a href="https://doi.org/10.1007/978-1-4939-6993-7_21" title="DOI URL">https://doi.org/10.1007/978-1-4939-6993-7_21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-6993-7_21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-6993-7_21%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BVitro%252BLong-Term%252BProliferation%252BAssays%252Bto%252BStudy%252BAntiproliferative%252BEffects%252Bof%252BPARP%252BInhibitors%252Bon%252BCancer%252BCells%26aulast%3DKeilhack%26aufirst%3DHeike%26date%3D2017%26date%3D2017%26spage%3D321%26epage%3D336%26pub%3DSpringer%2520New%2520York%26atitle%3DPoly%252528ADP-Ribose%252529%252BPolymerase%26aulast%3DTulin%26aufirst%3DAlexei%2BV.%26date%3D2017%26volume%3D1608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Redmond-Craig  Anderson</span>, <span class="hlFld-ContribAuthor ">Mehran  Makvandi</span>, <span class="hlFld-ContribAuthor ">Kuiying  Xu</span>, <span class="hlFld-ContribAuthor ">Brian P.  Lieberman</span>, <span class="hlFld-ContribAuthor ">Chenbo  Zeng</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Pryma</span>, <span class="hlFld-ContribAuthor ">Robert H.  Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression  in vitro  and  in vivo. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2016,</strong> <em>43 </em>
                                    (12)
                                     , 752-758. <a href="https://doi.org/10.1016/j.nucmedbio.2016.08.007" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2016.08.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2016.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2016.08.007%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DIodinated%252Bbenzimidazole%252BPARP%252Bradiotracer%252Bfor%252Bevaluating%252BPARP1%25252F2%252Bexpression%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DAnderson%26aufirst%3DRedmond-Craig%26date%3D2016%26volume%3D43%26issue%3D12%26spage%3D752%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leilei  Fu</span>, <span class="hlFld-ContribAuthor ">Shuya  Wang</span>, <span class="hlFld-ContribAuthor ">Xuan  Wang</span>, <span class="hlFld-ContribAuthor ">Peiqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yaxin  Zheng</span>, <span class="hlFld-ContribAuthor ">Dahong  Yao</span>, <span class="hlFld-ContribAuthor ">Mingrui  Guo</span>, <span class="hlFld-ContribAuthor ">Lan  Zhang</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2016,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-016-0007-2" title="DOI URL">https://doi.org/10.1038/s41598-016-0007-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-016-0007-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-016-0007-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DCrystal%252Bstructure-based%252Bdiscovery%252Bof%252Ba%252Bnovel%252Bsynthesized%252BPARP1%252Binhibitor%252B%252528OL-1%252529%252Bwith%252Bapoptosis-inducing%252Bmechanisms%252Bin%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DFu%26aufirst%3DLeilei%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aniello  Cerrato</span>, <span class="hlFld-ContribAuthor ">Francesco  Morra</span>, <span class="hlFld-ContribAuthor ">Angela  Celetti</span>. </span><span class="cited-content_cbyCitation_article-title">Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2016,</strong> <em>35 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-016-0456-2" title="DOI URL">https://doi.org/10.1186/s13046-016-0456-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-016-0456-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-016-0456-2%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DUse%252Bof%252Bpoly%252BADP-ribose%252Bpolymerase%252B%25255BPARP%25255D%252Binhibitors%252Bin%252Bcancer%252Bcells%252Bbearing%252BDDR%252Bdefects%25253A%252Bthe%252Brationale%252Bfor%252Btheir%252Binclusion%252Bin%252Bthe%252Bclinic%26aulast%3DCerrato%26aufirst%3DAniello%26date%3D2016%26date%3D2016%26volume%3D35%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. J.  Gray</span>, <span class="hlFld-ContribAuthor ">B.  Benigno</span>, <span class="hlFld-ContribAuthor ">J.  Berek</span>, <span class="hlFld-ContribAuthor ">J.  Chang</span>, <span class="hlFld-ContribAuthor ">J.  Mason</span>, <span class="hlFld-ContribAuthor ">L.  Mileshkin</span>, <span class="hlFld-ContribAuthor ">P.  Mitchell</span>, <span class="hlFld-ContribAuthor ">M.  Moradi</span>, <span class="hlFld-ContribAuthor ">F. O.  Recio</span>, <span class="hlFld-ContribAuthor ">C. M.  Michener</span>, <span class="hlFld-ContribAuthor ">A. Alvarez  Secord</span>, <span class="hlFld-ContribAuthor ">N E.  Tchabo</span>, <span class="hlFld-ContribAuthor ">J. K.  Chan</span>, <span class="hlFld-ContribAuthor ">J.  Young</span>, <span class="hlFld-ContribAuthor ">H.  Kohrt</span>, <span class="hlFld-ContribAuthor ">S. E.  Gargosky</span>, <span class="hlFld-ContribAuthor ">J. C.  Goh</span>. </span><span class="cited-content_cbyCitation_article-title">Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. </span><span class="cited-content_cbyCitation_journal-name">Journal for ImmunoTherapy of Cancer</span><span> <strong>2016,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s40425-016-0137-x" title="DOI URL">https://doi.org/10.1186/s40425-016-0137-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40425-016-0137-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40425-016-0137-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520for%2520ImmunoTherapy%2520of%2520Cancer%26atitle%3DProgression-free%252Band%252Boverall%252Bsurvival%252Bin%252Bovarian%252Bcancer%252Bpatients%252Btreated%252Bwith%252BCVac%25252C%252Ba%252Bmucin%252B1%252Bdendritic%252Bcell%252Btherapy%252Bin%252Ba%252Brandomized%252Bphase%252B2%252Btrial%26aulast%3DGray%26aufirst%3DH.%2BJ.%26date%3D2016%26date%3D2016%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert S.  Meehan</span>, <span class="hlFld-ContribAuthor ">Alice P.  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">New treatment option for ovarian cancer: PARP inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Gynecologic Oncology Research and Practice</span><span> <strong>2016,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s40661-016-0024-7" title="DOI URL">https://doi.org/10.1186/s40661-016-0024-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40661-016-0024-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40661-016-0024-7%26sid%3Dliteratum%253Aachs%26jtitle%3DGynecologic%2520Oncology%2520Research%2520and%2520Practice%26atitle%3DNew%252Btreatment%252Boption%252Bfor%252Bovarian%252Bcancer%25253A%252BPARP%252Binhibitors%26aulast%3DMeehan%26aufirst%3DRobert%2BS.%26date%3D2016%26date%3D2016%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pradip  De</span>, <span class="hlFld-ContribAuthor ">Jennifer H.  Carlson</span>, <span class="hlFld-ContribAuthor ">Brian  Leyland-Jones</span>, <span class="hlFld-ContribAuthor ">Nandini  Dey</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 65-108. <a href="https://doi.org/10.1007/978-3-319-34211-5_3" title="DOI URL">https://doi.org/10.1007/978-3-319-34211-5_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-34211-5_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-34211-5_3%26sid%3Dliteratum%253Aachs%26atitle%3DPI3K-AKT-mTOR%252BPathway%252BCooperates%252Bwith%252Bthe%252BDNA%252BDamage%252BRepair%252BPathway%25253A%252BCarcinogenesis%252Bin%252BTriple-Negative%252BBreast%252BCancers%252Band%252BBeyond%26aulast%3DDe%26aufirst%3DPradip%26date%3D2016%26date%3D2016%26spage%3D65%26epage%3D108%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DPI3K-mTOR%252Bin%252BCancer%252Band%252BCancer%252BTherapy%26aulast%3DDey%26aufirst%3DNandini%26date%3D2016%26volume%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Ning  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhi-yong  Xiao</span>, <span class="hlFld-ContribAuthor ">Jun-ping  Cheng</span>, <span class="hlFld-ContribAuthor ">Yi-zhou  Mei</span>, <span class="hlFld-ContribAuthor ">Pan  Zheng</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin-bo  Zhou</span>, <span class="hlFld-ContribAuthor ">Wen-xia  Zhou</span>, <span class="hlFld-ContribAuthor ">Yong-xiang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries
              in vitro
              and
              in vivo. </span><span class="cited-content_cbyCitation_journal-name">PeerJ</span><span> <strong>2016,</strong> <em>4 </em>, e1890. <a href="https://doi.org/10.7717/peerj.1890" title="DOI URL">https://doi.org/10.7717/peerj.1890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7717/peerj.1890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7717%2Fpeerj.1890%26sid%3Dliteratum%253Aachs%26jtitle%3DPeerJ%26atitle%3DEffects%252Bof%252Bpoly%252B%252528ADP-ribose%252529%252Bpolymerase-1%252B%252528PARP-1%252529%252Binhibition%252Bon%252Bsulfur%252Bmustard-induced%252Bcutaneous%252Binjuries%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DLiu%26aufirst%3DFeng%26date%3D2016%26date%3D2016%26volume%3D4%26spage%3De1890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Symeonides</span>, <span class="hlFld-ContribAuthor ">Charlie  Gourley</span>. </span><span class="cited-content_cbyCitation_article-title">Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2015,</strong> <em>5 </em><a href="https://doi.org/10.3389/fonc.2015.00229" title="DOI URL">https://doi.org/10.3389/fonc.2015.00229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2015.00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2015.00229%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DOvarian%252BCancer%252BMolecular%252BStratification%252Band%252BTumor%252BHeterogeneity%25253A%252BA%252BNecessity%252Band%252Ba%252BChallenge%26aulast%3DSymeonides%26aufirst%3DStefan%26date%3D2015%26date%3D2015%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. DNA repair pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic describing role of PARP-1/2 in base excision repair pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Tool compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Homologous recombination defective cells are hypersensitive to PARP inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Nicotinamide and a schematic of the H-bond pattern of PARP-1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of PARP inhibitors in mid to late stage clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Heterobicylic carboxamides as PARP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Functionalizing the core PARP inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Representative HPLC radiochromatograms of <b>8</b> incubated in the presence of rat, dog, and human hepatocytes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Efficacy in BRCA1 mutant mouse xenograft assay following 1, 2, 3, or 4 weeks once daily oral dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Efficacy in BRCA2 mutant mouse xenograft assay following 2, 3, or 4 weeks once daily oral dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pharmacodynamic activity of niraparib in MDA-MB-436 xenografts. % PARP activity is shown at 4, 8, and 24 h post po dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Iniparib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/medium/jm-2014-018237_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Antitumor activity in ovarian cancer *BRCA1/2 mutation carriers. â Reduction in overall sum of measurable disease but new lesion seen (overall: PD). Refractory patient (<i>BRCA</i> mutated) not included.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-8/jm5018237/20150417/images/large/jm-2014-018237_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5018237&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Plummer, R.</span><span> </span><span class="NLM_article-title">Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4527</span><span class="NLM_x">â</span> <span class="NLM_lpage">4531</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1078-0432.CCR-10-0984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=20823148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4527-4531&author=R.+Plummer&title=Perspective+on+the+pipeline+of+drugs+being+developed+with+modulation+of+DNA+damage+as+a+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target</span></div><div class="casAuthors">Plummer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4527-4531</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Inhibitors of various elements of the DNA repair pathways have entered clin. development or are in late preclin. stages of drug development.  It was initially considered that agents targeting DNA repair would act to overcome tumor resistance to chemotherapy and radiotherapy.  More recent data have shown that targeting DNA repair pathways can be effective in selected tumors via a synthetically lethal route, with single agent activity having been shown with poly-ADP ribose polymerase (PARP) inhibitors.  An increased understanding of the biol. and interaction of the DNA repair pathways also means that rational combination of DNA repair inhibitors may also give great benefit in the clinic.  Clin Cancer Res; 16(18); 4527-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ZUVcQq98zbVg90H21EOLACvtfcHk0lj2Ilmda-gPRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bP&md5=76990efc619368c2e364fc4e7b80be50</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0984%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26atitle%3DPerspective%2520on%2520the%2520pipeline%2520of%2520drugs%2520being%2520developed%2520with%2520modulation%2520of%2520DNA%2520damage%2520as%2520a%2520target%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4527%26epage%3D4531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">â</span> <span class="NLM_lpage">4584</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors.+From+concept+to+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></div><div class="casAuthors">Ferraris, Dana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4561-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) has been an actively pursued drug discovery target for almost 3 decades.  Often referred to as the "guardian angel of DNA", this abundant nuclear enzyme has been the focus of over 20 medicinal chem. programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes.  Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clin. trials.  Recent results from several PARP-1 inhibitors in phase II clin. trials for cancer therapy have attracted the attention of national media.  Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer.  This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs.  This Perspective will offer a historical account of the crit. PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s.  Furthermore, I will discuss why PARP- 1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chem. efforts today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhFTTs4raarVg90H21EOLACvtfcHk0lj2Ilmda-gPRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D&md5=6c093238562c908d45dfcd2f3055457d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2034</span><span class="NLM_x">â</span> <span class="NLM_lpage">2044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2174%2F138945011798829438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=21777194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFyisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=2034-2044&author=S.+K.+Sandhuauthor=T.+A.+Yapauthor=J.+S.+de+Bono&title=The+emerging+role+of+poly%28ADP-ribose%29+polymerase+inhibitors+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment</span></div><div class="casAuthors">Sandhu, Shahneen K.; Yap, Timothy A.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2034-2044</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase (PARP) is a crit. DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway.  PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and to also selectively kill homologous recombination repair-defective cancers, such as those arising in BRCA1 and BRCA2 mutation carriers.  Recent proof-of-concept clin. studies have demonstrated the safety and substantial antitumor activity of the PARP inhibitor, olaparib in BRCA1/2 mutation carriers, highlighting the wide therapeutic window that can be achieved with this synthetic lethal strategy.  Likewise, the PARP inhibitor, BSI-201, in combination with carboplatin and gemcitabine have produced promising results in "triple-neg." breast cancers.  There are also currently numerous other PARP inhibitors in clin. development.  The potential broader therapeutic application of these approaches to a wide range of sporadic tumors harboring specific defects in the homologous recombination repair pathway has generated a great deal of excitement within the oncol. community.  This review discusses the rationale for targeting PARP and details the strategies and challenges involved in the clin. development of such inhibitors and their future potential applications in cancer medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2fm_RjFRzq7Vg90H21EOLACvtfcHk0lj2Ilmda-gPRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFyisA%253D%253D&md5=55d1f258f6ecea5140a8de7bbc83927b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F138945011798829438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011798829438%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520emerging%2520role%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520in%2520cancer%2520treatment%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D2034%26epage%3D2044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Basu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">â</span> <span class="NLM_lpage">1590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1579-1590&author=B.+Basuauthor=S.+K.+Sandhuauthor=J.+S.+de+Bono&title=PARP+inhibitors%3A+mechanism+of+action+and+their+potential+role+in+the+prevention+and+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DPARP%2520inhibitors%253A%2520mechanism%2520of%2520action%2520and%2520their%2520potential%2520role%2520in%2520the%2520prevention%2520and%2520treatment%2520of%2520cancer%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26spage%3D1579%26epage%3D1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E. C.</span><span> </span><span class="NLM_article-title">PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">â</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1093%2Fannonc%2Fmdt384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=24225019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A280%3ADC%252BC2c7mtl2lsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=32-40&author=J.+M.+Leeauthor=J.+A.+Ledermannauthor=E.+C.+Kohn&title=PARP+inhibitors+for+BRCA1%2F2+mutation-associated+and+BRCA-like+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies</span></div><div class="casAuthors">Lee J-M; Ledermann J A; Kohn E C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poly(ADP-ribose)polymerase inhibitors (PARPis) have shown promising activity in patients with BRCA1/2 mutation-associated (BRCA1/2(MUT+)) ovarian and breast cancers.  Accumulating evidence suggests that PARPi may have a wider application in the treatment of sporadic high-grade serous ovarian cancer, and cancers defective in DNA repair pathways, such as prostate, endometrial, and pancreatic cancers.  Several PARPis are currently in phase 1/2 clinical investigation, with registration trials now being designed.  Olaparib, one of the most studied PARPis, has demonstrated activity in BRCA1/2(MUT+) and BRCA-like sporadic ovarian and breast cancers, and looks promising in prostate and pancreatic cancers.  Understanding more about the molecular abnormalities involved in BRCA-like tumors, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers, is critical to rapidly advancing the field of PARPi therapy and improve clinical outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtDJRDtld96tK0qsdY6Nc1fW6udTcc2eYGW-UpsWjW97ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7mtl2lsg%253D%253D&md5=7198a00ebba514a62de969ab28e42d3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt384%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26atitle%3DPARP%2520inhibitors%2520for%2520BRCA1%252F2%2520mutation-associated%2520and%2520BRCA-like%2520malignancies%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D32%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span> <span class="citation_source-journal">Front. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3046</span><span class="NLM_x">â</span> <span class="NLM_lpage">3082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2741%2F2909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17981777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=3046-3082&author=P.+O.+Hassaauthor=M.+O.+Hottiger&title=The+diverse+biological+roles+of+mammalian+PARPs%2C+a+small+but+powerful+family+of+poly-ADP-ribose+polymerases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span></div><div class="casAuthors">Hassa, Paul O.; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3046-3082</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Poly-ADP-ribose metab. plays a mayor role in a wide range of biol. processes, such as maintenance of genomic stability, transcriptional regulation, energy metab., and cell death.  Poly-ADP-ribose polymerases (PARPs) are an ancient family of enzymes, as evidenced by the poly-ADP-ribosylating activities reported in dinoflagellates and archaebacteria and by the identification of Parp-like genes in eubacterial and archaeabacterial genomes.  Six genes encoding "bona fide" PARP enzymes have been identified in mammalians: PARP1, PARP2, PARP3, PARP4/vPARP, PARP5/Tankyrases-1, and PARP6/Tankyrases-2.  The best studied of these enzymes, PARP1, plays a primary role in the process of poly-ADP-ribosylation.  PARP1-mediated poly-ADP-ribosylation has been implicated in the pathogenesis of cancer, inflammatory, and neurodegenerative disorders.  Here, the authors summarize novel findings and concepts for PARP enzymes and their poly-ADP-ribosylation activity in the regulation of physiol. and pathophysiol. processes.  A special focus is placed on the proposed mol. mechanisms involved in these processes, such as signaling, regulation of telomere dynamics, remodeling of chromatin structure, and transcriptional regulation.  A potential functional cross-talk between PARP family members and other NAD-consuming enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoNyzgIk1gtrVg90H21EOLACvtfcHk0lhffC1MbFmtPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D&md5=1e62c4597ec219b0797a29c1458b98b4</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.2741%2F2909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F2909%26sid%3Dliteratum%253Aachs%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DThe%2520diverse%2520biological%2520roles%2520of%2520mammalian%2520PARPs%252C%2520a%2520small%2520but%2520powerful%2520family%2520of%2520poly-ADP-ribose%2520polymerases%26jtitle%3DFront.%2520Biosci.%26date%3D2008%26volume%3D13%26spage%3D3046%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">AmÃ©, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlehauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">The PARP superfamily</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">â</span> <span class="NLM_lpage">893</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=882-893&author=J.-C.+Am%C3%A9author=C.+Spenlehauerauthor=G.+de+Murcia&title=The+PARP+superfamily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAm%25C3%25A9%26aufirst%3DJ.-C.%26aulast%3DSpenlehauer%26aufirst%3DC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DThe%2520PARP%2520superfamily%26jtitle%3DBioEssays%26date%3D2004%26volume%3D26%26spage%3D882%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Jagtap, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SzabÃ³, C.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">440</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=421-440&author=P.+Jagtapauthor=C.+Szab%C3%B3&title=Poly%28ADP-ribose%29+polymerase+and+the+therapeutic+effects+of+its+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%26aulast%3DSzab%25C3%25B3%26aufirst%3DC.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520and%2520the%2520therapeutic%2520effects%2520of%2520its%2520inhibitors%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D421%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Sejas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span> </span><span class="NLM_article-title">New PARP targets for cancer therapy</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">â</span> <span class="NLM_lpage">509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=502-509&author=V.+Sejasauthor=P.+Chang&title=New+PARP+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSejas%26aufirst%3DV.%26aulast%3DChang%26aufirst%3DP.%26atitle%3DNew%2520PARP%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2014%26volume%3D7%26spage%3D502%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Huber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">â</span> <span class="NLM_lpage">1108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1103-1108&author=A.+Huberauthor=P.+Baiauthor=J.+M.+de+Murciaauthor=G.+de+Murcia&title=PARP-1%2C+PARP-2+and+ATM+in+the+DNA+damage+response%3A+functional+synergy+in+mouse+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DA.%26aulast%3DBai%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPARP-1%252C%2520PARP-2%2520and%2520ATM%2520in%2520the%2520DNA%2520damage%2520response%253A%2520functional%2520synergy%2520in%2520mouse%2520development%26jtitle%3DDNA%2520Repair%26date%3D2004%26volume%3D3%26spage%3D1103%26epage%3D1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Durkacz, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omidiji, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shall, S.</span><span> </span><span class="NLM_article-title">(ADP-ribose)<sub>n</sub> participates in DNA excision repair</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">â</span> <span class="NLM_lpage">596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1980&pages=593-596&author=B.+W.+Durkaczauthor=O.+Omidijiauthor=D.+A.+Grayauthor=S.+Shall&title=%28ADP-ribose%29n+participates+in+DNA+excision+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurkacz%26aufirst%3DB.%2BW.%26aulast%3DOmidiji%26aufirst%3DO.%26aulast%3DGray%26aufirst%3DD.%2BA.%26aulast%3DShall%26aufirst%3DS.%26atitle%3D%2528ADP-ribose%2529n%2520participates%2520in%2520DNA%2520excision%2520repair%26jtitle%3DNature%26date%3D1980%26volume%3D283%26spage%3D593%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">de Murcia, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedergang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trucco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricoul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutrillaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dierich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMeur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walztinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">7303</span><span class="NLM_x">â</span> <span class="NLM_lpage">7307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1073%2Fpnas.94.14.7303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=9207086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=7303-7307&author=J.+M.+de+Murciaauthor=C.+Niedergangauthor=C.+Truccoauthor=M.+Ricoulauthor=B.+Dutrillauxauthor=M.+Markauthor=F.+J.+Oliverauthor=M.+Massonauthor=A.+Dierichauthor=M.+LeMeurauthor=C.+Walztingerauthor=P.+Chambonauthor=G.+de+Murcia&title=Requirement+of+poly%28ADP-ribose%29+polymerase+in+recovery+from+DNA+damage+in+mice+and+in+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells</span></div><div class="casAuthors">Menissier de Murcia, Josiane; Niedergang, Claude; Trucco, Carlotta; Ricoul, Michele; Dutrillaux, Bernard; Mark, Manuel; Oliver, F. Javier; Masson, Murielle; Dierich, Andree; LeMeur, Marianne; Walztinger, Caroline; Chambon, Pierre; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7303-7307</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase [PARP; NAD+ ADP-ribosyltransferase; NAD+:poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyltransferase, EC 2.4.2.30] is a zinc-finger DNA-binding protein that detects specifically DNA strand breaks generated by genotoxic agents.  To det. its biol. function, the authors have inactivated both alleles by gene targeting in mice.  Treatment of PARP-/- mice either by the alkylating agent N-methyl-N-nitrosourea (MNU) or by Î³-irradn. revealed an extreme sensitivity and a high genomic instability to both agents.  Following whole body Î³-irradn. (8 Gy) mutant mice died rapidly from acute radiation toxicity to the small intestine.  Mice-derived PARP-/- cells displayed a high sensitivity to MNU exposure: a G2/M arrest in mouse embryonic fibroblasts and a rapid apoptotic response and a p53 accumulation were obsd. in splenocytes.  Altogether these results demonstrate that PARP is a survival factor playing an essential and pos. role during DNA damage recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlwmTBk-nHc7Vg90H21EOLACvtfcHk0lj_J_HfTAgHFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFOntb4%253D&md5=a652d7d877fa0c29ff1aeb9769fbd86f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.14.7303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.14.7303%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMurcia%26aufirst%3DJ.%2BM.%26aulast%3DNiedergang%26aufirst%3DC.%26aulast%3DTrucco%26aufirst%3DC.%26aulast%3DRicoul%26aufirst%3DM.%26aulast%3DDutrillaux%26aufirst%3DB.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26aulast%3DMasson%26aufirst%3DM.%26aulast%3DDierich%26aufirst%3DA.%26aulast%3DLeMeur%26aufirst%3DM.%26aulast%3DWalztinger%26aufirst%3DC.%26aulast%3DChambon%26aufirst%3DP.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DRequirement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520recovery%2520from%2520DNA%2520damage%2520in%2520mice%2520and%2520in%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D7303%26epage%3D7307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">â</span> <span class="NLM_lpage">917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger Î³-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0ljqP0VMvZ1MaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">â</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.N.+J.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+B.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+M.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0ljqP0VMvZ1MaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.N.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluzek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bialkowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zdzienicka, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8109</span><span class="NLM_x">â</span> <span class="NLM_lpage">8115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8109-8115&author=N.+McCabeauthor=N.+C.+Turnerauthor=C.+J.+Lordauthor=K.+Kluzekauthor=A.+Bialkowskaauthor=S.+Swiftauthor=S.+Giavaraauthor=M.+J.+O%E2%80%99Connorauthor=A.+N.+Tuttauthor=M.+Z.+Zdzienickaauthor=G.+C.+M.+Smithauthor=A.+Ashworth&title=Deficiency+in+the+repair+of+DNA+damage+by+homologous+recombination+and+sensitivity+to+poly%28ADP-ribose%29+polymerase+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DKluzek%26aufirst%3DK.%26aulast%3DBialkowska%26aufirst%3DA.%26aulast%3DSwift%26aufirst%3DS.%26aulast%3DGiavara%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DZdzienicka%26aufirst%3DM.%2BZ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DDeficiency%2520in%2520the%2520repair%2520of%2520DNA%2520damage%2520by%2520homologous%2520recombination%2520and%2520sensitivity%2520to%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8109%26epage%3D8115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Nijman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, S. H.</span><span> </span><span class="NLM_article-title">Cancer. Potential of the synthetic lethality principle</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">811</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=809-811&author=S.+M.+Nijmanauthor=S.+H.+Friend&title=Cancer.+Potential+of+the+synthetic+lethality+principle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNijman%26aufirst%3DS.%2BM.%26aulast%3DFriend%26aufirst%3DS.%2BH.%26atitle%3DCancer.%2520Potential%2520of%2520the%2520synthetic%2520lethality%2520principle%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D809%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Venkitaraman, A. R.</span><span> </span><span class="NLM_article-title">Cancer susceptibility and the functions of BRCA1 and BRCA2</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2002&pages=171-182&author=A.+R.+Venkitaraman&title=Cancer+susceptibility+and+the+functions+of+BRCA1+and+BRCA2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DCancer%2520susceptibility%2520and%2520the%2520functions%2520of%2520BRCA1%2520and%2520BRCA2%26jtitle%3DCell%26date%3D2002%26volume%3D108%26spage%3D171%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Narod, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foulkes, W. D.</span><span> </span><span class="NLM_article-title">BRCA1 and BRCA2: 1994 and beyond</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">â</span> <span class="NLM_lpage">676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnrc1431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15343273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCmsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=665-676&author=S.+A.+Narodauthor=W.+D.+Foulkes&title=BRCA1+and+BRCA2%3A+1994+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">BRCA1 and BRCA2: 1994 and beyond</span></div><div class="casAuthors">Narod, Steven A.; Foulkes, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-676</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of the first gene assocd. with hereditary breast cancer, BRCA1, was anticipated to greatly increase our understanding of both hereditary and sporadic forms of breast cancer, and to lead to therapeutic and preventive breakthroughs.  Much has been learned during the past decade about the genetic epidemiol. of breast cancer, the ethnic distribution and clin. consequences of BRCA1 and BRCA2 mutations, and the central role of DNA repair in breast cancer susceptibility.  The ability to translate this knowledge into novel treatments, however, remains elusive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1a5S77C977bVg90H21EOLACvtfcHk0lhIJrtpM4LcvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCmsbk%253D&md5=200600041061619ba39dfbd8dfc91850</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1038%2Fnrc1431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1431%26sid%3Dliteratum%253Aachs%26aulast%3DNarod%26aufirst%3DS.%2BA.%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26atitle%3DBRCA1%2520and%2520BRCA2%253A%25201994%2520and%2520beyond%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D665%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">â</span> <span class="NLM_lpage">6591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.-l.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=I.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+W.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+B.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.-l.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DI.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%2BW.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Burg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, A. O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, S. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derksen, P. W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zevenhoven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">17079</span><span class="NLM_x">â</span> <span class="NLM_lpage">17084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1073%2Fpnas.0806092105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=18971340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=17079-17084&author=S.+Rottenbergauthor=J.+E.+Jaspersauthor=A.+Kersbergenauthor=E.+van+der+Burgauthor=A.+O.+H.+Nygrenauthor=S.+A.+L.+Zanderauthor=P.+W.+B.+Derksenauthor=M.+de+Bruinauthor=J.+Zevenhovenauthor=A.+Lauauthor=R.+Boulterauthor=A.+Cranstonauthor=M.+J.+O%E2%80%99Connorauthor=N.+M.+B.+Martinauthor=P.+Borstauthor=J.+Jonkers&title=High+sensitivity+of+BRCA1-deficient+mammary+tumors+to+the+PARP+inhibitor+AZD2281+alone+and+in+combination+with+platinum+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span></div><div class="casAuthors">Rottenberg, Sven; Jaspers, Janneke E.; Kersbergen, Ariena; van der Burg, Eline; Nygren, Anders O. H.; Zander, Serge A. L.; Derksen, Patrick W. B.; de Bruin, Michiel; Zevenhoven, John; Lau, Alan; Boulter, Robert; Cranston, Aaron; O'Connor, Mark J.; Martin, Niall M. B.; Borst, Piet; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17079-17084</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-pos. breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-neg. ("triple-neg.") mammary carcinomas.  Triple-neg. tumors account for 15% of all breast cancers and frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction.  The DNA-repair defects characteristic of BRCA1-deficient cells confer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which could be relevant to treatment of triple-neg. tumors.  To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-assocd. breast cancer.  Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival.  Long-term treatment with AZD2281 in this model did result in the development of drug resistance, caused by up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps.  This resistance to AZD2281 could be reversed by coadministration of the P-glycoprotein inhibitor tariquidar.  Combination of AZD2281 with cisplatin or carboplatin increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.  Our results demonstrate in vivo efficacy of AZD2281 against BRCA1-deficient breast cancer and illustrate how GEMMs of cancer can be used for preclin. evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95zB9OKZ4ObVg90H21EOLACvtfcHk0liGUjG3bz1Xtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F&md5=788a7d8b5341b731d007753d5a234dec</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0806092105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0806092105%26sid%3Dliteratum%253Aachs%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DNygren%26aufirst%3DA.%2BO.%2BH.%26aulast%3DZander%26aufirst%3DS.%2BA.%2BL.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%2BB.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3DZevenhoven%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHigh%2520sensitivity%2520of%2520BRCA1-deficient%2520mammary%2520tumors%2520to%2520the%2520PARP%2520inhibitor%2520AZD2281%2520alone%2520and%2520in%2520combination%2520with%2520platinum%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D17079%26epage%3D17084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">12</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2013&pages=1-12&author=S.+B.+De+Lorenzoauthor=A.+G.+Patelauthor=R.+M.+Hurleyauthor=S.+H.+Kaufmann&title=The+elephant+and+the+blind+men%3A+making+sense+of+PARP+inhibitors+in+homologous+recombination+deficient+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DHurley%26aufirst%3DR.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DThe%2520elephant%2520and%2520the%2520blind%2520men%253A%2520making%2520sense%2520of%2520PARP%2520inhibitors%2520in%2520homologous%2520recombination%2520deficient%2520tumor%2520cells%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D228%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP2 by clinical PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5588</span><span class="NLM_x">â</span> <span class="NLM_lpage">5599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23118055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.+Y.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP2+by+clinical+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-yin N.; Das, Benu Brata; Renaud, Amelie; Zhang, Yiping; Doroshow, James H.; Ji, Jiuping; Takeda, Shunichi; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5588-5599</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings indicate that PARP inhibitors in clin. trials not only block catalytic function but also trap PARP enzymes on DNA, illuminating the mechanistic basis for their cytotoxic activity in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3m55HXn9ObVg90H21EOLACvtfcHk0liGUjG3bz1Xtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE&md5=81c590b6a4fbb9efc9c64f7de5e89524</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP2%2520by%2520clinical%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Hallmarks of âBRCAnessâ in sporadic cancers</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">814</span><span class="NLM_x">â</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnrc1457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15510162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=814-819&author=N.+Turnerauthor=A.+Tuttauthor=A.+Ashworth&title=Hallmarks+of+%E2%80%99BRCAness%E2%80%99+in+sporadic+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of 'BRCAness' in sporadic cancers</span></div><div class="casAuthors">Turner, Nicholas; Tutt, Andrew; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">814-819</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Germline mutations in the BRCA1, BRCA2 and Fanconi anemia genes confer cancer susceptibility, and the proteins encoded by these genes have distinct functions in related DNA-repair processes.  Emerging evidence indicates that these processes are disrupted by numerous mechanisms in sporadic cancers.  Collectively, there are properties that define 'BRCAness' - i.e., traits that some sporadic cancers share with those occurring in either BRCA1- or BRCA2-mutation carriers.  These common properties might have important implications for the clin. management of these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSK5dEe3-aKLVg90H21EOLACvtfcHk0lgfo2viN3Tnlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1ymu7g%253D&md5=b2ec7c226f4ca388e2dc3a6c1d030e7d</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1457%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DHallmarks%2520of%2520%25E2%2580%2599BRCAness%25E2%2580%2599%2520in%2520sporadic%2520cancers%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D814%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Summa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambiasi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petriella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradiso, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradiso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommasi, S.</span><span> </span><span class="NLM_article-title">BRCAness: a deeper insight into basal-like breast tumors</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 8</span><span class="NLM_x">) </span> <span class="NLM_fpage">viii13</span><span class="NLM_x">â</span> <span class="NLM_lpage">viii21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1093%2Fannonc%2Fmdt306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=24131964" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=viii13-viii21&issue=Suppl.+8&author=S.+De+Summaauthor=R.+Pintoauthor=D.+Sambiasiauthor=D.+Petriellaauthor=V.+Paradisoauthor=A.+Paradisoauthor=S.+Tommasi&title=BRCAness%3A+a+deeper+insight+into+basal-like+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt306%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSumma%26aufirst%3DS.%26aulast%3DPinto%26aufirst%3DR.%26aulast%3DSambiasi%26aufirst%3DD.%26aulast%3DPetriella%26aufirst%3DD.%26aulast%3DParadiso%26aufirst%3DV.%26aulast%3DParadiso%26aufirst%3DA.%26aulast%3DTommasi%26aufirst%3DS.%26atitle%3DBRCAness%253A%2520a%2520deeper%2520insight%2520into%2520basal-like%2520breast%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26issue%3DSuppl.%25208%26spage%3Dviii13%26epage%3Dviii21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">The Cancer Genome Atlas Research Network.</span><span> </span><span class="NLM_article-title">Integrated genomic analyses of ovarian carcinoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">474</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=609-615&author=The+Cancer+Genome+Atlas+Research+Network.&title=Integrated+genomic+analyses+of+ovarian+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DIntegrated%2520genomic%2520analyses%2520of%2520ovarian%2520carcinoma%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">â</span> <span class="NLM_lpage">1575</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=1530940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=1569-1575&author=M.+Banasikauthor=H.+Komuraauthor=M.+Shimoyamaauthor=K.+Ueda&title=Specific+inhibitors+of+poly%28ADP-ribose%29+synthetase+and+mono%28ADP-ribosyl%29transferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase</span></div><div class="casAuthors">Banasik, Marek; Komura, Hajime; Shimoyama, Makoto; Ueda, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1569-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Two classes of enzymes, poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferases, catalyze covalent attachment of multiple or single residues, resp., of the ADP-ribose moiety of NAD to various proteins.  In order to find good inhibitors of poly(ADP-ribose) synthetase free of side actions and applicable to in vivo studies, a large scale survey was made using an in vitro assay system, and many potent inhibitors were found.  The four strongest were 4-amino-1,8-naphthalimide, 6(5H)- and 2-nitro-6(5H)-phenanthridinones, and 1,5-dihydroxyisoquinoline.  Their 50% inhibitory concns., 0.18-0.39 Î¼M, were about two orders of magnitude lower than that of 3-aminobenzamide that is currently most popularly used.  A common structural feature among all potent inhibitors, including 1-hydroxyisoquinoline, chlorthenoxazin, 3-hydroxybenzamide, and 4-hydroxyquinazoline, in addn. to the four mentioned above, was the presence of a carbonyl group built in a polyarom. heterocyclic skeleton or a carbamoyl group attached to an arom. ring.  Most of the inhibitors exhibited mixed-type inhibition with respect to NAD.  Comparative studies of the effects on poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase from hen heterophils revealed high specificity of most of the potent inhibitors for poly(ADP-ribose) synthetase.  On the other hand, unsatd. long-chain fatty acids inhibited both enzymes, and satd. long-chain fatty acids and vitamin K1 acted selectively on mono(ADP-ribosyl)transferase.  The finding of many inhibitors of ADP-ribosyltransferases, esp. poly(ADP-ribose) synthetase, supports the view that ADP-ribosylation of proteins may be regulated by a variety of metabolites or structural constituents in the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Jh_eRCjHdbVg90H21EOLACvtfcHk0lgfo2viN3Tnlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSjtLk%253D&md5=21bb51821a1caaeb30c42643a82116f4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DSpecific%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520synthetase%2520and%2520mono%2528ADP-ribosyl%2529transferase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D1569%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Arundel-Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scavone, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span> </span><span class="NLM_article-title">Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells</span> <span class="citation_source-journal">Radiat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">â</span> <span class="NLM_lpage">371</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2307%2F3577927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=1903547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK3MXksVGiu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1991&pages=367-371&author=C.+M.+Arundel-Sutoauthor=S.+V.+Scavoneauthor=W.+R.+Turnerauthor=M.+J.+Sutoauthor=J.+S.+Sebolt-Leopold&title=Effects+of+PD+128763%2C+a+new+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase%2C+on+X-ray-induced+cellular+recovery+processes+in+Chinese+hamster+V79+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on x-ray-induced cellular recovery processes in Chinese hamster V79 cells</span></div><div class="casAuthors">Arundel-Suto, Carla M.; Scavone, Sylvia V.; Turner, William R.; Suto, Mark J.; Sebolt-Leopold, Judith S.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-71</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">The modifying effects of PD 128763 (3,4-dihydro-5-methyl-1(2H)-isoquinolinone) (I), a potent inhibitor of poly(ADP-ribose)polymerase, on radiation-induced cell killing were examd. in Chinese hamster V79 cells.  I has an IC50 value against the purified enzyme 50-fold lower than 3-aminobenzamide (3-AB), a widely used specific inhibitor of the enzyme.  Exposure of exponentially growing cells to a noncytotoxic concn. (0.5 mM) of I for 2 h immediately following x-irradn. increased their radiation sensitivity, modifying both the shoulder and the slope of the survival curve.  When recovery from sublethal damage and potentially lethal damage was examd. in exponential and plateau-phase cells, resp., postirradn. incubation with 0.5 mM I not only to inhibited both these processes fully, but also enhanced further the level of radiation-induced cell killing.  This is in contrast to the slight effect seen with the less potent inhibitor, 3-AB.  The mechanism of radiosensitization by I is related to the potent inhibition of poly(ADP-ribose) polymerase by this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-K-Ex9TzkMbVg90H21EOLACvtfcHk0liZat4o1Y7btA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVGiu7c%253D&md5=7834088129032193a156f8cc6a832b38</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2307%2F3577927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3577927%26sid%3Dliteratum%253Aachs%26aulast%3DArundel-Suto%26aufirst%3DC.%2BM.%26aulast%3DScavone%26aufirst%3DS.%2BV.%26aulast%3DTurner%26aufirst%3DW.%2BR.%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26atitle%3DEffects%2520of%2520PD%2520128763%252C%2520a%2520new%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%252C%2520on%2520X-ray-induced%2520cellular%2520recovery%2520processes%2520in%2520Chinese%2520hamster%2520V79%2520cells%26jtitle%3DRadiat.%2520Res.%26date%3D1991%26volume%3D126%26spage%3D367%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wahlberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouznetsova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frostell, Ã.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ÃncÃ¼, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SchÃ¼ler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, J.</span><span> </span><span class="NLM_article-title">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnbt.2121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22343925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=283-288&author=E.+Wahlbergauthor=T.+Karlbergauthor=E.+Kouznetsovaauthor=N.+Markovaauthor=A.+Macchiaruloauthor=A.-G.+Thorsellauthor=E.+Polauthor=%C3%85.+Frostellauthor=T.+Ekbladauthor=D.+%C3%96nc%C3%BCauthor=B.+Kullauthor=G.+M.+Robertsonauthor=R.+Pellicciariauthor=H.+Sch%C3%BClerauthor=J.+Weigelt&title=Family-wide+chemical+profiling+and+structural+analysis+of+PARP+and+tankyrase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span></div><div class="casAuthors">Wahlberg, Elisabet; Karlberg, Tobias; Kouznetsova, Ekaterina; Markova, Natalia; Macchiarulo, Antonio; Thorsell, Ann-Gerd; Pol, Ewa; Frostell, Aasa; Ekblad, Torun; Oencue, Delal; Kull, Bjoern; Robertson, Graeme Michael; Pellicciari, Roberto; Schueler, Herwig; Weigelt, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clin. trials as cancer therapeutics, yet the specificity of many of these compds. is unknown.  Here we evaluated a series of 185 small-mol. inhibitors, including research reagents and compds. being tested clin., for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2.  Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these mols. lack specificity and have promiscuous inhibitory activity.  We also detd. X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes.  In addn. to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYSebsCVufibVg90H21EOLACvtfcHk0liZat4o1Y7btA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D&md5=71f17fd5b6bb602dd70c8fcc17df95f9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2121%26sid%3Dliteratum%253Aachs%26aulast%3DWahlberg%26aufirst%3DE.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DKouznetsova%26aufirst%3DE.%26aulast%3DMarkova%26aufirst%3DN.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DThorsell%26aufirst%3DA.-G.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DFrostell%26aufirst%3D%25C3%2585.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3D%25C3%2596nc%25C3%25BC%26aufirst%3DD.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DG.%2BM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DWeigelt%26aufirst%3DJ.%26atitle%3DFamily-wide%2520chemical%2520profiling%2520and%2520structural%2520analysis%2520of%2520PARP%2520and%2520tankyrase%2520inhibitors%26jtitle%3DNature%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D283%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">â</span> <span class="NLM_lpage">956</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.-Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0ljGNbUn7St6Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.-D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)Â·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. IÂ·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., IÂ·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0ljGNbUn7St6Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.-D.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3<i>S</i>)-piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA1 and 2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">â</span> <span class="NLM_lpage">7185</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+a+novel+oral+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA1+and+2+mutant+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520a%2520novel%2520oral%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA1%2520and%25202%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">DelloRusso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welcsh, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, E. M.</span><span> </span><span class="NLM_article-title">Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">â</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1541-7786.MCR-06-0234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17259345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptFequg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=35-45&author=C.+DelloRussoauthor=P.+L.+Welcshauthor=W.+Wangauthor=R.+L.+Garciaauthor=M.+C.+Kingauthor=E.+M.+Swisher&title=Functional+characterization+of+a+novel+BRCA1-null+ovarian+cancer+cell+line+in+response+to+ionizing+radiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation</span></div><div class="casAuthors">DelloRusso, Christiana; Welcsh, Piri L.; Wang, Weixin; Garcia, Rochelle L.; King, Mary-Claire; Swisher, Elizabeth M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The breast and ovarian cancer susceptibility gene BRCA1 plays a major role in the DNA damage response pathway.  The lack of well-characterized human BRCA1-null cell lines has limited the investigation of BRCA1 function, particularly with regard to its role in ovarian cancer.  We propagated a novel BRCA1-null human ovarian cancer cell line UWB1.289 from a tumor of papillary serous histol., the most common form of ovarian carcinoma.  UWB1.289 carries a germline BRCA1 mutation within exon 11 and has a deletion of the wild-type allele.  UWB1.289 is estrogen and progesterone receptor neg. and has an acquired somatic mutation in p53, similar to the commonly used BRCA1-null breast cancer cell line HCC1937.  We used ionizing radiation to induce DNA damage in both UWB1.289 and in a stable UWB1.289 line in which wild-type BRCA1 was restored.  We examd. several responses to DNA damage in these cell lines, including sensitivity to radiation, cell cycle checkpoint function, and changes in gene expression using microarray anal.  We obsd. that UWB1.289 is sensitive to ionizing radiation and lacks cell cycle checkpoint functions that are a normal part of the DNA damage response.  Restoration of wild-type BRCA1 function in these cells partially restores DNA damage responses.  Expression array anal. not only supports this partial functional correction but also reveals interesting new information regarding BRCA1-pos. regulation of the expression of claudin 6 and other metastasis-assocd. genes and neg. regulation of multiple IFN-inducible genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sXbCj4NcjrVg90H21EOLACvtfcHk0liMYjVRFiLWVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptFequg%253D%253D&md5=d550d27a49dba53d150d86b24f25bcd5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-06-0234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-06-0234%26sid%3Dliteratum%253Aachs%26aulast%3DDelloRusso%26aufirst%3DC.%26aulast%3DWelcsh%26aufirst%3DP.%2BL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGarcia%26aufirst%3DR.%2BL.%26aulast%3DKing%26aufirst%3DM.%2BC.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26atitle%3DFunctional%2520characterization%2520of%2520a%2520novel%2520BRCA1-null%2520ovarian%2520cancer%2520cell%2520line%2520in%2520response%2520to%2520ionizing%2520radiation%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2007%26volume%3D5%26spage%3D35%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">PARP inhibitor development for systemic cancer targeting</span> <span class="citation_source-journal">Anticancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">523</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.2174%2F187152007781668715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=17896912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtV2gtr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=515-523&author=T.+Zarembaauthor=N.+J.+Curtin&title=PARP+inhibitor+development+for+systemic+cancer+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitor development for systemic cancer targeting</span></div><div class="casAuthors">Zaremba, Tomasz; Curtin, Nicola Jane</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">515-523</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase 1 (PARP-1) is a DNA-binding enzyme that is activated by DNA breaks, converting them into an intracellular signal via poly(ADP-ribosyl)ation of nuclear proteins.  Neg. charged polymers of ADP-ribose (PAR) attached to PARP-1 itself and histones lead to chromatin relaxation, facilitating the access of base excision/single strand break repair proteins and activating these repair enzymes.  PARP inhibitors have been developed to investigate the role of PARP-1 in cell biol. and to overcome DNA repair-mediated resistance of cancer cells to cytotoxic therapy.  Since the early benzamide inhibitors of the 1980s PARP inhibitors, developed through structure-activity relationships and crystal structure-based drug design, that are 1,000x more potent have been identified.  These novel PARP inhibitors have been shown to enhance the antitumor activity of temozolomide (a DNA-methylating agent), topoisomerase poisons and ionising radiation in advanced pre-clin. studies and are now under clin. evaluation.  PARP inhibitors can also selectively kill cells and tumors with homozygous defects in the hereditary breast cancer genes, BRCA1 and BRCA2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGS5VD2eu5HLVg90H21EOLACvtfcHk0liMYjVRFiLWVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtV2gtr3I&md5=72d70ab6c45db578407192319ca6c5db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F187152007781668715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152007781668715%26sid%3Dliteratum%253Aachs%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPARP%2520inhibitor%2520development%2520for%2520systemic%2520cancer%2520targeting%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D515%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barrows, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâArpa, P.</span><span> </span><span class="NLM_article-title">The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication</span> <span class="citation_source-journal">Mutat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2FS0921-8777%2898%2900022-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=9739812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK1cXks1Ontr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=1998&pages=103-110&author=L.+R.+Barrowsauthor=J.+A.+Holdenauthor=M.+Andersonauthor=P.+D%E2%80%99Arpa&title=The+CHO+XRCC1+mutant%2C+EM9%2C+deficient+in+DNA+ligase+III+activity%2C+exhibits+hypersensitivity+to+camptothecin+independent+of+DNA+replication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication</span></div><div class="casAuthors">Barrows, Louis R.; Holden, Joseph A.; Anderson, Melvin; D'Arpa, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, DNA Repair</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-110</span>CODEN:
                <span class="NLM_cas:coden">MRDRBE</span>;
        ISSN:<span class="NLM_cas:issn">0921-8777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have analyzed the x-ray-sensitive CHO mutant cell line EM9 for sensitivity to the topoisomerase I inhibitor camptothecin.  These cells exhibit defective repair of single strand DNA breaks.  Recently, EM9 were complemented the DNA ligase III interactive protein, XRCC1.  Defective XRCC1 apparently accounts for the low DNA ligase III activity that may explain the single-strand break repair deficiency of EM9 cells.  Here, we demonstrate cytotoxic hypersensitivity of EM9 cells following a brief camptothecin treatment.  Both the S-phase and non-S-phase populations of EM9 exhibited camptothecin sensitivity relative to the parent cell line AA8.  In AA8 cells, only the 55% of the population corresponding to the S-phase subpopulation were sensitive to camptothecin, while the remainder of the population were totally resistant to doses as high as 10 Î¼M.  The role of DNA replication in the camptothecin sensitivity was studied using the DNA polymerase inhibitor aphidicolin in co-treatment with camptothecin.  Aphidicolin treatment fully protected AA8 cells from camptothecin cytotoxicity.  In EM9 cells, aphidicolin protected the S-phase fraction to some degree but all the cells remained sensitive to camptothecin cytotoxicity.  These results suggest that EM9 cells are sensitized to camptothecin by a mechanism that is independent of DNA replication and may be a consequence of the XRCC1 mutation or the assocd. deficiency in DNA ligase III activity.  Mechanistic models for the replication-independent cytotoxicity of camptothecin in EM9 cells are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB-XcFm3kSEbVg90H21EOLACvtfcHk0liMYjVRFiLWVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXks1Ontr4%253D&md5=da2a05f19c82888da655c65c00316258</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0921-8777%2898%2900022-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0921-8777%252898%252900022-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarrows%26aufirst%3DL.%2BR.%26aulast%3DHolden%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Arpa%26aufirst%3DP.%26atitle%3DThe%2520CHO%2520XRCC1%2520mutant%252C%2520EM9%252C%2520deficient%2520in%2520DNA%2520ligase%2520III%2520activity%252C%2520exhibits%2520hypersensitivity%2520to%2520camptothecin%2520independent%2520of%2520DNA%2520replication%26jtitle%3DMutat.%2520Res.%26date%3D1998%26volume%3D408%26spage%3D103%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Chaudhuri, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrador, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelsen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fachinetti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermejo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopes, M.</span><span> </span><span class="NLM_article-title">Topoisomerase I poisoning results in PARP-mediated replication fork reversal</span> <span class="citation_source-journal">Nature Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">â</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnsmb.2258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22388737" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=417-423&author=A.+R.+Chaudhuriauthor=Y.+Hashimotoauthor=R.+Herradorauthor=K.+J.+Neelsenauthor=D.+Fachinettiauthor=R.+Bermejoauthor=A.+Cocitoauthor=V.+Costanzoauthor=M.+Lopes&title=Topoisomerase+I+poisoning+results+in+PARP-mediated+replication+fork+reversal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2258%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhuri%26aufirst%3DA.%2BR.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DHerrador%26aufirst%3DR.%26aulast%3DNeelsen%26aufirst%3DK.%2BJ.%26aulast%3DFachinetti%26aufirst%3DD.%26aulast%3DBermejo%26aufirst%3DR.%26aulast%3DCocito%26aufirst%3DA.%26aulast%3DCostanzo%26aufirst%3DV.%26aulast%3DLopes%26aufirst%3DM.%26atitle%3DTopoisomerase%2520I%2520poisoning%2520results%2520in%2520PARP-mediated%2520replication%2520fork%2520reversal%26jtitle%3DNature%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D417%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tentori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span> </span><span class="NLM_article-title">Chemopotentiation by PARP inhibitors in cancer therapy</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2Fj.phrs.2005.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=15911331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Wltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=25-33&author=L.+Tentoriauthor=G.+Graziani&title=Chemopotentiation+by+PARP+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Chemopotentiation by PARP inhibitors in cancer therapy</span></div><div class="casAuthors">Tentori, Lucio; Graziani, Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-33</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARP) constitute a family of enzymes involved in the regulation of many cellular processes such as DNA repair, gene transcription, cell cycle progression, cell death, chromatin functions and genomic stability.  Among the 18 members identified so far, PARP-1 and PARP-2 are the only proteins stimulated by DNA strand breaks and implicated in the repair of DNA injury.  Therefore, these mols. have been exploited as potential targets for the development of pharmacol. strategies to increase the antitumor efficacy of chemotherapeutic agents, which induce DNA damage.  PARP inhibitors have been shown to restore sensitivity of resistant tumors to methylating agents or topoisomerase I inhibitors, drugs presently used for the treatment of primary and secondary brain tumors or malignancies refractory to std. chemotherapy.  Interestingly, PARP inhibitors may also provide protection from the untoward effects exerted by certain anticancer drugs, which cause oxidative stress and consequent PARP overactivation.  The aim of this article is to provide a brief overview of the recent literature on preclin. studies with the specific and potent inhibitors newly synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoImZCOb5elR7Vg90H21EOLACvtfcHk0liyzklbG58egQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Wltr8%253D&md5=2a2f1893efeefc3f1d140979beae6f4d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2005.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2005.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DGraziani%26aufirst%3DG.%26atitle%3DChemopotentiation%2520by%2520PARP%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Res.%26date%3D2005%26volume%3D52%26spage%3D25%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdecanas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser-Doepner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milas, L.</span><span> </span><span class="NLM_article-title">MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2113</span><span class="NLM_x">â</span> <span class="NLM_lpage">2120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2113-2120&author=L.+Wangauthor=K.+A.+Masonauthor=K.+K.+Angauthor=T.+Buchholzauthor=D.+Valdecanasauthor=A.+Mathurauthor=C.+Buser-Doepnerauthor=C.+Toniattiauthor=L.+Milas&title=MK-4827%2C+a+PARP-1%2F-2+inhibitor%2C+strongly+enhances+response+of+human+lung+and+breast+cancer+xenografts+to+radiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMason%26aufirst%3DK.%2BA.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DBuchholz%26aufirst%3DT.%26aulast%3DValdecanas%26aufirst%3DD.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DBuser-Doepner%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DMilas%26aufirst%3DL.%26atitle%3DMK-4827%252C%2520a%2520PARP-1%252F-2%2520inhibitor%252C%2520strongly%2520enhances%2520response%2520of%2520human%2520lung%2520and%2520breast%2520cancer%2520xenografts%2520to%2520radiation%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2113%26epage%3D2120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Bridges, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyn, R. E.</span><span> </span><span class="NLM_article-title">Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">5076</span><span class="NLM_x">â</span> <span class="NLM_lpage">5086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5076-5086&author=K.+A.+Bridgesauthor=C.+Toniattiauthor=C.+A.+Buserauthor=H.+Liuauthor=T.+A.+Buchholzauthor=R.+E.+Meyn&title=Niraparib+%28MK-4827%29%2C+a+novel+poly%28ADP-Ribose%29+polymerase+inhibitor%2C+radiosensitizes+human+lung+and+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DK.%2BA.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBuchholz%26aufirst%3DT.%2BA.%26aulast%3DMeyn%26aufirst%3DR.%2BE.%26atitle%3DNiraparib%2520%2528MK-4827%2529%252C%2520a%2520novel%2520poly%2528ADP-Ribose%2529%2520polymerase%2520inhibitor%252C%2520radiosensitizes%2520human%2520lung%2520and%2520breast%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5076%26epage%3D5086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Genther Williams, S. M.; Kuznicki, A. M.; Andrade, P.; Dolinski, B. M.; Elbi, C.; OâHagan, R. C.; Toniatti, C.</span><span> </span><span class="NLM_article-title">Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status</span>.  <span class="citation_source-journal">Cancer Cell Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span>, DOI: <span class="refDoi">Â DOI: 10.1186/s12935-015-0162-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1186%2Fs12935-015-0162-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=25685067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A280%3ADC%252BC2MrlvVyrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=14&author=S.+M.+Genther+Williams&author=A.+M.+Kuznicki&author=P.+Andrade&author=B.+M.+Dolinski&author=C.+Elbi&author=R.+C.+O%E2%80%99Hagan&author=C.+Toniatti&title=Treatment+with+the+PARP+inhibitor%2C+niraparib%2C+sensitizes+colorectal+cancer+cell+lines+to+irinotecan+regardless+of+MSI%2FMSS+status&doi=10.1186%2Fs12935-015-0162-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status</span></div><div class="casAuthors">Genther Williams Sybil M; Dolinski Brian M; O'Hagan Ronan C; Kuznicki Apryle M; Andrade Paula; Elbi Cem; Toniatti Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer cell international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cells with homologous recombination (HR) deficiency, most notably caused by mutations in the BRCA1 or BRCA2 genes, are sensitive to PARP inhibition.  Microsatellite instability (MSI) accounts for 10-15% of colorectal cancer (CRC) and is hypothesized to lead to HR defects due to altered expression of Mre11, a protein required for double strand break (DSB) repair.  Indeed, others have reported that PARP inhibition is efficacious in MSI CRC.  METHODS:  Here we examine the response to niraparib, a potent PARP-1/PARP-2 inhibitor currently under clinical evaluation, in MSI versus microsatellite stable (MSS) CRC cell lines in vitro and in vivo.  We compiled a large panel of MSI and MSS CRC cell lines and evaluated the anti-proliferative activity of niraparib.  In addition to testing single agent cytotoxic activity of niraparib, we also tested irinotecan (or SN-38, the active metabolite of irinotecan) activity alone and in combination with niraparib in vitro and in vivo.  RESULTS:  In contrast to earlier reports, MSI CRC cell lines were not more sensitive to niraparib than MSS CRC cell lines suggesting that the MSI phenotype does not sensitize CRC cell lines to PARP inhibition.  Moreover, even the most sensitive MSI cell lines had niraparib EC50s greater than 10 fold higher than BRCA-deficient cell lines.  However, MSI lines were more sensitive to SN-38 than MSS lines, consistent with previous findings.  We have also demonstrated that combination of niraparib and irinotecan was more efficacious than either agent alone in both MSI and MSS cell lines both in vitro and in vivo, and that niraparib potentiates the effect of irinotecan regardless of MSI status.  CONCLUSIONS:  Our results support the clinical evaluation of this combination in all CRC patients, regardless of MSI status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKbTxgn1b3ESnGiHuhFGv8fW6udTcc2eaZmwXwygM6Crntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrlvVyrsA%253D%253D&md5=6338ddf35e24a28c4d00d336a726a520</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2Fs12935-015-0162-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-015-0162-8%26sid%3Dliteratum%253Aachs%26aulast%3DGenther%2BWilliams%26aufirst%3DS.%2BM.%26atitle%3DTreatment%2520with%2520the%2520PARP%2520inhibitor%252C%2520niraparib%252C%2520sensitizes%2520colorectal%2520cancer%2520cell%2520lines%2520to%2520irinotecan%2520regardless%2520of%2520MSI%252FMSS%2520status%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2015%26volume%3D15%26spage%3D14%26doi%3D10.1186%2Fs12935-015-0162-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Papco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors in cancer therapy: an update</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">â</span> <span class="NLM_lpage">514</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1517%2F13543776.2013.768615" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=503-514&author=G.+Papcoauthor=E.+Casaleauthor=A.+Montagnoliauthor=A.+Cirla&title=PARP+inhibitors+in+cancer+therapy%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.768615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.768615%26sid%3Dliteratum%253Aachs%26aulast%3DPapco%26aufirst%3DG.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DCirla%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520an%2520update%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D503%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boshuizen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">â</span> <span class="NLM_lpage">5015</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1078-0432.CCR-13-1391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23881923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5003-5015&author=Y.+Shenauthor=F.+L.+Rehmanauthor=Y.+Fengauthor=J.+Boshuizenauthor=I.+Bajramiauthor=R.+Elliottauthor=B.+Wangauthor=C.+J.+Lordauthor=L.+E.+Postauthor=A.+Ashworth&title=BMN673%2C+a+novel+and+highly+potent+PARP1%2F2+inhibitor+for+the+treatment+of+human+cancers+with+DNA+repair+deficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency</span></div><div class="casAuthors">Shen, Yuqiao; Rehman, Farah L.; Feng, Ying; Boshuizen, Julia; Bajrami, Ilirjana; Elliott, Richard; Wang, Bing; Lord, Christopher J.; Post, Leonard E.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5003-5015</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.  Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  Exptl. Design: Potency and selectivity of BMN 673 was detd. by biochem. assays.  Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models.  Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested.  BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concns. than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib).  In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors.  BMN 673 is readily orally bioavailable, with more than 40% abs. oral bioavailability in rats when dosed in carboxylmethyl cellulose.  Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice.  Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs.  Conclusion: BMN 673 is currently in early-phase clin. development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.  Clin Cancer Res; 19(18); 5003-15. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdmHIVEuoz7Vg90H21EOLACvtfcHk0li3tcauGGHO7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J&md5=f58b67f14784c0a0fa1197caffd8d96d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1391%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBoshuizen%26aufirst%3DJ.%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBMN673%252C%2520a%2520novel%2520and%2520highly%2520potent%2520PARP1%252F2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%2520with%2520DNA%2520repair%2520deficiency%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5003%26epage%3D5015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Mateo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, D. S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Appraising iniparib, the PARP inhibitor that never wasâwhat must we learn?</span> <span class="citation_source-journal">Nature Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">688</span><span class="NLM_x">â</span> <span class="NLM_lpage">696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1038%2Fnrclinonc.2013.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Clt7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=688-696&author=J.+Mateoauthor=M.+Ongauthor=D.+S.+P.+Tanauthor=M.+A.+Gonzalezauthor=J.+S.+de+Bono&title=Appraising+iniparib%2C+the+PARP+inhibitor+that+never+was%E2%80%94what+must+we+learn%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Appraising iniparib, the PARP inhibitor that never was-what must we learn?</span></div><div class="casAuthors">Mateo, Joaquin; Ong, Michael; Tan, David S. P.; Gonzalez, Michael A.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">688-696</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several drugs targeting poly(ADP-ribose) polymerase (PARP) enzymes are under development.  Responses have been obsd. in patients with germline mutations in BRCA1 and BRCA2, with further data supporting antitumor activity of PARP inhibitors in sporadic ovarian cancer.  Strategies to identify other predictive biomarkers remain under investigation.  Iniparib was purported to be a PARP inhibitor that showed promising results in randomized phase II trials in patients with triple-neg. breast cancer.  Neg. results from a phase III study in this disease setting, however, tempered enthusiasm for this agent.  Recently, data from in vitro expts. suggest that iniparib is not only structurally distinct from other described PARP inhibitors, but is also a poor inhibitor of PARP activity.  In this context, the neg. iniparib phase III data might have erroneously promulgated the notion that PARP inhibition is not an effective therapeutic strategy.  Here, we scrutinize the development of iniparib from preclin. studies to registration trials, and identify and discuss the pitfalls in the development of anticancer drugs to prevent future late-stage trial failures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWfclKdXsYk7Vg90H21EOLACvtfcHk0li3tcauGGHO7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Clt7fP&md5=d61aa0cc7ab5f4375e33c6059bc9928c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.177%26sid%3Dliteratum%253Aachs%26aulast%3DMateo%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BP.%26aulast%3DGonzalez%26aufirst%3DM.%2BA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DAppraising%2520iniparib%252C%2520the%2520PARP%2520inhibitor%2520that%2520never%2520was%25E2%2580%2594what%2520must%2520we%2520learn%253F%26jtitle%3DNature%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D688%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">OâShaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippen, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span> </span><span class="NLM_article-title">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">â</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1056%2FNEJMoa1011418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=21208101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=205-214&author=J.+O%E2%80%99Shaughnessyauthor=C.+Osborneauthor=J.+E.+Pippenauthor=M.+Yoffeauthor=D.+Pattauthor=C.+Rochaauthor=I.+C.+Kooauthor=B.+M.+Shermanauthor=C.+Bradley&title=Iniparib+plus+chemotherapy+in+metastatic+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span></div><div class="casAuthors">O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.; Yoffe, Mark; Patt, Debra; Rocha, Christine; Koo, Ingrid Chou; Sherman, Barry M.; Bradley, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(ADP-ribose) polymerase (PARP) inhibition.  We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small mol. with PARP-inhibitory activity, in patients with metastatic triple-neg. breast cancer.  A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equiv. to an area under the concn.-time curve of 2) on days 1 and 8 - with or without iniparib (at a dose of 5.6 mg per kg of body wt.) on days 1, 4, 8, and 11 - every 21 days.  Primary end points were the rate of clin. benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for â¥6 mo) and safety.  Addnl. end points included the rate of objective response, progression-free survival, and overall survival.  The addn. of iniparib to gemcitabine and carboplatin improved the rate of clin. benefit from 34 to 56% and the rate of overall response from 32 to 52%.  The addn. of iniparib also prolonged the median progression-free survival from 3.6 mo to 5.9 mo (hazard ratio for progression, 0.59) and the median overall survival from 7.7 mo to 12.3 mo (hazard ratio for death, 0.57).  The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level.  No significant difference was seen between the 2 groups in the rate of adverse events.  The addn. of iniparib to chemotherapy improved the clin. benefit and survival of patients with metastatic triple-neg. breast cancer without, significantly increased toxic effects.  On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7tn6oRjsja7Vg90H21EOLACvtfcHk0ljGDttpfX6Fbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D&md5=d50866c03ab6a61f780f14e13fdbae28</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1011418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1011418%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DPippen%26aufirst%3DJ.%2BE.%26aulast%3DYoffe%26aufirst%3DM.%26aulast%3DPatt%26aufirst%3DD.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DKoo%26aufirst%3DI.%2BC.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%26atitle%3DIniparib%2520plus%2520chemotherapy%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">OâShaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danso, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charpentier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood-Chirchir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span> </span><span class="NLM_article-title">A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstract 1007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=Abstract+1007&issue=Suppl&author=J.+O%E2%80%99Shaughnessyauthor=L.+S.+Schwartzbergauthor=M.+A.+Dansoauthor=H.+S.+Rugoauthor=K.+Millerauthor=D.+A.+Yardleyauthor=R.+W.+Carlsonauthor=R.+S.+Finnauthor=E.+Charpentierauthor=M.+Freeseauthor=S.+Guptaauthor=A.+Blackwood-Chirchirauthor=E.+P.+Winer&title=A+randomized+phase+III+study+of+iniparib+%28BSI-201%29+in+combination+with+gemcitabine%2Fcarboplatin+%28G%2FC%29+in+metastatic+triple-negative+breast+cancer+%28TNBC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DDanso%26aufirst%3DM.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DCarlson%26aufirst%3DR.%2BW.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCharpentier%26aufirst%3DE.%26aulast%3DFreese%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DBlackwood-Chirchir%26aufirst%3DA.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3DA%2520randomized%2520phase%2520III%2520study%2520of%2520iniparib%2520%2528BSI-201%2529%2520in%2520combination%2520with%2520gemcitabine%252Fcarboplatin%2520%2528G%252FC%2529%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3DSuppl%26spage%3DAbstract%25201007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">â</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1158%2F1078-0432.CCR-11-2890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22291137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1655-1662&author=A.+G.+Patelauthor=S.+B.+De+Lorenzoauthor=K.+S.+Flattenauthor=G.+G.+Poirierauthor=S.+H.+Kaufmann&title=Failure+of+iniparib+to+inhibit+poly%28ADP-ribose%29+polymerase+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro</span></div><div class="casAuthors">Patel, Anand G.; De Lorenzo, Silvana B.; Flatten, Karen S.; Poirier, Guy G.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clin. testing for their single-agent activity in homologous recombination (HR)-deficient tumors and ability to enhance the action of certain DNA-damaging agents.  Compared with other PARP inhibitors in development, iniparib (4-iodo-3-nitrobenzamide) is notable for its simple structure and the reported ability of its intracellular metabolite 4-iodo-3-nitrosobenzamide to covalently inhibit PARP1 under cell-free conditions.  The present preclin. studies were conducted to compare the actions iniparib with the more extensively characterized PARP inhibitors olaparib and veliparib.  Exptl. Design: The abilities of iniparib, olaparib, and veliparib to (i) selectively induce apoptosis or inhibit colony formation in HR-deficient cell lines, (ii) selectively sensitize HR-proficient cells to topoisomerase I poisons, and (iii) inhibit formation of poly(ADP-ribose) polymer (pADPr) in intact cells were compared.  RESULTS: Consistent with earlier reports, olaparib and veliparib selectively induced apoptosis and inhibited colony formation in cells lacking BRCA2 or ATM.  Moreover, like earlier generation PARP inhibitors, olaparib and veliparib sensitized cells to the topoisomerase I poisons camptothecin and topotecan.  Finally, olaparib and veliparib inhibited formation of pADPr in intact cells.  In contrast, iniparib exhibited little or no ability to selectively kill HR-deficient cells, sensitize cells to topoisomerase I poisons, or inhibit pADPr formation in situ.  In further expts., iniparib also failed to sensitize cells to cisplatin, gemcitabine, or paclitaxel.  CONCLUSIONS: While iniparib kills normal and neoplastic cells at high (>40 Î¼mol/L) concns., its effects are unlikely to reflect PARP inhibition and should not be used to guide decisions about other PARP inhibitors.  Clin Cancer Res; 18(6); 1655-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6PlliVCr5ErVg90H21EOLACvtfcHk0ljGDttpfX6Fbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D&md5=82cb650b8bb7114cfc6afdc68fc5c3d9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2890%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DFlatten%26aufirst%3DK.%2BS.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DFailure%2520of%2520iniparib%2520to%2520inhibit%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520vitro%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span>AstraZeneca updates on olaparib and TC-5214 development programmes; <span class="NLM_publisher-name">AstraZeneca</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_month">December</span><span class="NLM_day">20</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development" class="extLink">http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development</a> (accessed 19 February<span class="NLM_x"> </span><span class="NLM_year">2015)</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AstraZeneca+updates+on+olaparib+and+TC-5214+development+programmes%3B+AstraZeneca%3A+London%2C+December20%2C+2011%3B+http%3A%2F%2Fwww.astrazeneca.com%2FMedia%2FPress-releases%2FArticle%2F20111220-az-updates-olaparib-TC5214-development+%28accessed+19+February+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAstraZeneca%2520updates%2520on%2520olaparib%2520and%2520TC-5214%2520development%2520programmes%26pub%3DAstraZeneca%26date%3D2011%26date%3D2015%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in patients with platinum sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">â</span> <span class="NLM_lpage">861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2FS1470-2045%2814%2970228-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=24882434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=852-861&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+L.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=A.+Fieldingauthor=S.+Spencerauthor=B.+Doughertyauthor=M.+Orrauthor=D.+Hodgsonauthor=J.+C.+Barrettauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+patients+with+platinum+sensitive+relapsed+serous+ovarian+cancer%3A+a+preplanned+retrospective+analysis+of+outcomes+by+BRCA+status+in+a+randomised+phase+2+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare L.; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Dougherty, Brian; Orr, Maria; Hodgson, Darren; Barrett, J. Carl; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-861</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer.  We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.We present data from the second interim anal. of overall survival and a retrospective, preplanned anal. of data by BRCA mutation status from our randomised, double-blind, phase 2 study that assessed maintenance treatment with olaparib 400 mg twice daily (capsules) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen.  Randomisation was by an interactive voice response system, stratified by time to progression on penultimate platinum-based regimen, response to the most recent platinum-based regimen before randomisation, and ethnic descent.  The primary endpoint was PFS, analyzed for the overall population and by BRCA status.  This study is registered with ClinicalTrials.gov, no. NCT00753545.Between Aug 28, 2008, and Feb 9, 2010, 136 patients were assigned to olaparib and 129 to placebo.  BRCA status was known for 131 (96%) patients in the olaparib group vs. 123 (95%) in the placebo group, of whom 74 (56%) vs. 62 (50%) had a deleterious or suspected deleterious germline or tumor BRCA mutation.  Of patients with a BRCA mutation, median PFS was significantly longer in the olaparib group than in the placebo group (11Â·2 mo [95% CI 8Â·3-not calculable] vs 4Â·3 mo [3Â·0-5Â·4]; HR 0Â·18 [0Â·10-0Â·31]; p<0Â·0001); similar findings were noted for patients with wild-type BRCA, although the difference between groups was lower (7Â·4 mo [5Â·5-10Â·3] vs 5Â·5 mo [3Â·7-5Â·6]; HR 0Â·54 [0Â·34-0Â·85]; p=0Â·0075).  At the second interim anal. of overall survival (58% maturity), overall survival did not significantly differ between the groups (HR 0Â·88 [95% CI 0Â·64-1Â·21]; p=0Â·44); similar findings were noted for patients with mutated BRCA (HR 0Â·73 [0Â·45-1Â·17]; p=0Â·19) and wild-type BRCA (HR 0Â·99 [0Â·63-1Â·55]; p=0Â·96).  The most common grade 3 or worse adverse events in the olaparib group were fatigue (in ten [7%] patients in the olaparib group vs four [3%] in the placebo group) and anemia (seven [5%] vs one [<1%]).  Serious adverse events were reported in 25 (18%) patients who received olaparib and 11 (9%) who received placebo.  Tolerability was similar in patients with mutated BRCA and the overall population.These results support the hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment.AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozZjZdcu1e4rVg90H21EOLACvtfcHk0litpavutxCNZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK&md5=bfc15e933746672148dd7237e3f67f01</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970228-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970228-1%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DOrr%26aufirst%3DM.%26aulast%3DHodgson%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520patients%2520with%2520platinum%2520sensitive%2520relapsed%2520serous%2520ovarian%2520cancer%253A%2520a%2520preplanned%2520retrospective%2520analysis%2520of%2520outcomes%2520by%2520BRCA%2520status%2520in%2520a%2520randomised%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D852%26epage%3D861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span>AstraZeneca initiates phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer; <span class="NLM_publisher-name">AstraZeneca</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_month">September</span><span class="NLM_day">4</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-enrollment-patient-phaseIII-olaparib" class="extLink">http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-enrollment-patient-phaseIII-olaparib</a> (accessed 19 February<span class="NLM_x"> </span><span class="NLM_year">2015)</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AstraZeneca+initiates+phase+III+clinical+programme+for+olaparib%2C+a+treatment+in+development+for+patients+with+BRCA+mutated+ovarian+cancer%3B+AstraZeneca%3A+London%2C+September4%2C+2013%3B+http%3A%2F%2Fwww.astrazeneca.com%2FMedia%2FPress-releases%2FArticle%2Fastrazeneca-enrollment-patient-phaseIII-olaparib+%28accessed+19+February+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAstraZeneca%2520initiates%2520phase%2520III%2520clinical%2520programme%2520for%2520olaparib%252C%2520a%2520treatment%2520in%2520development%2520for%2520patients%2520with%2520BRCA%2520mutated%2520ovarian%2520cancer%26pub%3DAstraZeneca%26date%3D2013%26date%3D2015%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Chung, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulger, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosjek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belyk, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphrey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limanto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachert, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, K. M.</span><span> </span><span class="NLM_article-title">Process development of CâN cross-coupling and enantioselective biocatalytic reactions for the asymmetric synthesis of niraparib</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/doi/10.1021/op400233z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=215-227&author=C.+K.+Chungauthor=P.+G.+Bulgerauthor=B.+Kosjekauthor=K.+M.+Belykauthor=N.+Riveraauthor=M.+E.+Scottauthor=G.+Humphreyauthor=J.+Limantoauthor=D.+C.+Bachertauthor=K.+M.+Emerson&title=Process+development+of+C%E2%80%93N+cross-coupling+and+enantioselective+biocatalytic+reactions+for+the+asymmetric+synthesis+of+niraparib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fop400233z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400233z%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DC.%2BK.%26aulast%3DBulger%26aufirst%3DP.%2BG.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BE.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DLimanto%26aufirst%3DJ.%26aulast%3DBachert%26aufirst%3DD.%2BC.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520development%2520of%2520C%25E2%2580%2593N%2520cross-coupling%2520and%2520enantioselective%2520biocatalytic%2520reactions%2520for%2520the%2520asymmetric%2520synthesis%2520of%2520niraparib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D215%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelman, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hylands, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreischer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thway, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevensleben, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iannone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenham, R. M.</span><span> </span><span class="NLM_article-title">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">â</span> <span class="NLM_lpage">892</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2FS1470-2045%2813%2970240-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23810788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=882-892&author=S.+K.+Sandhuauthor=W.+R.+Schelmanauthor=G.+Wildingauthor=V.+Morenoauthor=R.+D.+Bairdauthor=S.+Mirandaauthor=L.+Hylandsauthor=R.+Riisnaesauthor=M.+Forsterauthor=A.+Omlinauthor=N.+Kreischerauthor=K.+Thwayauthor=H.+Gevenslebenauthor=L.+Sunauthor=J.+Loughneyauthor=M.+Chatterjeeauthor=C.+Toniattiauthor=C.+L.+Carpenterauthor=R.+Iannoneauthor=S.+B.+Kayeauthor=J.+S.+de+Bonoauthor=R.+M.+Wenham&title=The+poly%28ADP-ribose%29+polymerase+inhibitor+niraparib+%28MK4827%29+in+BRCA+mutation+carriers+and+patients+with+sporadic+cancer%3A+a+phase+1+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Sandhu, Shahneen K.; Schelman, William R.; Wilding, George; Moreno, Victor; Baird, Richard D.; Miranda, Susana; Hylands, Lucy; Riisnaes, Ruth; Forster, Martin; Omlin, Aurelius; Kreischer, Nathan; Thway, Khin; Gevensleben, Heidrun; Sun, Linda; Loughney, John; Chatterjee, Manash; Toniatti, Carlo; Carpenter, Christopher L.; Iannone, Robert; Kaye, Stan B.; de Bono, Johann S.; Wenham, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">882-892</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation.  Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclin. tumor models with loss of BRCA and PTEN function.  We investigated the safety, tolerability, max. tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumor activity of niraparib.In a phase 1 dose-escalation study, we enrolled patients with advanced solid tumors at one site in the UK and two sites in the USA.  Eligible patients were aged at least 18 years; had a life expectancy of at least 12 wk; had an Eastern Cooperative Oncol. Group performance status of 2 or less; had assessable disease; were not suitable to receive any established treatments; had adequate organ function; and had discontinued any previous anticancer treatments at least 4 wk previously.  In part A, cohorts of three to six patients, enriched for BRCA1 and BRCA2 mutation carriers, received niraparib daily at ten escalating doses from 30 mg to 400 mg in a 21-day cycle to establish the max. tolerated dose.  Dose expansion at the max. tolerated dose was pursued in 15 patients to confirm tolerability.  In part B, we further investigated the max. tolerated dose in patients with sporadic platinum-resistant high-grade serous ovarian cancer and sporadic prostate cancer.  We obtained blood, circulating tumor cells, and optional paired tumor biopsies for pharmacokinetic and pharmacodynamic assessments.  Toxic effects were assessed by common toxicity criteria and tumor responses ascribed by Response Evaluation Criteria in Solid Tumors (RECIST).  Circulating tumor cells and archival tumor tissue in prostate patients were analyzed for exploratory putative predictive biomarkers, such as loss of PTEN expression and ETS rearrangements.  This trial is registered with ClinicalTrials.gov, NCT00749502.Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B. 300 mg/day was established as the max. tolerated dose.  Dose-limiting toxic effects reported in the first cycle were grade 3 fatigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocytopenia (two given 400 mg/day).  Common treatment-related toxic effects were anemia (48 patients [48%]), nausea (42 [42%]), fatigue (42 [42%]), thrombocytopenia (35 [35%]), anorexia (26 [26%]), neutropenia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2.  Pharmacokinetics were dose proportional and the mean terminal elimination half-life was 36Â·4 h (range 32Â·8-46Â·0).  Pharmacodynamic analyses confirmed PARP inhibition exceeded 50% at doses greater than 80 mg/day and antitumor activity was documented beyond doses of 60 mg/day.  Eight (40% [95% CI 19-64]) of 20 BRCA1 or BRCA2 mutation carriers with ovarian cancer had RECIST partial responses, as did two (50% [7-93]) of four mutation carriers with breast cancer.  Antitumor activity was also reported in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer.  We recorded no correlation between loss of PTEN expression or ETS rearrangements and measures of antitumor activity in patients with prostate cancer.A recommended phase 2 dose of 300 mg/day niraparib is well tolerated.  Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.Merck Sharp and Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGQBD4DZcJn7Vg90H21EOLACvtfcHk0ljdOUgUyDSNbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF&md5=b6f27019bb7887156d1abcf05db2bca3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970240-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970240-7%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DSchelman%26aufirst%3DW.%2BR.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DHylands%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DForster%26aufirst%3DM.%26aulast%3DOmlin%26aufirst%3DA.%26aulast%3DKreischer%26aufirst%3DN.%26aulast%3DThway%26aufirst%3DK.%26aulast%3DGevensleben%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLoughney%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DCarpenter%26aufirst%3DC.%2BL.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DWenham%26aufirst%3DR.%2BM.%26atitle%3DThe%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520niraparib%2520%2528MK4827%2529%2520in%2520BRCA%2520mutation%2520carriers%2520and%2520patients%2520with%2520sporadic%2520cancer%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D882%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Simon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidlin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuck, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christian, M. C.</span><span> </span><span class="NLM_article-title">Accelerated titration designs for phase I clinical trials in oncology</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">â</span> <span class="NLM_lpage">114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1093%2Fjnci%2F89.15.1138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=9262252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADyaK2sXls1WnurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1138-114&author=R.+Simonauthor=B.+Freidlinauthor=L.+Rubinsteinauthor=S.+G.+Arbuckauthor=J.+Collinsauthor=M.+C.+Christian&title=Accelerated+titration+designs+for+phase+I+clinical+trials+in+oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerated titration designs for phase i clinical trials in oncology</span></div><div class="casAuthors">Simon, Richard; Freidlin, Boris; Rubinstein, Larry; Arbuck, Susan G.; Collins, Jerry; Christian, Michaele C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1138-1147</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Many cancer patients in phase I clin. trials are treated at doses of chemotherapeutic agents that are below the biol. active level, thus reducing their chances for therapeutic benefit.  Current phase I trials often take a long time to complete and provide little information about interpatient variability or cumulative toxicity.  Our objective was to develop alternative designs for phase I trials so that fewer patients are treated at subtherapeutic dose levels, trials are of reduced duration, and important information (i.e., cumulative toxicity and max. tolerated dose) needed to plan phase II trials is obtained.  We fit a stochastic model to data from 20 phase I trials involving the study of nine different drugs.  We then simulated new data from the model with the parameters estd. from the actual trials and evaluated the performance of alternative phase I designs on this simulated data.  Four designs were evaluated.  Design 1 was a conventional design (similar to the commonly used modified Fibonacci method) using cohorts of three to six patients, with 40% dose-step increments and no intrapatient dose escalation.  Designs 2 through 4 included only one patient per cohort until one patient experienced dose-limiting toxic effects or two patients experienced grade 2 toxic effects (during their first course of treatment for designs 2 and 3 or during any course of treatment for design 4).  Designs 3 and 4 used 100% dose steps during this initial accelerated phase.  After the initial accelerated phase, designs 2 through 4 resorted to std. cohorts of three to six patients, with 40% dose-step increments.  Designs 2 through 4 used intrapatient dose escalation if the worst toxicity is grade 0-1 in the previous course for that patient.  Only three of the actual trials demonstrated cumulative toxic effects of the chemotherapeutic agents in patients.  The av. no. of patients required for a phase I trial was reduced from 39.9 for design 1 to 24.4, 20.7, and 21.2 for designs 2, 3, and 4, resp.  The av. no. of patients who would be expected to have grade 0-1 toxicity as their worst toxicity over three cycles of treatment is 23.3 for design 1, but only 7.9, 3.9, and 4.8 for designs 2, 3, and 4, resp.  The av. no. of patients with grade 3 toxicity as their worst toxicity increases from 5.5 for design 1 to 6.2, 6.8, and 6.2 for designs 2, 3, and 4, resp.  The av. no. of patients with grade 4 toxicity as their worst toxicity increases from 1.9 for design 1 to 3.0, 4.3, and 3.2 for designs 2, 3, and 4, resp.  Accelerated titrn. (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the no. of patients who are undertreated, speed the completion of phase I trials, and provide a substantial increase in the information obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJZU1U_6M84LVg90H21EOLACvtfcHk0ljdOUgUyDSNbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1WnurY%253D&md5=9bd1e7a56e6070e2f2ce4b1c1e339f59</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F89.15.1138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F89.15.1138%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DR.%26aulast%3DFreidlin%26aufirst%3DB.%26aulast%3DRubinstein%26aufirst%3DL.%26aulast%3DArbuck%26aufirst%3DS.%2BG.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DChristian%26aufirst%3DM.%2BC.%26atitle%3DAccelerated%2520titration%2520designs%2520for%2520phase%2520I%2520clinical%2520trials%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1997%26volume%3D89%26spage%3D1138%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SzabÃ³, C.</span><span> </span><span class="NLM_article-title">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">â</span> <span class="NLM_lpage">1256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1016%2Fj.mam.2013.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=23370117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1217-1256&author=N.+J.+Curtinauthor=C.+Szab%C3%B3&title=Therapeutic+applications+of+PARP+inhibitors%3A+Anticancer+therapy+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span></div><div class="casAuthors">Curtin, Nicola J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1256</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this article is to describe the current and potential clin. translation of pharmacol. inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases.  The first section of the present review summarizes the available preclin. and clin. data with PARP inhibitors in various forms of cancer.  In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-assocd. lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer.  HRR defects are classically assocd. with BRCA1 and 2 mutations assocd. with familial breast and ovarian cancer, but there may be many other causes of HRR defects.  Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects.  Multiple lines of preclin. data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation.  Both single agent and combination clin. trials are underway.  The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clin. development.  The second section of the present review summarizes the role of PARP in selected non-oncol. indications.  In a no. of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clin. translatability of PARP inhibition is supported by multiple lines of preclin. data, as well as observational data demonstrating PARP activation in human tissue samples.  In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathol.  Accordingly, multiple lines of preclin. data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses.  As the clin. trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clin. investigations, aimed at testing of PARP inhibitors for various non-oncol. indications, will be initiated, as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4INVXcZ0zbVg90H21EOLACvtfcHk0ljdOUgUyDSNbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D&md5=6a514e160666b5dde38e1365211cd41e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DSzab%25C3%25B3%26aufirst%3DC.%26atitle%3DTherapeutic%2520applications%2520of%2520PARP%2520inhibitors%253A%2520Anticancer%2520therapy%2520and%2520beyond%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1217%26epage%3D1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span> <span class="citation_source-journal">N. Eng. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">1382</span><span class="NLM_x">â</span> <span class="NLM_lpage">1392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm5018237&amp;key=10.1056%2FNEJMoa1105535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm5018237&amp;key=22452356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm5018237&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1382-1392&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=E.+Macphersonauthor=C.+Watkinsauthor=J.+Carmichaelauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+platinum-sensitive+relapsed+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; MacPherson, Euan; Watkins, Claire; Carmichael, James; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1382-1392</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Olaparib (AZD2281) is an oral poly(ADP [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.  METHODS We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen.  Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo.  The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines.  RESULTS Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group.  Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 mo vs. 4.8 mo from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001).  Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression.  Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2.  An interim anal. of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P = 0.75).  CONCLUSIONS Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.  Interim anal. showed no overall survival benefit.  The toxicity profile of olaparib in this population was consistent with that in previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGMJNLsHGObVg90H21EOLACvtfcHk0lje1yPT3yLlhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D&md5=1612aa24cd17a29f03599a7c2acf5f0f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105535%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520platinum-sensitive%2520relapsed%2520ovarian%2520cancer%26jtitle%3DN.%2520Eng.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1382%26epage%3D1392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Garber, K.</span><span> </span><span class="NLM_article-title">PARP inhibitors bounce back</span> <span class="citation_source-journal">Nature Rev. Drug. Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">â</span> <span class="NLM_lpage">727</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=725-727&author=K.+Garber&title=PARP+inhibitors+bounce+back"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarber%26aufirst%3DK.%26atitle%3DPARP%2520inhibitors%2520bounce%2520back%26jtitle%3DNature%2520Rev.%2520Drug.%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D725%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5018237&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-8%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm5018237%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5018237" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799573ffef52290","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
